

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 5, 2005, 08:19:22 / Search time 23.9545 Seconds  
(without alignments)  
85.823 Million cell updates/sec

Title: US-09-931-700-3

Perfect score: 163  
Sequence: 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGCY 31

Scoring table: BIOSUM62

Gapop 10.0, Gapext 0.5

Searched: 478139 seqs, 66318000 residues

Total number of hits satisfying chosen parameters: 478139

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database:

Issued Patents AA: \*  
1: /cgn2\_6/ptodata/1/1aa/5A.COMB.pep: \*  
2: /cgn2\_6/ptodata/1/1aa/5B.COMB.pep: \*  
3: /cgn2\_6/ptodata/1/1aa/6A.COMB.pep: \*  
4: /cgn2\_6/ptodata/1/1aa/6B.COMB.pep: \*  
5: /cgn2\_6/ptodata/1/1aa/PTCUS.COMB.pep: \*  
6: /cgn2\_6/ptodata/1/1aa/backfile1.pep: \*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	163	100.0	31	3	US-09-070-504-23
2	163	100.0	31	3	US-09-011-922A-3
3	163	100.0	31	3	US-09-011-922A-14
4	163	100.0	31	4	US-09-280-501-9
5	163	100.0	31	4	US-09-813-245C-23
6	163	100.0	38	4	US-09-280-501-6
7	163	100.0	40	4	US-09-280-501-14
8	163	100.0	52	3	US-09-070-504-14
9	163	100.0	52	4	US-09-813-245C-14
10	163	100.0	185	2	US-08-233-389C-1
11	163	100.0	185	2	US-08-801-863-3
12	163	100.0	185	2	US-08-486-596A-3
13	163	100.0	185	2	US-08-004-713-3
14	158	96.9	30	5	US-09-280-501-5
15	157	96.3	188	1	US-08-233-389C-3
16	157	96.3	188	2	US-08-801-863-3
17	157	96.3	188	2	US-08-486-596A-3
18	157	96.3	188	2	US-08-004-713-3
19	154	94.5	29	4	US-09-280-501-4
20	150	92.0	40	4	US-09-280-501-8
21	150	92.0	50	4	US-09-280-501-7
22	149	91.4	28	4	US-09-280-501-3
23	148	90.8	50	3	US-09-070-504-15
24	148	90.8	50	4	US-09-813-345C-15
25	144	88.3	27	4	US-09-280-501-2
26	140	85.9	26	4	US-09-280-501-1
27	123	75.5	23	4	US-09-280-501-17

28	112	68.7	21	4	US-09-280-501-16	Sequence 16, Appl
29	74	45.4	13	4	US-09-280-501-15	Sequence 15, Appl
30	68	41.7	13	4	US-09-280-501-10	Sequence 10, Appl
31	57	35.0	13	3	US-09-011-922A-2	Sequence 2, Appl
32	52	31.9	775	2	US-08-966-388-4	Sequence 4, Appl
33	52	31.9	775	3	US-09-188-403-4	Sequence 4, Appl
34	52	31.9	775	3	US-09-188-404-4	Sequence 4, Appl
35	52	31.9	775	3	US-09-281-359-4	Sequence 4, Appl
36	52	31.9	1005	4	US-09-252-691A-24655	Sequence 24655, A
37	51	31.3	10	2	US-08-934-222-17	Sequence 17, Appl
38	51	31.3	10	2	US-08-933-402-17	Sequence 17, Appl
39	51	31.3	10	2	US-09-207-621-17	Sequence 17, Appl
40	51	31.3	10	2	US-08-532-818-17	Sequence 17, Appl
41	51	31.3	10	3	US-09-231-797-17	Sequence 17, Appl
42	51	31.3	10	3	US-08-934-224-17	Sequence 17, Appl
43	51	31.3	10	3	US-08-933-843-17	Sequence 17, Appl
44	51	31.3	10	3	US-08-934-223-17	Sequence 17, Appl
45	51	31.3	10	3	US-09-413-492-17	Sequence 17, Appl

#### ALIGNMENTS

RESULT 1  
US-09-070-504-23  
Sequence 23, Application US/09070504  
Patent No. 6268474  
GENERAL INFORMATION:  
APPLICANT: Smith, Derek D.  
APPLICANT: Saha, Shankar  
TITLE OF INVENTION: PEPTIDE ANTAGONISTS OF CGRP-RECEPTOR  
NUMBER OF SEQUENCES: 23  
CORRESPONDENCE ADDRESSES:  
ADDRESSER: Muehling, Raasch & Gebhardt, P.A.  
STREET: 119 No. 6268474th Fourth Street  
CITY: Minneapolis  
STATE: MN  
COUNTRY: USA  
ZIP: 55401  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/070,504  
FILING DATE: 30-APR-1998  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: McCormack, Myra H  
REGISTRATION NUMBER: 36,602  
REFERENCE/DOCKET NUMBER: 180,00020101  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 612/305-1220  
TELEFAX: 612/305-1228  
INFORMATION FOR SEQ ID NO: 23:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 31 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-09-070-504-23  
Query Match 100.0%; Score 163; DB 3; Length 31;  
Best Local Similarity 100.0%; Pred. No. 3.6e-19;  
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Cy 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGCY 31  
Db 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGCY 31

```
RESULT 2
US-09-011-922A-3
; Sequence 3, Application US/09011922A
; Patent No. 6320022
; GENERAL INFORMATION:
; APPLICANT: Cuticla, Frank; Martinez,
; APPLICANT: Alfredo; Miller, Mae Jean; Unsworth, Edward
; APPLICANT: J.; Hook, William; Walsh, Thomas; Grey,
; APPLICANT: Karen; Macri, Charles
; TITLE OF INVENTION: Functional Role of
; TITLE OF INVENTION: Adrenomedullin (AM) and the Gene-Related
; TITLE OF INVENTION: Product (PAMP) in Human Pathology and
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
; STREET: 345 Park Avenue
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10154-0053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy Disk
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: MS WORD 97
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,922A
; FILING DATE: 17-Feb-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/60/002,514
; FILING DATE: 18-Aug-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/60/002,936
; FILING DATE: 30-Aug-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/60/013,172
; FILING DATE: 12-Mar-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/13286
; FILING DATE: 16-Aug-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Leslie A. Serunian
; REGISTRATION NUMBER: 35,353
; REFERENCE/DOCKET NUMBER: 2026-4202US3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 758-4800
; TELEFAX: (212) 751-6849
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 31 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHEICAL: No
; FEATURE:
; NAME/KEY: P072
; OTHER INFORMATION: PreproAM(116-146)
US-09-011-922A-3

Query Match      100.0%; Score 163; DB 3; Length 31;
Best Local Similarity 100.0%; Pred. No. 3.6e-19;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGY 31
DB      1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGY 31

RESULT 3
US-09-011-922A-14
```

```
; Sequence 14, Application US/09011922A
; Patent No. 6320022
; GENERAL INFORMATION:
; APPLICANT: Cuticla, Frank; Martinez,
; APPLICANT: Alfredo; Miller, Mae Jean; Unsworth, Edward
; APPLICANT: J.; Hook, William; Walsh, Thomas; Grey,
; APPLICANT: Karen; Macri, Charles
; TITLE OF INVENTION: Functional Role of
; TITLE OF INVENTION: Adrenomedullin (AM) and the Gene-Related
; TITLE OF INVENTION: Product (PAMP) in Human Pathology and
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
; STREET: 345 Park Avenue
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10154-0053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy Disk
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: MS WORD 97
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,922A
; FILING DATE: 17-Feb-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/60/002,514
; FILING DATE: 18-Aug-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/60/002,936
; FILING DATE: 30-Aug-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/60/013,172
; FILING DATE: 12-Mar-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/13286
; FILING DATE: 16-Aug-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Leslie A. Serunian
; REGISTRATION NUMBER: 35,353
; REFERENCE/DOCKET NUMBER: 2026-4202US3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 758-4800
; TELEFAX: (212) 751-6849
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 31 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHEICAL: No
; FEATURE:
; OTHER INFORMATION: Synthetic homolog of
; OTHER INFORMATION: two-thirds of the intact AM peptide
US-09-011-922A-14

Query Match      100.0%; Score 163; DB 3; Length 31;
Best Local Similarity 100.0%; Pred. No. 3.6e-19;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGY 31
DB      1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGY 31

RESULT 4
US-09-280-501-9
; Sequence 9, Application US/09280501
; Patent No. 6440421
; GENERAL INFORMATION:
; APPLICANT: Cooper, Garth James Smith
```

```

; APPLICANT: Reid, Ian Reginald
; APPLICANT: Cornish, Jillian
; TITLE OF INVENTION: TREATMENT OF BONE DISORDERS WITH
; TITLE OF INVENTION: ADRENOMEDULLIN OR ADRENOMEDULLIN AGONISTS
; FILE REFERENCE: 08987-005001
; CURRENT APPLICATION NUMBER: US/09/280,501
; CURRENT FILING DATE: 1999-03-30
; PRIOR APPLICATION NUMBER: 08/634,562
; PRIOR FILING DATE: 1996-04-18
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-280-501-9

Query Match          100.0%; Score 163; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 3,6e-19;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 TVOKLAHQIYQFTDKDKDNVAPRSKISPOGY 31
DB      1 TVOKLAHQIYQFTDKDKDNVAPRSKISPOGY 31

RESULT 5
US-09-813-345C-23
; Sequence 23, Application US/09813345C
; Patent No. 6756205
; GENERAL INFORMATION:
; APPLICANT: CREIGHTON UNIVERSITY
; APPLICANT: SMITH, Derek D.
; APPLICANT: SABA, Shankar
; APPLICANT: ABEL, Peter W.
; TITLE OF INVENTION: PEPTIDE ANTAGONISTS OF CGRP-RECEPTOR SUPERFAMILY AND METHODS OF
; TITLE OF INVENTION: USE
; FILE REFERENCE: 180.00020102
; CURRENT APPLICATION NUMBER: US/09/813,345C
; CURRENT FILING DATE: 2001-03-20
; PRIOR APPLICATION NUMBER: 09/070,504
; PRIOR FILING DATE: 1998-04-30
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificially Synthesized Peptide
US-09-813-345C-23

Query Match          100.0%; Score 163; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 3,6e-19;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 TVOKLAHQIYQFTDKDKDNVAPRSKISPOGY 31
DB      1 TVOKLAHQIYQFTDKDKDNVAPRSKISPOGY 31

RESULT 6
US-09-280-501-6
; Sequence 6, Application US/09280501
; Patent No. 6440421
; GENERAL INFORMATION:
; APPLICANT: Cooper, Garth James Smith
; APPLICANT: Reid, Ian Reginald
; APPLICANT: Cornish, Jillian
; TITLE OF INVENTION: TREATMENT OF BONE DISORDERS WITH
; TITLE OF INVENTION: ADRENOMEDULLIN OR ADRENOMEDULLIN AGONISTS
; FILE REFERENCE: 08987-005001
; CURRENT APPLICATION NUMBER: US/09/280,501
```

```

; CURRENT FILING DATE: 1999-03-30
; PRIOR APPLICATION NUMBER: 08/634,562
; PRIOR FILING DATE: 1996-04-18
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 38
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-280-501-6

Query Match          100.0%; Score 163; DB 4; Length 38;
Best Local Similarity 100.0%; Pred. No. 4,6e-19;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 TVOKLAHQIYQFTDKDKDNVAPRSKISPOGY 31
DB      8 TVOKLAHQIYQFTDKDKDNVAPRSKISPOGY 38

RESULT 7
US-09-280-501-11
; Sequence 11, Application US/09280501
; Patent No. 6440421
; GENERAL INFORMATION:
; APPLICANT: Cooper, Garth James Smith
; APPLICANT: Reid, Ian Reginald
; APPLICANT: Cornish, Jillian
; TITLE OF INVENTION: TREATMENT OF BONE DISORDERS WITH
; TITLE OF INVENTION: ADRENOMEDULLIN OR ADRENOMEDULLIN AGONISTS
; FILE REFERENCE: 08987-005001
; CURRENT APPLICATION NUMBER: US/09/280,501
; CURRENT FILING DATE: 1999-03-30
; PRIOR APPLICATION NUMBER: 08/634,562
; PRIOR FILING DATE: 1996-04-18
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 11
; LENGTH: 40
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-280-501-11

Query Match          100.0%; Score 163; DB 4; Length 40;
Best Local Similarity 100.0%; Pred. No. 4,9e-19;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 TVOKLAHQIYQFTDKDKDNVAPRSKISPOGY 31
DB      10 TVOKLAHQIYQFTDKDKDNVAPRSKISPOGY 40

RESULT 8
US-09-070-504-14
; Sequence 14, Application US/09070504
; Patent No. 6268474
; GENERAL INFORMATION:
; APPLICANT: Smith, Derek D.
; APPLICANT: SABA, Shankar
; APPLICANT: ABEL, Peter W.
; TITLE OF INVENTION: PEPTIDE ANTAGONISTS OF CGRP-RECEPTOR
; TITLE OF INVENTION: SUPERFAMILY AND METHODS OF USE
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Mueling, Raasch & Gebhardt, P.A.
; STREET: 119 No. 6268474th Fourth Street
; CITY: Minneapolis
; STATE: MN
; COUNTRY: USA
; ZIP: 55401
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
```

OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/070,504  
FILING DATE: 30-APR-1998  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: McCormack, Myra H  
REGISTRATION NUMBER: 36,602  
REFERENCE/DOCKET NUMBER: 180,00020101  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 612/305-1220  
TELEFAX: 612/305-1228  
INFORMATION FOR SEQ ID NO: 14:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 52 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
US-09-070-504-14

Query Match 100.0%; Score 163; DB 3; Length 52;  
Best Local Similarity 100.0%; Pred. No. 6.8e-19;  
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVOKLAHQIYQFTDKDKDNVAPRSKISPOGY 31  
DB 22 TVOKLAHQIYQFTDKDKDNVAPRSKISPOGY 52

RESULT 9  
US-09-813-345C-14  
Sequence 14, Application US/09813345C  
GENERAL INFORMATION:  
APPLICANT: CREIGHTON UNIVERSITY  
APPLICANT: SMITH, Derek D.  
APPLICANT: SAHA, Shankar W.  
APPLICANT: ABEL, Peter W.  
TITLE OF INVENTION: PEPTIDE ANTAGONISTS OF CGRP-RECEPTOR SUPERFAMILY AND METHODS OF  
TITLE OF INVENTION: USR  
FILE REFERENCE: 180,00020102  
CURRENT APPLICATION NUMBER: US/09/813,345C  
CURRENT FILING DATE: 2001-03-20  
PRIOR APPLICATION NUMBER: 09/070,504  
PRIOR FILING DATE: 1998-04-30  
NUMBER OF SEQ ID NOS: 23  
SOFTWARE: Patentin version 3.2  
SEQ ID NO 14  
LENGTH: 52  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Artificially Synthesized Peptide  
US-09-813-345C-14

Query Match 100.0%; Score 163; DB 4; Length 52;  
Best Local Similarity 100.0%; Pred. No. 6.8e-19;  
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVOKLAHQIYQFTDKDKDNVAPRSKISPOGY 31  
DB 22 TVOKLAHQIYQFTDKDKDNVAPRSKISPOGY 52

RESULT 10  
US-08-233-389C-1  
Sequence 1, Application US/08233389C  
Patent No. 5639855  
GENERAL INFORMATION:  
APPLICANT: KITAMURA, Kazuo  
APPLICANT: KANGAWA, Kenji

APPLICANT: MATSUO, Hiroyuki  
APPLICANT: ETO, Tanenao  
TITLE OF INVENTION: ADRENOMEDULLIN  
NUMBER OF SEQUENCES: 10  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: c/o FISH & NEAVE  
STREET: 1251 Avenue of the Americas  
CITY: New York  
STATE: NY  
COUNTRY: USA  
ZIP: 10020  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/233,389C  
FILING DATE: 26-APR-1994  
CLASSIFICATION: 530  
ATTORNEY/AGENT INFORMATION:  
NAME: HALEY Jr., James F.  
REGISTRATION NUMBER: 27,794  
REFERENCE/DOCKET NUMBER: SHGN-5  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 596-9090  
TELEFAX: (212) 596-9090  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 185 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-233-389C-1

Query Match 100.0%; Score 163; DB 1; Length 185;  
Best Local Similarity 100.0%; Pred. No. 3.2e-18;  
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVOKLAHQIYQFTDKDKDNVAPRSKISPOGY 31  
DB 116 TVOKLAHQIYQFTDKDKDNVAPRSKISPOGY 146

RESULT 11  
US-08-801-863-1  
Sequence 1, Application US/08801863  
Patent No. 5830703  
GENERAL INFORMATION:  
APPLICANT: KITAMURA, Kazuo  
APPLICANT: KANGAWA, Kenji  
APPLICANT: MATSUO, Hiroyuki  
APPLICANT: ETO, Tanenao  
TITLE OF INVENTION: ADRENOMEDULLIN  
NUMBER OF SEQUENCES: 10  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: c/o FISH & NEAVE  
STREET: 1251 Avenue of the Americas  
CITY: New York  
STATE: NY  
COUNTRY: USA  
ZIP: 10020  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/801,863  
FILING DATE: CONCURRENTLY HERewith  
CLASSIFICATION: 530  
ATTORNEY/AGENT INFORMATION:  
NAME: HALEY Jr., James F.

REGISTRATION NUMBER: 27,794  
REFERENCE/DOCKET NUMBER: SHGN-5 DIV3  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 596-9000  
TELEFAX: (212) 596-9090  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 185 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-801-863-1

Query Match 100.0%; Score 163; DB 2; Length 185;  
Best Local Similarity 100.0%; Pred. No. 3.2e-18;  
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVQKLAHQIYQFTDKDKNVAPRSKISPOGY 31  
DB 116 TVQKLAHQIYQFTDKDKNVAPRSKISPOGY 146

RESULT 12  
US-08-486-596A-1  
Sequence 1, Application US/08486596A  
Patent No. 5837823  
GENERAL INFORMATION:  
APPLICANT: KITAMURA, Kazuo  
APPLICANT: KANGAWA, Kenji  
APPLICANT: MATSUO, Hiroyuki  
APPLICANT: ETO, Tanenao  
TITLE OF INVENTION: ADRENOMEDULLIN  
NUMBER OF SEQUENCES: 10  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: C/O FISH & NEAVE  
STREET: 1251 Avenue of the Americas  
CITY: New York  
STATE: NY  
COUNTRY: USA  
ZIP: 10020  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/486,596A  
FILING DATE: JUNE 7, 1995  
CLASSIFICATION: 530  
ATTORNEY/AGENT INFORMATION:  
NAME: HALEY Jr., James F.  
REGISTRATION NUMBER: 27,794  
REFERENCE/DOCKET NUMBER: SHGN-5 DIV1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 596-9000  
TELEFAX: (212) 596-9090  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 185 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-486-596A-1

Query Match 100.0%; Score 163; DB 2; Length 185;  
Best Local Similarity 100.0%; Pred. No. 3.2e-18;  
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVQKLAHQIYQFTDKDKNVAPRSKISPOGY 31  
DB 116 TVQKLAHQIYQFTDKDKNVAPRSKISPOGY 146

RESULT 13  
US-09-004-713-1  
Sequence 1, Application US/09004713  
Patent No. 5910416  
GENERAL INFORMATION:  
APPLICANT: KITAMURA, Kazuo  
APPLICANT: KANGAWA, Kenji  
APPLICANT: MATSUO, Hiroyuki  
APPLICANT: ETO, Tanenao  
TITLE OF INVENTION: ADRENOMEDULLIN  
NUMBER OF SEQUENCES: 10  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: C/O FISH & NEAVE  
STREET: 1251 Avenue of the Americas  
CITY: New York  
STATE: NY  
COUNTRY: USA  
ZIP: 10020  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/004,713  
FILING DATE: JANUARY 7, 1998  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: HALEY Jr., James F.  
REGISTRATION NUMBER: 27,794  
REFERENCE/DOCKET NUMBER: SHGN-5 DIV2 CON  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 596-9000  
TELEFAX: (212) 596-9090  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 185 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-09-004-713-1

Query Match 100.0%; Score 163; DB 2; Length 185;  
Best Local Similarity 100.0%; Pred. No. 3.2e-18;  
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVQKLAHQIYQFTDKDKNVAPRSKISPOGY 31  
DB 116 TVQKLAHQIYQFTDKDKNVAPRSKISPOGY 146

RESULT 14  
US-09-280-501-5  
Sequence 5, Application US/09280501  
Patent No. 6440421  
GENERAL INFORMATION:  
APPLICANT: Cooper, Garth James Smith  
APPLICANT: Reid, Ian Reginald  
APPLICANT: Cornish, Jillian  
TITLE OF INVENTION: TREATMENT OF BONE DISORDERS WITH  
ADRENOMEDULLIN OR ADRENOMEDULLIN AGONISTS  
FILE REFERENCE: 08987-005001  
CURRENT APPLICATION NUMBER: US/09/280,501  
CURRENT FILING DATE: 1999-03-30  
PRIOR APPLICATION NUMBER: 08/634,562  
PRIOR FILING DATE: 1996-04-18  
NUMBER OF SEQ ID NOS: 17  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 5  
LENGTH: 30  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-09-280-501-5

Query Match 100.0%; Score 163; DB 2; Length 185;  
Best Local Similarity 100.0%; Pred. No. 3.2e-18;  
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVQKLAHQIYQFTDKDKNVAPRSKISPOGY 31  
DB 116 TVQKLAHQIYQFTDKDKNVAPRSKISPOGY 146

RESULT 14  
US-09-280-501-5  
Sequence 5, Application US/09280501  
Patent No. 6440421  
GENERAL INFORMATION:  
APPLICANT: Cooper, Garth James Smith  
APPLICANT: Reid, Ian Reginald  
APPLICANT: Cornish, Jillian  
TITLE OF INVENTION: TREATMENT OF BONE DISORDERS WITH  
ADRENOMEDULLIN OR ADRENOMEDULLIN AGONISTS  
FILE REFERENCE: 08987-005001  
CURRENT APPLICATION NUMBER: US/09/280,501  
CURRENT FILING DATE: 1999-03-30  
PRIOR APPLICATION NUMBER: 08/634,562  
PRIOR FILING DATE: 1996-04-18  
NUMBER OF SEQ ID NOS: 17  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 5  
LENGTH: 30  
TYPE: PRT  
ORGANISM: Homo sapiens  
US-09-280-501-5

Query Match 96.9%; Score 158; DB 4; Length 30;  
 Best Local Similarity 100.0%; Pred. No. 2.2e-18;  
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 TVOKLAHQIYQFTDKDKNVAPRSKISPOGY 31  
 |||||  
 Db 1 TVOKLAHQIYQFTDKDKNVAPRSKISPOGY 30

RESULT 15

US-08-233-389C-3  
 ; Sequence 3, Application US/08233389C  
 ; Patent No. 5639855

GENERAL INFORMATION:

APPLICANT: KITAMURA, Kazuo  
 APPLICANT: KANGAWA, Kenji  
 APPLICANT: MATSUDO, Hisayuki  
 APPLICANT: ETO, Tanenao  
 TITLE OF INVENTION: ADRENOMEDULLIN  
 NUMBER OF SEQUENCES: 10  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: c/o FISH & NEAVE  
 STREET: 1251 Avenue of the Americas  
 CITY: New York  
 STATE: NY  
 COUNTRY: USA  
 ZIP: 10020

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/233,389C  
 FILING DATE: 26-APR-1994  
 CLASSIFICATION: 530

ATTORNEY/AGENT INFORMATION:

NAME: HALEY Jr., James F.  
 REGISTRATION NUMBER: 27,794  
 REFERENCE/DOCKET NUMBER: SHGN-5  
 TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 596-9000

TELEFAX: (212) 596-9090

INFORMATION FOR SEQ ID NO: 3:

SEQUENCE CHARACTERISTICS:

LENGTH: 188 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: protein

US-08-233-389C-3

Query Match 96.3%; Score 157; DB 1; Length 188;  
 Best Local Similarity 96.8%; Pred. No. 3e-17;  
 Matches 30; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 TVOKLAHQIYQFTDKDKNVAPRSKISPOGY 31  
 |||||  
 Db 116 TVOKLAHQIYQFTDKDKNVAPRSKISPOGY 146

Search completed: January 5, 2005, 08:45:19  
 Job time : 24.9545 secs



CC amino acids (aa) 34-41 with the sequence Tyr-Tyr attached at the N-terminus; P071 represents preproAM a 122-131 with the sequence Tyr-Gly-Gly attached at the N-terminus; P072 represents preproAM aa 116-146 and CC PMMP-20 represents the proAM N-terminus. The Ab are useful for the CC prevention and/or treatment of cancers, e.g. adrenal, nervous system, lung, colon, ovarian and breast cancer by inhibiting cell growth. They CC are also useful for regulating insulin secretion and blood glucose CC metabolism and therefore for treating and/or preventing diabetes type II. CC They may be used for the diagnosis or treatment of conditions relating to CC pregnancy e.g. preeclampsia. The Ab are also useful for the following:

CC (i) regulating neurotransmission or neuron growth in areas of the central nervous system; (ii) lessening or inhibiting mast cell degranulation and CC hence reducing the effects of an allergic response; (iii) inhibiting or CC preventing bacterial and fungal growth (to treat infection); (iv) CC facilitating wound healing; and (v) promoting organ and bone development

XX  
XX Sequence 13 AA;

SO Query Match 100.0%; Score 76; DB 2; Length 13;  
Best Local Similarity 100.0%; Pred. No. 1.9e-06;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 YGSHQIVQPTDKD 13  
Db 1 YGSHQIVQPTDKD 13

RESULT 2  
ADP16710  
ID ADP16710 standard; protein; 26 AA.  
AC ADP16710;  
XX  
XX 12-FEB-2004 (first entry)  
DE Human albumin fusion protein-related protein SegID1812.  
XX  
XX  
KW albumin fusion protein; albumin activity; human serum albumin;  
KW serum osmotic pressure; shelf-life; stability; antidiabetic;  
KW gene therapy; diabetes mellitus; human; gene; ds.  
XX  
XX Homo sapiens.  
XX  
XX WO2003060071-A2.  
XX  
XX 24-JUL-2003.  
XX  
XX 23-DEC-2002; 2002WO-US040891.  
XX  
XX 21-DEC-2001; 2001US-0341811P.  
PR 24-JAN-2002; 2002US-0350358P.  
PR 28-JAN-2002; 2002US-0351360P.  
PR 26-FEB-2002; 2002US-0359370P.  
PR 28-FEB-2002; 2002US-0360000P.  
PR 27-MAR-2002; 2002US-0367500P.  
PR 08-APR-2002; 2002US-0370227P.  
PR 10-MAY-2002; 2002US-0378950P.  
PR 24-MAY-2002; 2002US-0382617P.  
PR 28-MAY-2002; 2002US-0383123P.  
PR 05-JUN-2002; 2002US-0385708P.  
PR 10-JUL-2002; 2002US-0394625P.  
PR 24-JUL-2002; 2002US-0398008P.  
PR 09-AUG-2002; 2002US-0402131P.  
PR 13-AUG-2002; 2002US-0402708P.  
PR 18-SEP-2002; 2002US-0411355P.  
PR 18-SEP-2002; 2002US-0411426P.  
PR 02-OCT-2002; 2002US-0414984P.  
PR 11-OCT-2002; 2002US-0417611P.  
PR 23-OCT-2002; 2002US-0420246P.  
PR 05-NOV-2002; 2002US-0423623P.  
XX  
XX (HUMA-) HUMAN GENOME SCI INC.  
PA (DEL2 ) DELTA BIOTECHNOLOGY LTD.

PA (PRIN-) PRINCIPIA PHARM CORP.  
XX  
XX PI Balance DJ, Turner AJ, Rosen CA, Haseltine WA;  
XX WPI; 2003-598517/56.  
DR N-PSDB; ADP16384.  
XX  
XX  
PT New albumin fusion protein, useful for preparing a composition for  
XX treating diabetes mellitus.  
PS Example 4; SEQ ID NO 1812; 24pp; English.  
XX  
XX This invention relates to a novel albumin fusion protein having albumin  
CC or biological activity. Human serum albumin is responsible for a  
CC significant proportion of the osmotic pressure of serum and also  
CC functions as a carrier of endogenous and exogenous ligands. The fusion of  
CC albumin to a therapeutic protein may increase shelf-life and stability of  
CC the therapeutic protein. The albumin fusion protein of the invention may  
CC allow production of compositions with antidiabetic activity whilst the  
CC nucleotide sequence which encodes it may be useful for gene therapy. The  
CC albumin fusion protein is useful for preparing a composition for treating  
CC diabetes mellitus. The present sequence is that of a therapeutic protein  
CC which was fused with human albumin to create a novel albumin fusion  
CC protein of the invention. Note: The sequence data for this patent did not  
CC form part of the printed specification, but was obtained in electronic  
CC format directly from WIPO at ftp.wipo.int/pub/publishepct\_sequences

SO Query Match 75.0%; Score 57; DB 7; Length 26;  
Best Local Similarity 100.0%; Pred. No. 0.009;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 HQIVQPTDKD 13  
Db 2 HQIVQPTDKD 11

RESULT 3  
ADP18404  
ID ADP18404 standard; peptide; 27 AA.  
AC ADP18404;  
XX  
XX 26-AUG-2004 (first entry)  
DE Neurogenesis modulation-related peptide SegID18.  
XX  
XX  
KW neurogenesis modulation; neural tissue; central nervous system disorder;  
KW neurodegenerative; ischaemic; learning and memory disorder;  
KW neurological trauma; nootropic; neuroprotective; CNS-Gen;  
KW cerebroprotective; vasotropic; anticonvulsant; antiparkinsonian;  
KW haemostatic; hypertensive; muscular-Gen; ophthalmological;  
KW antiinflammatory; analgesic; antidiabetic; neurogenesis modulator;  
KW neural stem cell; progenitor cell;  
KW neural tissue G-protein coupled receptor activator; neurogenesis inducer;  
KW intracellular neural Ca 2+ enhancer; intracellular neural cAMP stimulator;  
KW intracellular neural Ca 2+ enhancer; Parkinson's disease;  
KW Parkinson's disorder; Huntington's disease; Alzheimer's disease;  
KW multiple sclerosis; amyotrophic lateral sclerosis; Shy-Drager syndrome;  
KW progressive supranuclear palsy; Lewy body disease; spinal ischaemia;  
KW ischaemic stroke; cerebral infarction; spinal cord injury;  
KW cancer-related brain; spinal cord injury; multi-infarct dementia;  
KW geriatric dementia; cAMP level; embryonic tissue; human.  
XX  
XX Homo sapiens.  
XX  
XX WO2004045592-A2.  
XX  
XX 03-JUN-2004.  
XX  
XX 20-NOV-2003; 2003WO-IB005311.  
XX  
XX



PR 20-NOV-2002; 2002US-0427912P.  
 XX (NEUR-) NEURONOVA AB.  
 PA (BERT) BERTILSSON G.  
 PA (ERLA) ERLANDSSON R.  
 PA (FRIS) FRISSEN J.  
 PA (HAEG) HAEGESTRAND A.  
 PA (HEID) HEIDRICH J.  
 PA (HELL) HELSTROM K.  
 PA (HAEG) HAEGBLAD J.  
 PA (JANS) JANSSEN K.  
 PA (KORT) KORTESMAA J.  
 PA (LUND) LINDQUIST P.  
 PA (MCGR) MCGIRE J.  
 PA (MERC) MERCER A.  
 PA (NJBG) NJBERG K.  
 PA (OSSO) OSSOLINAK A.  
 PA (PATR) PATRONE C.  
 PA (ROEN) ROENHOLM H.  
 PA (ZACH) ZACHRISSON O.  
 PA (WIKS) WIKSTROM L.  
 XX Bertilsson G, Eriandsson R, Frisen J, Haegestr nd A, Heidrich J;  
 PI Hellerroem K, Haegblad J, Jansson K, Kortesmaa J, Lindquist P;  
 PI Lundh H, Mergure J, Mercer A, Njberg K, Ossolinak A, Patrone C;  
 PI Roenholm H, Zachrisson O, Wikstrom L;  
 XX WPI; 2004-449666/42.  
 XX  
 PT Use of agent(s) that elevate intracellular cyclic adenosine monophosphate  
 PT or intracellular calcium levels in neural tissue for modulating  
 PT neurogenesis to treat central nervous system disorder.  
 XX  
 PS Disclosure; SEQ ID NO 18; 77pp; English.  
 XX  
 CC This invention relates to a novel method of modulating neurogenesis in  
 CC the neural tissue of a patient exhibiting symptom(s) of a central nervous  
 CC system disorder, such as neurodegenerative, ischemic or learning and  
 CC memory disorder or neurological trauma. The method involves at least one  
 CC agent (A) that elevates intracellular cyclic adenosine monophosphate  
 CC (cAMP) levels or at least one agent (B) that elevates intracellular Ca<sup>2+</sup>  
 CC levels in the neural tissue, which is administered where (A) modulates  
 CC and (B) induces neurogenesis. The invention may be useful for the  
 CC production of compounds with a neurotropic, neuroprotective, CNS-Gen,  
 CC cerebroprotective, vasotropic, anticonvulsant, antiparkinsonian,  
 CC haemostatic, hypertensive, muscular-Gen, ophthalmological,  
 CC antiinflammatory, analgesic or antidiabetic activity. These compounds may  
 CC act as neurogenesis modulators, neural stem or progenitor cell  
 CC proliferation, differentiation and/or migration modulators, neural tissue  
 CC G-protein coupled receptor activators, neurogenesis inducers,  
 CC intracellular neural cAMP enhancers, intracellular neural cAMP  
 CC stimulators or intracellular neural Ca<sup>2+</sup> enhancers. The invention is  
 CC useful for modulating neurogenesis in neural tissue of a patient  
 CC exhibiting at least one symptom of central nervous system disorder, such  
 CC as Parkinson's disease and Parkinson's disorders, Huntington's disease,  
 CC Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis,  
 CC Shy-Drager syndrome, progressive supranuclear palsy, Lewy body disease,  
 CC spinal ischaemia, ischemic stroke, cerebral infarction, spinal cord  
 CC injury, cancer-related brain and spinal cord injury, multi-infarct  
 CC dementia and geriatric dementia; for increasing the intracellular levels  
 CC of or stimulating cAMP levels in a cell (preferably a cell from a neural  
 CC tissue); and for in vitro modulation of neurogenesis. The agent modulates  
 CC neurogenesis in neural tissue by modulating proliferation,  
 CC differentiation, migration or survival of neural stem cells or progenitor  
 CC cells in the tissue; by maintaining or increasing the amount or  
 CC percentage of doublecortin positive cells in the neural tissue relative  
 CC to a patient not dosed with the agent or by activation of a G-protein  
 CC coupled receptor in the neural tissue. The method results in treatment of  
 CC cAMP levels of the neural stem cells by over 20% compared to untreated  
 CC tissue. The in vivo induction of neurogenesis allows treatment of  
 CC disorders caused by cell loss, injury or disease by endogenous  
 CC replacement and obviates the need for transplanting foreign cells into a

CC patient. Neurogenesis can also be induced by administration of the  
 CC neurogenesis-modulating agent directly into a desired site, which avoids  
 CC unnecessary systemic administration and possible side effects and further  
 CC provides an alternative to the use of drugs and the controversial use of  
 CC large quantities of embryonic tissue for treatment of Parkinson's  
 CC disease. The present sequence is that of a polypeptide which has been  
 CC shown to have the ability to increase intracellular cAMP levels and which  
 CC is related to the method of the invention.  
 XX  
 XX Sequence 27 AA;  
 SQ  
 Query Match 75.0%; Score 57; DB 8; Length 27;  
 Best Local Similarity 100.0%; Pred. No. 0.0094;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 4 HQIYQPTDKD 13  
 Db 3 HQIYQPTDKD 12  
 RESULT 4  
 AAW25160  
 ID AAW25160 standard; peptide; 31 AA.  
 XX  
 AC AAW25160;  
 XX  
 DT 08-DEC-1997 (first entry)  
 XX  
 DE Human preproadrenomedullin derived immunogen, P072.  
 XX  
 KW Adrenomedullin; antibody; detection; diagnosis; cancer; renal; bone;  
 KW skin; blood related; disease; type II diabetes; preclampsia;  
 KW neurotransmission regulation; allergy; mast cell degranulation;  
 KW antibacterial; antifungal; wound repair.  
 XX  
 OS Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FT Peptide 1..31  
 FT Modified-site /note= "residues 116-146 of preproadrenomedullin"  
 FT 31  
 FT /note= "amidated"  
 XX  
 PN M09707214-A1.  
 XX  
 PD 27-FEB-1997.  
 XX  
 PF 16-AUG-1996; 96WC-US013286.  
 XX  
 PR 18-AUG-1995; 95US-0002514P.  
 PR 30-AUG-1995; 95US-0002916P.  
 PR 12-MAR-1996; 96US-0013172P.  
 XX  
 PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.  
 XX  
 PI Cuttitta F, Martinez A, Miller MJ, Unsworth EJ, Hook W, Walsh T;  
 PI Gray K, Macri C;  
 XX  
 WPI; 1997-165298/15.  
 DR  
 XX Human adrenomedullin peptide(s), P070, P071, P072 and PAMP-20 - used in  
 PT the diagnosis and treatment of type II diabetes and cancer.  
 PT  
 PS Claim 1; Page 43; 106pp; English.  
 XX  
 CC Human adrenomedullin (AM) peptides P070, P071, P072 and PAMP-20 were used  
 CC for the production of anti-AM antibodies (Ab). P070 represents preproAM  
 CC amino acids (aa) 34-41 with the sequence Tyr-Tyr attached at the N-  
 CC terminus, P071 represents preproAM aa 122-131 with the sequence Tyr-Gly-  
 CC Gly attached at the N-terminus, P072 represents preproAM aa 116-146 and  
 CC PAMP-20 represents the proAM N-terminus. The Ab are useful for the  
 CC prevention and/or treatment of cancers, e.g. adrenal, nervous system,  
 CC lung, colon, ovarian and breast cancer by inhibiting cell growth. They

CC are also useful for regulating insulin secretion and blood glucose  
CC metabolism and therefore for treating and/or preventing diabetes type II.  
CC They may be used for the diagnosis or treatment of conditions relating to  
CC pregnancy e.g. preeclampsia. The Ab are also useful for the following:  
CC (i) regulating neurotransmission or neuron growth in areas of the central  
CC nervous system; (ii) lessening or inhibiting mast cell degranulation and  
CC hence reducing the effects of an allergic response; (iii) inhibiting or  
CC preventing bacterial and fungal growth (to treat infection); (iv)  
CC facilitating wound healing; and (v) promoting organ and bone development  
XX

SO Sequence 31 AA;

QY Query Match 75.0%; Score 57; DB 2; Length 31;  
Best Local Similarity 100.0%; Pred. No. 0.011;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 HQIYQFTDKD 13  
DB 7 HQIYQFTDKD 16

#### RESULT 5

ID AAB91762 standard; peptide; 31 AA.

AC AAB91762;

DT 22-JUN-2001 (first entry)

DE Adrenomedullin peptide (AM) SEQ ID NO:938.

KM Protection; endogenous therapeutic peptide; peptidase; conjugation;  
KM blood component; modification; succinimide; maleimide group; amino;  
KM hydroxyl; thiol; hormone; growth factor; neurotransmitter.

OS Homo sapiens.  
OS Synthetic.

PN WO200069900-A2.

PD 23-NOV-2000.

PF 17-MAY-2000; 2000WO-US013576.

PR 17-MAY-1999; 99US-0134406P.

PR 10-SEP-1999; 99US-0153406P.

PR 15-OCT-1999; 99US-0159783P.

PA (CONU-) CONUCHEM INC.

PI Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibaudau K;

PT WPI; 2001-112059/12.

PT Modifying and attaching therapeutic peptides to albumin prevents  
PT peptidase degradation, useful for increasing length of in vivo activity.

PS Disclosure; Page 499-500; 733pp; English.

CC The present invention describes a modified therapeutic peptide (1)  
CC comprising a therapeutically active amino acid region (III) and a  
CC reactive group (II) (e.g. succinimide and maleimide groups) attached to  
CC a less therapeutically active amino acid region (IV), which covalently  
CC bonds with amino/hydroxyl/thiol groups on blood components to form a  
CC peptidease stabilised therapeutic peptide composed of 3-50 amino acids.  
CC (1) are useful for modifying therapeutic peptides e.g. hormones, growth  
CC factors and neurotransmitters, to protect them from peptidase activity in  
CC vivo for the treatment of various disorders. Endogenous therapeutic  
CC peptides are not suitable as drug candidates as they require frequent  
CC administration due to rapid degradation by peptidases in the body.  
CC Modifying and attaching therapeutic peptides to albumin prevents or  
CC reduces the action of peptidases to increase length of activity (half  
CC life) and specificity as bonding to large molecules decreases

CC intracellular uptake and interference with physiological processes.  
CC AAB90829 to AAB92441 represent peptides which can be used in the  
CC exemplification of the present invention  
XX

SO Sequence 31 AA;

QY Query Match 75.0%; Score 57; DB 4; Length 31;  
Best Local Similarity 100.0%; Pred. No. 0.011;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 HQIYQFTDKD 13  
DB 7 HQIYQFTDKD 16

#### RESULT 6

ID AAB09827 standard; peptide; 31 AA.

AC AAB09827;

DT 29-NOV-2001 (first entry)

DE Human adrenomedullin peptide #2.

KM Human; vasoactive peptide; calcitonin gene related peptide; CGRP;  
KM CGRP-receptor identification; adrenomedullin.

OS Homo sapiens.

FT Key Location/Qualifiers  
FT Modified-site 31

FT /note="C-terminal amide"

PN US6268474-B1.

PD 31-JUL-2001.

PF 30-APR-1998; 98US-00070504.

PR 30-APR-1998; 98US-00070504.

PA (UYCR-) UNIV CREIGHTON.

PI Smith DD, Saha S, Abel PW;

PT WPI; 2001-564216/63.

PT Vasoactive peptides useful for inhibiting calcitonin gene related peptide  
PT receptor activity.

PS Claim 5; Col 6; 24pp; English.

CC The invention relates to antagonists of the vasoactive peptide calcitonin  
CC gene related peptide (CGRP) and other members of the CGRP superfamily.  
CC The invention also relates to amino the terminal modifications of  
CC peptides to improve their ability to bind to a member of the CGRP-  
CC receptor super-family. CGRP antagonists are used for inhibiting CGRP  
CC activity which can be used in vitro e.g. in assays to identify and/or  
CC isolate CGRP receptors or with intact cells either in vitro or in vivo to  
CC inhibit the effect of CGRP binding to its receptor. The present sequence  
CC is human adrenomedullin peptide  
XX

SO Sequence 31 AA;

QY Query Match 75.0%; Score 57; DB 4; Length 31;  
Best Local Similarity 100.0%; Pred. No. 0.011;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 HQIYQFTDKD 13  
DB 7 HQIYQFTDKD 16

RESULT 7  
ID ADC25153 standard; peptide; 31 AA.  
AC  
XX ADC25153;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE Human angiogenesis inhibiting peptide #SEQ ID 2.  
XX  
XX Cytostatic; gene therapy; cancer; stomach; colon; pulmonary; ovarian;  
KM liver; pancreatic; human.  
XX  
OS Homo sapiens.  
XX  
PN MO2003078460-A1.  
XX  
PD 25-SEP-2003.  
XX  
PF 19-MAR-2003; 2003MO-JF003344.  
XX  
PR 19-MAR-2002; 2002JP-00075575.  
XX  
PA (HOKK-) HOKKAIDO TECHNOLOGY LICENSING OFFICE CO.  
XX  
PI Kobayashi M;  
XX  
DR WPI; 2003-767505/72.  
XX  
PT Peptides with effect on inhibiting angiogenesis in cancer cells and  
XX inhibiting proliferation of cancer cells, and encoded polynucleotides,  
PT applicable in drug compositions for treating cancer.  
XX  
XX Example 2; SEQ ID NO 2; 41bp; Japanese.  
XX  
PS The invention relates to peptide comprising an amino acid sequence  
CC derived from a fully defined 52 amino acid sequence (SI) given in the  
CC specification. Peptides may be created by deletion of some amino acids  
CC from the N-terminal of SI. The peptides are applicable in drug  
CC compositions for treating cancer e.g. stomach cancer, colon cancer,  
CC pulmonary cancer, ovarian cancer, liver cancer or pancreatic cancer. The  
CC current sequence represents an angiogenesis inhibiting peptide of the  
CC invention.  
XX  
SQ Sequence 31 AA;  
XX  
Query Match 75.0%; Score 57; DB 7; Length 31;  
Best Local Similarity 100.0%; Pred. No. 0.011;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 4 HQIYQFTDKD 13  
Db 7 HQIYQFTDKD 16  
RESULT 8  
ADP18403  
ID ADP18403 standard; peptide; 31 AA.  
XX  
XX ADP18403;  
XX  
DT 26-AUG-2004 (first entry)  
XX  
DE Neurogenesis modulation-related peptide SeqID17.  
XX  
XX neurogenesis modulation; neural tissue; central nervous system disorder;  
KM neurodegenerative; ischemic; learning and memory disorder;  
KM neurological trauma; nootropic; neuroprotective; CNS-Gen;  
KM cerebroprotective; vasotropic; anticonvulsant; antiparkinsonian;  
KM haemostatic; hypertensive; muscular-Gen; ophthalmological;  
KM antiinflammatory; analgesic; antidiabetic; neurogenesis modulator;  
KM neural stem cell; progenitor cell;

KM neural tissue G-protein coupled receptor activator; neurogenesis inducer;  
KM intracellular neural Ca 2+ enhancer; intracellular neural CAMP stimulator;  
KM Parkinson's disorder; Huntington's disease; Alzheimer's disease;  
KM multiple sclerosis; amyotrophic lateral sclerosis; Shy-Drager syndrome;  
KM progressive supranuclear palsy; Lewy body disease; spinal ischaemia;  
KM ischaemic stroke; cerebral infarction; spinal cord injury;  
KM cancer-related brain; spinal cord injury; multi-infarct dementia;  
KM geriatric dementia; CAMP level; embryonic tissue; human.  
XX  
OS Homo sapiens.  
XX  
PN MO2004045592-A2.  
XX  
PD 03-JUN-2004.  
XX  
PF 20-NOV-2003; 2003MO-IB005311.  
XX  
PR 20-NOV-2002; 2002US-0427912P.  
XX  
PA (NEUR-) NEURONOVA AB.  
PA (BERT) BERTILSSON G.  
PA (ERLA) ERLANDSSON R.  
PA (FRIS) FRISSEN J.  
PA (HAEG) HAEGSTRAND A.  
PA (HEID) HEIDRICH J.  
PA (HELL) HELSTROM K.  
PA (HAEG) HAEGGBLAD J.  
PA (JANS) JANSSEN K.  
PA (KORT) KORTESMAA J.  
PA (LUND) LINDQUIST P.  
PA (LUND) LUNDH H.  
PA (MCGU) MCGUIRE J.  
PA (MERC) MERCER A.  
PA (NJBK) NJBERG K.  
PA (OSSO) OSSOINAK A.  
PA (PATR) PATRONE C.  
PA (ROEN) ROENNHOLM H.  
PA (ZACH) ZACHRISSON O.  
PA (WIKS) WIKSTROM L.  
XX  
PI Bertilsson G, Erlandsson R, Frissen J, Haegstrand A, Heidrich J;  
PI Helstrom K, Haegblad J, Jansson K, Kortesmaa J, Lindquist P;  
PI Lundh H, McGuire J, Mercer A, Njberg K, Ossoinak A, Patrone C;  
PI Roennholm H, Zachrisson O, Wikstrom L;  
XX  
DR WPI; 2004-44966/42.  
XX  
PT Use of agent(s) that elevate intracellular cyclic adenosine monophosphate  
PT or intracellular calcium levels in neural tissue for modulating  
PT neurogenesis to treat central nervous system disorder.  
XX  
XX Disclosure; SEQ ID NO 17; 77bp; English.  
XX  
CC This invention relates to a novel method of modulating neurogenesis in  
CC the neural tissue of a patient exhibiting symptom(s) of a central nervous  
CC system disorder, such as neurodegenerative, ischemic or learning and  
CC memory disorder or neurological trauma. The method involves at least one  
CC agent (A) that elevates intracellular cyclic adenosine monophosphate  
CC (cAMP) levels or at least one agent (B) that elevates intracellular Ca 2+  
CC levels in the neural tissue, which is administered where (A) modulates  
CC and (B) induces neurogenesis. The invention may be useful for the  
CC production of compounds with a nootropic, neuroprotective, CNS-Gen,  
CC cerebroprotective, vasotropic, anticonvulsant, antiparkinsonian,  
CC haemostatic, hypertensive, muscular-Gen, ophthalmological,  
CC antiinflammatory, analgesic or antidiabetic activity. These compounds may  
CC act as neurogenesis modulators, neural stem or progenitor cell  
CC proliferation, differentiation and/or migration modulators, neural tissue  
CC G-protein coupled receptor activators, neurogenesis inducers,  
CC intracellular neural CAMP enhancers, intracellular neural CAMP  
CC stimulators or intracellular neural Ca 2+ enhancers. The invention is  
CC useful for modulating neurogenesis in neural tissue of a patient  
CC exhibiting at least one symptom of central nervous system disorder, such

CC as Parkinson's disease and Parkinson's disorders, Huntington's disease,  
 CC Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis,  
 CC Shy-Drager syndrome, progressive supranuclear palsy, Lewy body disease,  
 CC spinal ischemia, ischemic stroke, cerebral infarction, spinal cord  
 CC injury, cancer-related brain and spinal cord injury, multi-infarct  
 CC dementia and geriatric dementia; for increasing the intracellular levels  
 CC of or stimulating cAMP levels in a cell (preferably a cell from a neural  
 CC tissue); and for in vitro modulation of neurogenesis. The agent modulates  
 CC neurogenesis in neural tissue by modulating proliferation,  
 CC differentiation, migration or survival of neural stem cells or progenitor  
 CC cells in the tissue; by maintaining or increasing the amount or  
 CC percentage of doublecortin positive cells in the neural tissue relative  
 CC to a patient not dosed with the agent or by activation of a G-protein  
 CC coupled receptor in the neural tissue. The method results in elevation of  
 CC cAMP levels of the neural stem cells by over 20% compared to untreated  
 CC tissue. The in vivo induction of neurogenesis allows treatment of  
 CC disorders caused by cell loss, injury or disease by endogenous  
 CC replacement and obviates the need for transplanting foreign cells into a  
 CC patient. Neurogenesis can also be induced by administration of the  
 CC neurogenesis-modulating agent directly into a desired site, which avoids  
 CC unnecessary systemic administration and possible side effects and further  
 CC provides an alternative to the use of drugs and the controversial use of  
 CC large quantities of embryonic tissue for treatment of Parkinson's  
 CC disease. The present sequence is that of a polypeptide which has been  
 CC shown to have the ability to increase intracellular cAMP levels and which  
 CC is related to the method of the invention.

CC  
 XX  
 SQ Sequence 31 AA;

Query Match 75.0%; Score 57; DB 8; Length 31;  
 Best Local Similarity 100.0%; Pred. No. 0.011,  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 HQIYQFTDKD 13  
 |||||  
 Db 7 HQIYQFTDKD 16

RESULT 9  
 AAB91768  
 ID AAB91768 standard; peptide; 40 AA.

AC AAB91768;  
 DT 22-JUN-2001 (first entry)  
 XX  
 DE Adrenomedullin peptide (AM) SEQ ID NO:944.

KW Protection; endogenous therapeutic peptide; peptidase; conjugation;  
 KW blood component; modification; succinimide; maleimido group; amino;  
 KW hydroxyl; thiol; hormone; growth factor; neurotransmitter.

OS Homo sapiens.  
 OS Synthetic.

PN WO200069900-A2.

PD 23-NOV-2000.

PP 17-MAY-2000; 2000WO-US013576.

PR 17-MAY-1999; 99US-0134406P.

PR 10-SEP-1999; 99US-0153406P.

PR 15-OCT-1999; 99US-0159783P.

XX (CONJ-) CONJUCHEM INC.

PI Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibaudau K,

XX WPI; 2001-112059/12.  
 DR  
 XX  
 PT Modifying and attaching therapeutic peptides to albumin prevents  
 PT peptidase degradation, useful for increasing length of in vivo activity.

XX  
 PS Disclosure; Page 502; 733p; English.

XX The present invention describes a modified therapeutic peptide (I)  
 CC comprising a therapeutically active amino acid region (III) and a  
 CC reactive group (II) (e.g. succinimide and maleimido groups) attached to  
 CC a less therapeutically active amino acid region (IV), which covalently  
 CC bonds with amino/hydroxyl/thiol groups on blood components to form a  
 CC peptide stabilized therapeutic peptide composed of 3-50 amino acids.  
 CC (I) are useful for modifying therapeutic peptides e.g. hormones, growth  
 CC factors and neurotransmitters, to protect them from peptidase activity in  
 CC vivo for the treatment of various disorders. Endogenous therapeutic  
 CC peptides are not suitable as drug candidates as they require frequent  
 CC administration due to rapid degradation by peptidases in the body.  
 CC Modifying and attaching therapeutic peptides to albumin prevents or  
 CC reduces the action of peptidases to increase length of activity (half  
 CC life) and specifically as bonding to large molecules decreases  
 CC intracellular uptake and interference with physiological processes.  
 CC AAB90829 to AAB92441 represent peptides which can be used in the  
 CC exemplification of the present invention

SQ Sequence 40 AA;

Query Match 75.0%; Score 57; DB 4; Length 40;  
 Best Local Similarity 100.0%; Pred. No. 0.014,  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 HQIYQFTDKD 13  
 |||||  
 Db 16 HQIYQFTDKD 25

RESULT 10  
 AAE09819  
 ID AAE09819 standard; peptide; 50 AA.

AC AAE09819;

DT 29-NOV-2001 (first entry)

XX  
 DB Rat adrenomedullin peptide.

KW Rat; vasoactive peptide; calcitonin gene related peptide; CGRP;  
 KW CGRP-receptor identification; adrenomedullin.

OS Rattus sp.

PN US6268474-B1.

PD 31-JUL-2001.

PP 30-APR-1998; 98US-00070504.

PR 30-APR-1998; 98US-00070504.

XX (UYCR-) UNIV CREIGHTON.

PI Smith DP, Saha S, Abel PW;

XX WPI; 2001-564216/63.

PT Vasoactive peptides useful for inhibiting calcitonin gene related peptide  
 PT receptor activity.

PS Claim 5; Col 25-26; 24pp; English.

XX The invention relates to antagonists of the vasoactive peptide calcitonin  
 CC gene related peptide (CGRP) and other members of the CGRP superfamily.  
 CC The invention also relates to amino the terminal modifications of  
 CC peptides to improve their ability to bind to a member of the CGRP-  
 CC receptor super-family. CGRP antagonists are used for inhibiting CGRP  
 CC activity which can be used in vitro e.g. in assays to identify and/or  
 CC isolate CGRP receptors or with intact cells either in vitro or in vivo to

CC inhibit the effect of CGRP binding to its receptor. The present sequence  
CC is rat adrenomedullin peptide  
XX  
SQ Sequence 50 AA;

Query Match 75.0%; Score 57; DB 4; Length 50;  
Best Local Similarity 100.0%; Pred. No. 0.019;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 HQIYQFTDKD 13  
|||  
DB 26 HQIYQFTDKD 35

## RESULT 11

ADE51616  
ID ADE51616 standard; protein; 50 AA.

AC ADE51616;

DT 29-JUN-2004 (first entry)

DE Adrenomedullin protein #2.

KM vasoactive; calcitonin gene related peptide; CGRP; migraine; diabetes;

KM sepsis; inflammation; cardiac disorder; vasodilator; adrenomedullin; rat.

OS Rattus sp.

PN US2002068814-A1.

PD 06-JUN-2002.

PF 20-MAR-2001; 2001US-00813345.

PR 30-APR-1998; 98US-00070504.

PA (UYCR-) UNIV CREIGHTON.

PI Smith DD, Saha S, Abel FW;

DR WPI; 2003-874533/81.

PT New modified vasoactive calcitonin related gene peptides (CGRP), useful  
PT in the treatment of migraines and cardiac disorders, and in the  
PT identification of CGRP antagonists.

PS Claim 7; SEQ ID NO 15; 26pp; English.

CC The invention relates to a new modified vasoactive peptide. The  
CC vasoactive peptides are useful in inhibiting calcitonin gene related  
CC peptide CGRP binding to one or more receptors, identifying CGRP  
CC antagonists, and identifying a CGRP receptor in a cell. The peptides are  
CC also useful in treating migraine, diabetes, sepsis, inflammation, cardiac  
CC disorders, and acts as a potent vasodilator. The present sequence  
CC represents the amino acid sequence of an adrenomedullin protein.

XX  
SQ Sequence 50 AA;

Query Match 75.0%; Score 57; DB 7; Length 50;  
Best Local Similarity 100.0%; Pred. No. 0.019;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 HQIYQFTDKD 13  
|||  
DB 26 HQIYQFTDKD 35

## RESULT 12

AAB91765  
ID AAB91765 standard; peptide; 52 AA.

AC AAB91765;

XX 22-JUN-2001 (first entry)

DE Adrenomedullin peptide (AM) SEQ ID NO:941.

KM Protection; endogenous therapeutic peptide; peptidase; conjugation;  
KM blood component; modification; succinimide; maleimido group; amino;  
KM hydroxyl; thiol; hormone; growth factor; neurotransmitter.

OS Homo sapiens.

OS Synthetic.

PN WO200069900-A2.

PD 23-NOV-2000.

PF 17-MAY-2000; 2000WO-US013576.

PR 17-MAY-1999; 99US-0134406P.

PR 10-SEP-1999; 99US-0153406P.

PR 15-OCT-1999; 99US-0159783P.

PA (CONU-) CONUTCHEM INC.

PI Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibaudau K;

DR WPI; 2001-112059/12.

PT Modifying and attaching therapeutic peptides to albumin prevents  
PT peptidase degradation, useful for increasing length of in vivo activity.

XX Disclosure; Page 501; 733pp; English.

CC The present invention describes a modified therapeutic peptide (I)  
CC comprising a therapeutically active amino acid region (III) and a  
CC reactive group (II) (e.g. succinimide and maleimido groups) attached to  
CC a less therapeutically active amino acid region (IV), which covalently  
CC bonds with amino/hydroxyl/thiol groups on blood components to form a  
CC peptidease stabilised therapeutic peptide composed of 3-50 amino acids.  
CC (1) are useful for modifying therapeutic peptides e.g. hormones, growth  
CC factors and neurotransmitters, to protect them from peptidase activity in  
CC vivo for the treatment of various disorders. Endogenous therapeutic  
CC peptides are not suitable as drug candidates as they require frequent  
CC administration due to rapid degradation by peptidases in the body.  
CC Modifying and attaching therapeutic peptides to albumin prevents or  
CC reduces the action of peptidases to increase length of activity (half  
CC life) and specifically as bonding to large molecules decreases  
CC intracellular uptake and interference with physiological processes.  
CC AAB90829 to AAB92441 represent peptides which can be used in the  
CC exemplification of the present invention

XX  
SQ Sequence 52 AA;

Query Match 75.0%; Score 57; DB 4; Length 52;  
Best Local Similarity 100.0%; Pred. No. 0.019;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 HQIYQFTDKD 13  
|||  
DB 27 HQIYQFTDKD 36

## RESULT 13

AAB91759  
ID AAB91759 standard; peptide; 52 AA.

AC AAB91759;

DT 22-JUN-2001 (first entry)

DE Adrenomedullin peptide (AM) SEQ ID NO:935.

KM Protection; endogenous therapeutic peptide; peptidase; conjugation;

KM blood component; modification; succinimideyl; maleimido group; amino;  
 KW hydroxyl; thiol; hormone; growth factor; neurotransmitter.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 PN WO200069900-A2.  
 XX  
 PD 23-NOV-2000.  
 XX  
 PF 17-MAY-2000; 2000MO-US013576.  
 XX  
 PR 17-MAY-1999; 99US-0134406P.  
 PR 10-SEP-1999; 99US-0153406P.  
 PR 15-OCT-1999; 99US-0159783P.  
 XX  
 PA (CONJ-) CONJUCHEM INC.  
 XX  
 PI Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibaudau K;  
 XX  
 DR WPI; 2001-112059/12.  
 XX  
 PT Modifying and attaching therapeutic peptides to albumin prevents  
 PT peptidase degradation, useful for increasing length of in vivo activity.  
 XX  
 PS Disclosure; Page 498; 733pp; English.  
 XX  
 SQ The present invention describes a modified therapeutic peptide (I)  
 CC comprising a therapeutically active amino acid region (III) and a  
 CC reactive group (II) (e.g. succinimideyl and maleimido groups) attached to  
 CC a less therapeutically active amino acid region (IV), which covalently  
 CC bonds with amino/hydroxyl/thiol groups on blood components to form a  
 CC peptide stabilised therapeutic peptide composed of 3-50 amino acids.  
 CC (I) are useful for modifying therapeutic peptides e.g. hormones, growth  
 CC factors and neurotransmitters, to protect them from peptidase activity in  
 CC vivo for the treatment of various disorders. Endogenous therapeutic  
 CC peptides are not suitable as drug candidates as they require frequent  
 CC administration due to rapid degradation by peptidases in the body.  
 CC Modifying and attaching therapeutic peptides to albumin prevents or  
 CC reduces the action of peptidases to increase length of activity (half  
 CC life) and specifically as bonding to large molecules decreases  
 CC intracellular uptake and interference with physiological processes.  
 CC AAB90829 to AAB92441 represent peptides which can be used in the  
 CC exemplification of the present invention  
 CC  
 XX  
 SQ Sequence 52 AA;  
 XX  
 Query Match 75.0%; Score 57; DB 4; Length 52;  
 Best Local Similarity 100.0%; Pred. No. 0.019;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 4 HQIYQFTDKD 13  
 |||||  
 DB 28 HQIYQFTDKD 37  
 XX  
 RESULT 14  
 AAB75110  
 ID AAB75110 standard; protein; 52 AA.  
 XX  
 AC AAB75110;  
 XX  
 DT 31-JUL-2001 (first entry)  
 XX  
 DE Human adrenomedullin (AM) protein.  
 XX  
 KW Adrenomedullin; glycine extended adrenomedullin; AM; AM-gly;  
 KW adrenomedullin precursor; fusion protein; pharmaceutical; diagnostic.  
 XX  
 OS Homo sapiens.  
 OS  
 PN WO200127310-A1.  
 XX

PD 19-APR-2001.  
 XX  
 XX 10-OCT-2000; 2000MO-JP007023.  
 PF  
 XX  
 PR 15-OCT-1999; 99JP-00294147.  
 PR  
 XX (SHIO) SHIONOGI & CO LTD.  
 PA  
 XX Takimoto A, Mitsuda Y, Nakayama T, Mitsuishima K;  
 PI  
 XX  
 DR WPI; 2001-282044/29.  
 DR N-PSDB; AAH19806.  
 XX  
 XX  
 PT Producing adrenomedullin useful for pharmaceutical and diagnostic  
 PT application comprises producing fused adrenomedullin precursor using a  
 PT recombinant host.  
 XX  
 PS Disclosure; Page 45; 75pp; Japanese.  
 XX  
 SQ The present invention describes a method (M1) for producing  
 CC adrenomedullin precursor. The method comprises: (a) producing the fused  
 CC protein using a recombinant host cell; (b) restricted digestion of the  
 CC fused protein by a protease followed by collection of sediment; and (c)  
 CC dissolving the sediment and extracting adrenomedullin precursor. The  
 CC method can be used for the production of adrenomedullin precursor for  
 CC pharmaceutical and diagnostic applications. AAH19806 to AAH19866 and  
 CC AAB75110 to AAB75124 represent sequences which are used in the  
 CC exemplification of the present invention  
 CC  
 XX  
 SQ Sequence 52 AA;  
 XX  
 Query Match 75.0%; Score 57; DB 4; Length 52;  
 Best Local Similarity 100.0%; Pred. No. 0.019;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 4 HQIYQFTDKD 13  
 |||||  
 DB 28 HQIYQFTDKD 37  
 XX  
 RESULT 15  
 AAB09818  
 ID AAB09818 standard; peptide; 52 AA.  
 XX  
 AC AAB09818;  
 XX  
 DT 29-NOV-2001 (first entry)  
 XX  
 DE Human adrenomedullin peptide #1.  
 XX  
 KW Human; vasoactive peptide; calcitonin gene related peptide; CGRP;  
 KW CGRP-receptor identification; adrenomedullin.  
 XX  
 OS Homo sapiens.  
 OS  
 PN US6268474-B1.  
 PN  
 PD 31-JUL-2001.  
 XX  
 PF 30-APR-1998; 98US-00070504.  
 XX  
 PR 30-APR-1998; 98US-00070504.  
 PR  
 XX (UYCR-) UNIV CREIGHTON.  
 PA  
 XX Smith DD, Saha S, Abel PW;  
 PI  
 DR WPI; 2001-564216/63.  
 DR  
 XX Vasoactive peptides useful for inhibiting calcitonin gene related peptide  
 PT receptor activity.  
 PT  
 PS Claim 5; Col 25-26; 24pp; English.  
 PS

XX The invention relates to antagonists of the vasoactive peptide calcitonin  
CC gene related peptide (CGRP) and other members of the CGRP superfamily.  
CC The invention also relates to amino the terminal modifications of  
CC peptides to improve their ability to bind to a member of the CGRP-  
CC receptor super-family. CGRP antagonists are used for inhibiting CGRP  
CC activity which can be used in vitro e.g. in assays to identify and/or  
CC isolate CGRP receptors or with intact cells either in vitro or in vivo to  
CC inhibit the effect of CGRP binding to its receptor. The present sequence  
XX is human adrenomedullin peptide  
SQ Sequence 52 AA;

Query Match 75.0%; Score 57; DB 4; Length 52;  
Best Local Similarity 100.0%; Pred. No. 0.019;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 4 HQIYQFTDKD 13  
Db 28 HQIYQFTDKD 37

Search completed: January 5, 2005, 08:49:13  
Job time : 69.0682 secs

**This Page Blank (uspto)**



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 5, 2005, 08:39:22 ; Search time 10.0455 Seconds  
(Without alignments)  
85.823 Million cell updates/sec

Title: US-09-931-700-2

Sequence: 1 YGHHQYQFTDKD 13

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 478139 seqs, 66318000 residues

Total number of hits satisfying chosen parameters: 478139

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%  
Listing first 45 summaries

Database :

1: Issued Patents AA:  
2: /cgn2\_6/ptodata/1/1aa/5A COMB.pep.\*  
3: /cgn2\_6/ptodata/1/1aa/6A COMB.pep.\*  
4: /cgn2\_6/ptodata/1/1aa/6B COMB.pep.\*  
5: /cgn2\_6/ptodata/1/1aa/PTUS COMB.pep.\*  
6: /cgn2\_6/ptodata/1/1aa/backfile1.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	76	100.0	13	3	US-09-011-922A-2
2	57	75.0	13	4	US-09-280-501-15
3	57	75.0	26	4	US-09-280-501-1
4	57	75.0	27	4	US-09-280-501-2
5	57	75.0	28	4	US-09-280-501-3
6	57	75.0	29	4	US-09-280-501-4
7	57	75.0	30	4	US-09-280-501-5
8	57	75.0	31	3	US-09-070-504-23
9	57	75.0	31	3	US-09-011-922A-3
10	57	75.0	31	3	US-09-011-922A-14
11	57	75.0	31	4	US-09-280-501-9
12	57	75.0	31	4	US-09-813-345C-23
13	57	75.0	38	4	US-09-280-501-6
14	57	75.0	40	4	US-09-280-501-8
15	57	75.0	40	4	US-09-280-501-11
16	57	75.0	50	3	US-09-070-504-15
17	57	75.0	50	4	US-09-280-501-7
18	57	75.0	50	4	US-09-813-345C-15
19	57	75.0	52	3	US-09-070-504-14
20	57	75.0	52	4	US-09-813-345C-14
21	57	75.0	185	1	US-08-233-389C-1
22	57	75.0	185	2	US-08-801-863-1
23	57	75.0	185	2	US-08-486-596A-1
24	57	75.0	185	2	US-09-004-713-1
25	57	75.0	188	1	US-08-233-389C-3
26	57	75.0	188	2	US-08-801-863-3
27	57	75.0	188	2	US-08-486-596A-3

28	57	75.0	188	2	US-09-004-713-3	Sequence 3, Appl1
29	44	57.9	70	4	US-09-280-501-17	Sequence 17, Appl1
30	44	57.9	73	4	US-09-248-796A-21094	Sequence 21094, A
31	44	57.9	514	4	US-09-265-965-116	Sequence 116, App
32	41	53.9	264	4	US-09-252-991A-19737	Sequence 19737, A
33	41	53.9	317	4	US-09-634-238-241	Sequence 241, App
34	41	53.9	519	4	US-08-956-171B-5230	Sequence 5230, Ap
35	41	53.9	519	4	US-08-781-986A-5230	Sequence 5230, Ap
36	40	52.6	157	4	US-09-252-991A-25900	Sequence 25900, A
37	39	51.3	433	4	US-09-252-991A-21838	Sequence 21838, A
38	39	51.3	686	3	US-09-368-169-8	Sequence 8, Appl1
39	38.5	50.7	374	3	US-09-306-881-2	Sequence 2, Appl1
40	38.5	50.7	396	4	US-09-107-532A-5962	Sequence 5962, Ap
41	38	50.0	370	4	US-09-134-000C-4746	Sequence 4746, Ap
42	38	50.0	408	4	US-09-270-767-60172	Sequence 60172, A
43	38	50.0	418	4	US-09-107-532A-6073	Sequence 6073, Ap
44	38	50.0	586	4	US-09-583-110-3470	Sequence 3470, Ap
45	38	50.0	598	4	US-09-270-767-44718	Sequence 44718, A

#### ALIGNMENTS

RESULT 1  
US-09-011-922A-2  
; Sequence 2, Application US/09011922A  
; Patent No. 6320022  
; GENERAL INFORMATION:  
; APPLICANT: Cuttitta, Frank; Martinez,  
; APPLICANT: Alfredo; Miller, Mae Jean; Unsworth, Edward  
; APPLICANT: J. Hook, William; Walsh, Thomas; Grey,  
; APPLICANT: Karen; Macri, Charles  
; TITLE OF INVENTION: Functional Role of  
; TITLE OF INVENTION: Adrenomedullin (AM) and the Gene-Related  
; TITLE OF INVENTION: Product (PMP) in Human Pathology and  
; NUMBER OF SEQUENCES: 17  
; CORRESPONDENCE ADDRESS:  
; ADDRESS: MORAN & FINNEGAN, L.L.P.  
; STREET: 345 Park Avenue  
; CITY: New York  
; STATE: NY  
; COUNTRY: USA  
; ZIP: 10154-0053  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy Disk  
; OPERATING SYSTEM: MS WORD 97  
; SOFTWARE: ASCII  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/011,922A  
; FILING DATE: 17-Feb-1998  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/60/002,514  
; FILING DATE: 18-Aug-1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/60/002,936  
; FILING DATE: 30-Aug-1995  
; APPLICATION NUMBER: US/60/013,172  
; FILING DATE: 12-Mar-1996  
; PRIOR APPLICATION DATA: PCT/US96/13286  
; FILING DATE: 16-Aug-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Leslie A. Semanlan  
; REGISTRATION NUMBER: 35,353  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212) 758-4800  
; TELEFAX: (212) 751-6849  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:

```

; LENGTH: 13 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHEICAL: No
; FEATURE:
; NAME/KEY: P071
; OTHER INFORMATION: YGG-PreproAM (122-131)
US-09-011-922A-2
```

```
Query Match          100.0%; Score 76; DB 3; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e-06;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1 YGGHQIYQFTDKD 13
         |||||
Db      1 YGGHQIYQFTDKD 13
```

```
RESULT 2
US-09-280-501-15
; Sequence 15, Application US/09280501
; Patent No. 6440421
; GENERAL INFORMATION:
; APPLICANT: Cooper, Garth James Smith
; APPLICANT: Reid, Ian Reginald
; APPLICANT: Cornish, Jillian
; TITLE OF INVENTION: TREATMENT OF BONE DISORDERS WITH
; FILE REFERENCE: 08987-005001
; CURRENT APPLICATION NUMBER: US/09/280,501
; PRIOR FILING DATE: 1999-03-30
; PRIOR APPLICATION NUMBER: 08/634,562
; PRIOR FILING DATE: 1996-04-18
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 13
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-280-501-15
```

```
Query Match          75.0%; Score 57; DB 4; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.0023;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      4 HQIYQFTDKD 13
         |||||
Db      1 HQIYQFTDKD 10
```

```
RESULT 3
US-09-280-501-1
; Sequence 1, Application US/09280501
; Patent No. 6440421
; GENERAL INFORMATION:
; APPLICANT: Cooper, Garth James Smith
; APPLICANT: Reid, Ian Reginald
; APPLICANT: Cornish, Jillian
; TITLE OF INVENTION: TREATMENT OF BONE DISORDERS WITH
; FILE REFERENCE: 08987-005001
; CURRENT APPLICATION NUMBER: US/09/280,501
; CURRENT FILING DATE: 1999-03-30
; PRIOR APPLICATION NUMBER: 08/634,562
; PRIOR FILING DATE: 1996-04-18
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 26
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-280-501-1
```

```
Query Match          75.0%; Score 57; DB 4; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.0049;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      4 HQIYQFTDKD 13
         |||||
Db      2 HQIYQFTDKD 11
```

```
RESULT 4
US-09-280-501-2
; Sequence 2, Application US/09280501
; Patent No. 6440421
; GENERAL INFORMATION:
; APPLICANT: Cooper, Garth James Smith
; APPLICANT: Reid, Ian Reginald
; APPLICANT: Cornish, Jillian
; TITLE OF INVENTION: TREATMENT OF BONE DISORDERS WITH
; FILE REFERENCE: 08987-005001
; CURRENT APPLICATION NUMBER: US/09/280,501
; CURRENT FILING DATE: 1999-03-30
; PRIOR APPLICATION NUMBER: 08/634,562
; PRIOR FILING DATE: 1996-04-18
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 27
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-280-501-2
```

```
Query Match          75.0%; Score 57; DB 4; Length 27;
Best Local Similarity 100.0%; Pred. No. 0.0051;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      4 HQIYQFTDKD 13
         |||||
Db      3 HQIYQFTDKD 12
```

```
RESULT 5
US-09-280-501-3
; Sequence 3, Application US/09280501
; Patent No. 6440421
; GENERAL INFORMATION:
; APPLICANT: Cooper, Garth James Smith
; APPLICANT: Reid, Ian Reginald
; APPLICANT: Cornish, Jillian
; TITLE OF INVENTION: TREATMENT OF BONE DISORDERS WITH
; FILE REFERENCE: 08987-005001
; CURRENT APPLICATION NUMBER: US/09/280,501
; CURRENT FILING DATE: 1999-03-30
; PRIOR APPLICATION NUMBER: 08/634,562
; PRIOR FILING DATE: 1996-04-18
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 28
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-280-501-3
```

```
Query Match          75.0%; Score 57; DB 4; Length 28;
Best Local Similarity 100.0%; Pred. No. 0.0053;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      4 HQIYQFTDKD 13
         |||||
Db      4 HQIYQFTDKD 13
```

```

RESULT 6
US-09-280-501-4
; Sequence 4, Application US/09280501
; Patent No. 6440421
; GENERAL INFORMATION:
; APPLICANT: Cooper, Garth James Smith
; APPLICANT: Reid, Ian Reginald
; APPLICANT: Cornish, Jillian
; TITLE OF INVENTION: TREATMENT OF BONE DISORDERS WITH
; TITLE OF INVENTION: ADRENOMEDULLIN OR ADRENOMEDULLIN AGONISTS
; FILE REFERENCE: 08987-005001
; CURRENT FILING DATE: 1999-03-30
; PRIOR APPLICATION NUMBER: 08/634,562
; PRIOR FILING DATE: 1996-04-18
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-280-501-5

Query Match
Best Local Similarity 75.0%; Score 57; DB 4; Length 30;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 HQIYQFTDKD 13
|||
|||
|||
|||
|||
|||
|||
|||
|||
|||
Db 6 HQIYQFTDKD 15

RESULT 7
US-09-280-501-5
; Sequence 5, Application US/09280501
; Patent No. 6440421
; GENERAL INFORMATION:
; APPLICANT: Cooper, Garth James Smith
; APPLICANT: Reid, Ian Reginald
; APPLICANT: Cornish, Jillian
; TITLE OF INVENTION: TREATMENT OF BONE DISORDERS WITH
; TITLE OF INVENTION: ADRENOMEDULLIN OR ADRENOMEDULLIN AGONISTS
; FILE REFERENCE: 08987-005001
; CURRENT FILING DATE: 1999-03-30
; PRIOR APPLICATION NUMBER: 08/634,562
; PRIOR FILING DATE: 1996-04-18
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 30
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-280-501-5

Query Match
Best Local Similarity 75.0%; Score 57; DB 4; Length 29;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 HQIYQFTDKD 13
|||
|||
|||
|||
|||
|||
|||
|||
|||
|||
Db 5 HQIYQFTDKD 14

RESULT 8
US-09-070-504-23
; Sequence 23, Application US/09070504
; Patent No. 6268474
; GENERAL INFORMATION:
; APPLICANT: Smith, Derek D.
; APPLICANT: Saha, Shankar
; APPLICANT: Abel, Peter W.
US-09-070-504-23

Query Match
Best Local Similarity 100.0%; Score 100; DB 23; Length 100;
Matches 100; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 HQIYQFTDKD 13
|||
|||
|||
|||
|||
|||
|||
|||
|||
|||
Db 6 HQIYQFTDKD 15

```

```

1 TITLE OF INVENTION: PEPTIDE ANTAGONISTS OF CGRP-RECEPTOR
2 TITLE OF INVENTION: SUPERFAMILY AND METHODS OF USE
3 NUMBER OF SEQUENCES: 23
4
5 CORRESPONDENCE ADDRESS:
6 ADDRESSEE: Muelting, Raasch & Gebhardt, P.A.
7 STREET: 119 No. 6268474th Fourth Street
8 CITY: Minneapolis
9 STATE: MN
10 COUNTRY: USA
11 ZIP: 55401
12
13 COMPUTER READABLE FORM:
14 MEDIUM TYPE: Floppy disk
15 COMPUTER: IBM PC compatible
16 OPERATING SYSTEM: PC-DOS/MS-DOS
17 SOFTWARE: Patent Release #1.0, Version #1.30
18 CURRENT APPLICATION DATA:
19 APPLICATION NUMBER: US/09/070,504
20 FILING DATE: 30-APR-1998
21 CLASSIFICATION:
22 ATTORNEY/AGENT INFORMATION:
23 NAME: McCormack, Myra H
24 REGISTRATION NUMBER: 36,602
25 REFERENCE/DOCKET NUMBER: 180,00020101
26 TELECOMMUNICATION INFORMATION:
27 TELEPHONE: 612/305-1220
28 TELEFAX: 612/305-1228
29 INFORMATION FOR SEQ ID NO: 23:
30 SEQUENCE CHARACTERISTICS:
31 LENGTH: 31 amino acids
32 TYPE: amino acid
33 STRANDEDNESS: single
34 TOPOLOGY: linear
35 MOLECULE TYPE: peptide
36
37 US-09-070-504-23
38
39 Query Match 75.0%; Score 57; DB 3; Length 31;
40 Best Local Similarity 100.0%; Pred. No. 0.0059;
41 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0.
42
43 QY 4 HQIYQPTDKD 13
44 |||||
45 Db 7 HQIYQPTDKD 16
46
47 RESULT 9
48 US-09-011-922A-3
49 Sequence 3, Application US/09011922A
50 Patent No. 6320022
51 GENERAL INFORMATION:
52 APPLICANT: Cuticita, Frank; Martinez,
53 APPLICANT: Alfredo; Miller, Mae Jean; Unsworth, Edward
54 APPLICANT: J.; Hook, William; Walsh, Thomas; Grey,
55 APPLICANT: Karen; Macri, Charles
56 TITLE OF INVENTION: Functional Role of
57 TITLE OF INVENTION: Adrenomedullin (Am) and the Gene-Related
58 TITLE OF INVENTION: Product (PAMP) in Human Pathology and
59 NUMBER OF INVENTION: Physiology
60 NUMBER OF SEQUENCES: 17
61 CORRESPONDENCE ADDRESS:
62 ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
63 STREET: 345 Park Avenue
64 CITY: New York
65 STATE: NY
66 COUNTRY: USA
67 ZIP: 10154-0053
68 COMPUTER READABLE FORM:
69 MEDIUM TYPE: Floppy Disk
70 COMPUTER: IBM PC Compatible
71 OPERATING SYSTEM: MS WORD 97
72 SOFTWARE: ASCII
73 CURRENT APPLICATION DATA:
74 APPLICATION NUMBER: US/09/011,922A
75 FILING DATE: 17-Feb-1998

```

```
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/60/002,514
; FILING DATE: 18-Aug-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/60/002,936
; FILING DATE: 30-Aug-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/60/013,172
; FILING DATE: 12-Mar-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/13286
; FILING DATE: 16-Aug-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Leslie A. Serunian
; REGISTRATION NUMBER: 35,353
; REFERENCE/DOCKET NUMBER: 2026-4202US3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 758-4800
; TELEFAX: (212) 751-6849
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 31 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHEICAL: No
; FEATURE:
; NAME/KEY: P072
; OTHER INFORMATION: PreproAM(116-146)
US-09-011-922A-3
```

```
Query Match          75.0%; Score 57; DB 3; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.0059;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 4 HQIYOPTDKD 13
      |||||
Db 7 HQIYOPTDKD 16
```

```
RESULT 10
US-09-011-922A-14
; Sequence 14, Application US/09011922A
; Patent No. 6320022
; GENERAL INFORMATION:
; APPLICANT: Cuttitta, Frank; Martinez,
; APPLICANT: Alfredo; Miller, Mae Jean; Unsworth, Edward
; APPLICANT: J.; Hook, William; Walsh, Thomas; Grey,
; TITLE OF INVENTION: Functional Role of
; TITLE OF INVENTION: Adrenomedullin (AM) and the Gene-Related
; TITLE OF INVENTION: Product (PAMP) in Human Pathology and
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
; STREET: 345 Park Avenue
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10154-0053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: MS WORD 97
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/011,922A
; FILING DATE: 17-Feb-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/60/002,514
; FILING DATE: 18-Aug-1995
; PRIOR APPLICATION DATA:
```

```
; APPLICATION NUMBER: US/60/002,936
; FILING DATE: 30-Aug-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/60/013,172
; FILING DATE: 12-Mar-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/13286
; FILING DATE: 16-Aug-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Leslie A. Serunian
; REGISTRATION NUMBER: 35,353
; REFERENCE/DOCKET NUMBER: 2026-4202US3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 758-4800
; TELEFAX: (212) 751-6849
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 31 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHEICAL: No
; FEATURE:
; OTHER INFORMATION: Synthetic homolog of
; OTHER INFORMATION: two-thirds of the intact AM peptide
US-09-011-922A-14
```

```
Query Match          75.0%; Score 57; DB 3; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.0059;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 4 HQIYOPTDKD 13
      |||||
Db 7 HQIYOPTDKD 16
```

```
RESULT 11
US-09-280-501-9
; Sequence 9, Application US/09280501
; Patent No. 6440421
; GENERAL INFORMATION:
; APPLICANT: Cooper, Garth James Smith
; APPLICANT: Reid, Ian Reginald
; APPLICANT: Cornish, Jillian
; TITLE OF INVENTION: TREATMENT OF BONE DISORDERS WITH
; TITLE OF INVENTION: ADRENOMEDULLIN OR ADRENOMEDULLIN AGONISTS
; FILE REFERENCE: 08987-005001
; CURRENT APPLICATION NUMBER: US/09/280,501
; PRIOR FILING DATE: 1999-03-30
; PRIOR APPLICATION NUMBER: 08/634,562
; PRIOR FILING DATE: 1996-04-18
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatsSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-280-501-9
```

```
Query Match          75.0%; Score 57; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.0059;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 4 HQIYOPTDKD 13
      |||||
Db 7 HQIYOPTDKD 16
```

```
RESULT 12
US-09-813-345C-23
; Sequence 23, Application US/09813345C
; Patent No. 6756205
; GENERAL INFORMATION:
```

```

; APPLICANT: CREIGHTON UNIVERSITY
; APPLICANT: SMITH, Derek D.
; APPLICANT: SAHA, Shankar
; APPLICANT: ABEL, Peter W.
; TITLE OF INVENTION: PEPTIDE ANTAGONISTS OF CCRP-RECEPTOR SUPERFAMILY AND METHODS OF
; FILE REFERENCE: 180.00020102
; CURRENT APPLICATION NUMBER: US/09/813,345C
; CURRENT FILING DATE: 2001-03-20
; PRIOR APPLICATION NUMBER: 09/070,504
; PRIOR FILING DATE: 1998-04-30
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 23
; LENGTH: 31
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificially Synthesized Peptide
US-09-813-345C-23
```

```
Query Match          75.0%; Score 57; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.0059;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      4 HQIYQFTDKD 13
        |||||||
Db       7 HQIYQFTDKD 16
```

```

RESULT 13
US-09-280-501-6
; Sequence 6, Application US/09280501
; Patent No. 6440421
; GENERAL INFORMATION:
; APPLICANT: Cooper, Garth James Smith
; APPLICANT: Reid, Ian Reginald
; APPLICANT: Cornish, Jillian
; TITLE OF INVENTION: TREATMENT OF BONE DISORDERS WITH
; TITLE OF INVENTION: ADRENOMEDULLIN OR ADRENOMEDULLIN AGONISTS
; FILE REFERENCE: 08987-005001
; CURRENT APPLICATION NUMBER: US/09/280,501
; CURRENT FILING DATE: 1999-03-30
; PRIOR APPLICATION NUMBER: 08/634,562
; PRIOR FILING DATE: 1996-04-18
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 38
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-280-501-6
```

```
Query Match          75.0%; Score 57; DB 4; Length 38;
Best Local Similarity 100.0%; Pred. No. 0.0073;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      4 HQIYQFTDKD 13
        |||||||
Db       14 HQIYQFTDKD 23
```

```

RESULT 14
US-09-280-501-8
; Sequence 8, Application US/09280501
; Patent No. 6440421
; GENERAL INFORMATION:
; APPLICANT: Cooper, Garth James Smith
; APPLICANT: Reid, Ian Reginald
; APPLICANT: Cornish, Jillian
; TITLE OF INVENTION: TREATMENT OF BONE DISORDERS WITH
; TITLE OF INVENTION: ADRENOMEDULLIN OR ADRENOMEDULLIN AGONISTS
; FILE REFERENCE: 08987-005001
```

```

; CURRENT APPLICATION NUMBER: US/09/280,501
; CURRENT FILING DATE: 1999-03-30
; PRIOR APPLICATION NUMBER: 08/634,562
; PRIOR FILING DATE: 1996-04-18
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 40
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-280-501-8
```

```
Query Match          75.0%; Score 57; DB 4; Length 40;
Best Local Similarity 100.0%; Pred. No. 0.0077;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      4 HQIYQFTDKD 13
        |||||||
Db       18 HQIYQFTDKD 27
```

```

RESULT 15
US-09-280-501-11
; Sequence 11, Application US/09280501
; Patent No. 6440421
; GENERAL INFORMATION:
; APPLICANT: Cooper, Garth James Smith
; APPLICANT: Reid, Ian Reginald
; APPLICANT: Cornish, Jillian
; TITLE OF INVENTION: TREATMENT OF BONE DISORDERS WITH
; TITLE OF INVENTION: ADRENOMEDULLIN OR ADRENOMEDULLIN AGONISTS
; FILE REFERENCE: 08987-005001
; CURRENT APPLICATION NUMBER: US/09/280,501
; CURRENT FILING DATE: 1999-03-30
; PRIOR APPLICATION NUMBER: 08/634,562
; PRIOR FILING DATE: 1996-04-18
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 11
; LENGTH: 40
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-280-501-11
```

```
Query Match          75.0%; Score 57; DB 4; Length 40;
Best Local Similarity 100.0%; Pred. No. 0.0077;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      4 HQIYQFTDKD 13
        |||||||
Db       16 HQIYQFTDKD 25
```

```

Search completed: January 5, 2005, 08:45:18
Job time : 11.0455 secs
```

**This Page Blank (uspio)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using SW model

Run on: January 5, 2005, 08:44:46 ; Search time 229.864 Seconds  
(without alignments)  
20.344 Million cell updates/sec

Title: US-09-931-700-2

Perfect score: 76

Sequence: 1 YGHHQIYQFTDKD 13

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1599051 seqs, 359727711 residues

Total number of hits satisfying chosen parameters: 1599051

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database :

Published Applications AA:\*

- 1: /cgn2\_6/ptodata/2/pubppa/US07\_PUBCOMB.pep:\*
- 2: /cgn2\_6/ptodata/2/pubppa/PCT\_NEW\_PUB.pep:\*
- 3: /cgn2\_6/ptodata/2/pubppa/US06\_NEW\_PUB.pep:\*
- 4: /cgn2\_6/ptodata/2/pubppa/US06\_PUBCOMB.pep:\*
- 5: /cgn2\_6/ptodata/2/pubppa/US07\_NEW\_PUB.pep:\*
- 6: /cgn2\_6/ptodata/2/pubppa/PCTUS\_PUBCOMB.pep:\*
- 7: /cgn2\_6/ptodata/2/pubppa/US08\_NEW\_PUB.pep:\*
- 8: /cgn2\_6/ptodata/2/pubppa/US08\_PUBCOMB.pep:\*
- 9: /cgn2\_6/ptodata/2/pubppa/US09A\_PUBCOMB.pep:\*
- 10: /cgn2\_6/ptodata/2/pubppa/US09B\_PUBCOMB.pep:\*
- 11: /cgn2\_6/ptodata/2/pubppa/US09C\_PUBCOMB.pep:\*
- 12: /cgn2\_6/ptodata/2/pubppa/US09C\_NEW\_PUB.pep:\*
- 13: /cgn2\_6/ptodata/2/pubppa/US10\_PUBCOMB.pep:\*
- 14: /cgn2\_6/ptodata/2/pubppa/US10B\_PUBCOMB.pep:\*
- 15: /cgn2\_6/ptodata/2/pubppa/US10C\_PUBCOMB.pep:\*
- 16: /cgn2\_6/ptodata/2/pubppa/US10D\_PUBCOMB.pep:\*
- 17: /cgn2\_6/ptodata/2/pubppa/US10E\_PUBCOMB.pep:\*
- 18: /cgn2\_6/ptodata/2/pubppa/US11\_NEW\_PUB.pep:\*
- 19: /cgn2\_6/ptodata/2/pubppa/US60\_NEW\_PUB.pep:\*
- 20: /cgn2\_6/ptodata/2/pubppa/US60\_PUBCOMB.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	76	100.0	13	9	US-09-931-700-2
2	57	75.0	31	9	US-09-931-700-3
3	57	75.0	31	9	US-09-931-700-14
4	57	75.0	31	9	US-09-813-345-23
5	57	75.0	50	9	US-09-813-345-15
6	57	75.0	52	9	US-09-813-345-14
7	57	75.0	52	14	US-10-197-954-2
8	57	75.0	52	15	US-10-360-101-74
9	57	75.0	52	16	US-10-474-635A-19
10	57	75.0	185	14	US-10-364-889-6
11	57	75.0	185	15	US-10-372-683-12
12	57	75.0	185	16	US-10-675-406A-7
13	57	75.0	185	16	US-10-755-889-148

14	45	59.2	117	17	US-10-425-115-194068
15	44	57.9	157	15	US-10-424-599-207877
16	44	57.9	514	10	US-09-953-348-116
17	44	57.9	514	14	US-10-267-253-116
18	44	57.9	833	14	US-10-027-000-2
19	44	57.9	2384	15	US-10-335-977-8087
20	44	57.9	2440	15	US-10-335-977-8088
21	42	55.3	107	15	US-10-424-599-211456
22	42	55.3	324	14	US-10-369-493-16979
23	41.5	54.6	158	14	US-10-369-493-9990
24	41	53.9	181	16	US-10-767-701-59836
25	41	53.9	164	17	US-10-425-115-239182
26	41	53.9	317	15	US-10-264-213-147
27	41	53.9	519	8	US-08-781-986A-5230
28	41	53.9	519	15	US-10-329-624-5230
29	41	53.9	1234	16	US-10-437-963-137236
30	40	52.6	55	17	US-10-425-115-254064
31	40	52.6	63	17	US-10-425-115-345298
32	40	52.6	177	16	US-10-767-701-53889
33	40	52.6	261	15	US-10-335-977-7714
34	40	52.6	279	15	US-10-425-114-44570
35	40	52.6	281	15	US-10-335-977-7715
36	40	52.6	308	17	US-10-425-115-367230
37	40	52.6	593	15	US-10-425-115-43323
38	40	52.6	666	16	US-10-437-963-108953
39	40	52.6	675	15	US-10-424-599-229257
40	40	52.6	770	17	US-10-425-115-275151
41	40	52.6	952	16	US-10-437-963-115492
42	40	52.6	1849	15	US-10-276-774-2188
43	40	52.6	1905	15	US-10-259-194A-86
44	39	51.3	112	15	US-10-424-599-253952
45	39	51.3	116	15	US-10-424-599-176774

#### ALIGNMENTS

Sequence 194068,  
Sequence 207877,  
Sequence 116, App  
Sequence 116, App  
Sequence 2, Appl1  
Sequence 8087, Ap  
Sequence 8088, Ap  
Sequence 211456,  
Sequence 16979, A  
Sequence 9990, Ap  
Sequence 59836, A  
Sequence 239182,  
Sequence 147, App  
Sequence 5230, Ap  
Sequence 5230, Ap  
Sequence 137236,  
Sequence 254064,  
Sequence 345298,  
Sequence 53889, A  
Sequence 7714, Ap  
Sequence 44570, A  
Sequence 7715, Ap  
Sequence 367230,  
Sequence 43323, A  
Sequence 108953,  
Sequence 229257,  
Sequence 275151,  
Sequence 115492,  
Sequence 2188, Ap  
Sequence 86, Appl1  
Sequence 253952,  
Sequence 176774,

US-09-931-700-2  
Sequence 2, Appl1  
Patent No. US20020055615A1  
GENERAL INFORMATION:  
APPLICANT: CUTTITTA, FRANK  
APPLICANT: MARTINEZ, ALFREDO  
APPLICANT: MILLER, MAE JEAN  
APPLICANT: UNSWORTH, EDWARD J.  
APPLICANT: HOOK, WILLIAM  
APPLICANT: WALSH, THOMAS  
APPLICANT: GREY, KAREN  
APPLICANT: MACRI, CHARLES  
TITLE OF INVENTION: Functional Role of Adrenomedullin (AM) and the  
TITLE OF INVENTION: Gene-Related Product (GAMP) in Human Pathology and  
FILE REFERENCE: 2026-4202US4  
CURRENT APPLICATION NUMBER: US/09/931,700  
CURRENT FILING DATE: 2001-08-16  
PRIOR APPLICATION NUMBER: 09/011,922  
PRIOR FILING DATE: 1998-02-17  
PRIOR APPLICATION NUMBER: PCT/US96/13286  
PRIOR FILING DATE: 1996-08-16  
PRIOR APPLICATION NUMBER: US/60/013,172  
PRIOR FILING DATE: 1996-03-12  
PRIOR APPLICATION NUMBER: US60/002,936  
PRIOR FILING DATE: 1995-08-30  
PRIOR APPLICATION NUMBER: US/60/002,514  
PRIOR FILING DATE: 1995-08-18  
NUMBER OF SEQ ID NOS: 17  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 2  
LENGTH: 13  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:

US-09-931-700-2

OTHER INFORMATION: Description of Artificial Sequence: Peptide  
; OTHER INFORMATION: P071, YGG-PreproAM (amino acids 122-131)

Query Match	100.0%	Score 76;	DB 9;	Length 13;
Best Local Similarity	100.0%	Pred. No. 5.3e-06;		
Matches 13; Conservative	0;	Mismatches 0;	Indels 0;	Gaps 0;

Qy	1	YGGHQIYQFTDKD	13
Db	1	YGGHQIYQFTDKD	13

RESULT 2  
US-09-931-700-3  
; Sequence 3, Application US/09931700  
; Patent No. US20020055615A1  
; Inventor: ZURRO, JUAN

Query Match	75.0%;	Score 57;	DB 9;	Length 31,
Best Local Similarity	100.0%;	Pred. No. 0.021;		
Matches 10;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

```
QY      4 HQIYQFTDKD 13
         |||||
Db      7 HQIYQFTDKD 16
```

RESULT 3  
 US-09-931-700-14  
 ; Sequence 14, Application US/099317000  
 ; Patent No. US2002005561S.A1  
 ; GENERAL INFORMATION  
 ; APPLICANT: CUTTITTA, PSANK  
 ; APPLICANT: MARTINEZ, ALFREDO  
 ; APPLICANT: MILLER, MAE JEAN  
 ; APPLICANT: UNSWORTH, EDWARD J.  
 ; APPLICANT: HOOK, WILLIAM  
 ; APPLICANT: WALSH, THOMAS

APPLICANT: GREY, KAREN  
 APPLICANT: MACRI, CHARLES  
 TITLE OF INVENTION: Functional Role of Adrenomedullin (AM) and the  
 TITLE OF INVENTION: Gene-Related Product (PAMP) in Human Pathology and  
 TITLE OF INVENTION: Physiology  
 FILE REFERENCE: 2026-4202USA  
 CURRENT APPLICATION NUMBER: US/09/931,700  
 CURRENT FILING DATE: 2001-08-16  
 PRIOR APPLICATION NUMBER: 09/011,922  
 PRIOR FILING DATE: 1998-02-17  
 PRIOR APPLICATION NUMBER: PCT/US96/13286  
 PRIOR FILING DATE: 1996-08-16  
 PRIOR APPLICATION NUMBER: US/60/013,172  
 PRIOR FILING DATE: 1996-03-12  
 PRIOR APPLICATION NUMBER: US60/002,936  
 PRIOR FILING DATE: 1995-08-30  
 PRIOR APPLICATION NUMBER: US/60/002,514  
 PRIOR FILING DATE: 1995-08-18  
 NUMBER OF SEQ ID NOS: 17  
 SOFTWARE: PatentIn Ver. 2.1  
 SEQ ID NO 14  
 LENGTH: 31  
 TYPE: PRT  
 ORGANISM: Artificial Sequence  
 FEATURE:  
 OTHER INFORMATION: Description of Artificial Sequence: Peptide,  
 OTHER INFORMATION: Synthetic homolog of AM (P072), Structural amino  
 OTHER INFORMATION: acid sequence representing two-thirds of the  
 OTHER INFORMATION: intact AM peptide  
 US-09-931-700-14

Query Match	75.0%	Score 57	DB 9	Length 31
Similarity	100.0%	Pred. No. 0.021		
Best Local	0	Mismatches 0	Indels 0	Gaps 0
Matches 10	Conservative			

```
QY      4 HQIYQFTDKD 13
         |||||
Db      7 HQIYQFTDKD 16
```

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
84



TELEFAX: 612/305-1228  
INFORMATION FOR SEQ ID NO: 23:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 31 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
SEQUENCE DESCRIPTION: SEQ ID NO: 23:  
US-09-813-345-23

Query Match 75.0%; Score 57; DB 9; Length 31;  
Best Local Similarity 100.0%; Pred. No. 0.021;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 HOIYOPTDKD 13  
DB 7 HOIYOPTDKD 16

RESULT 5  
US-09-813-345-15  
Sequence 15, Application US/09813345  
Patent No. US20020068814A1  
GENERAL INFORMATION:  
APPLICANT: Smith, Derek D.  
Saha, Shankar  
Abel, Peter W.  
TITLE OF INVENTION: PEPTIDE ANTAGONISTS OF CGRP-RECEPTOR  
SUPERFAMILY AND METHODS OF USE  
NUMBER OF SEQUENCES: 23  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Muehling, Raasch & Gebhardt, P.A.  
STREET: 119 No. US20020068814A1n Fourth Street  
CITY: Minneapolis  
STATE: MN  
COUNTRY: USA  
ZIP: 55401  
COMPUTER READABLE FORM:  
MEDIUM TYPE: floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/813,345  
FILING DATE: 20-Mar-2001  
CLASSIFICATION: <Unknown>  
ATTORNEY/AGENT INFORMATION:  
NAME: McCormack, Myra H  
REGISTRATION NUMBER: 36,602  
REFERENCE/DOCKET NUMBER: 180.00020101  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 612/305-1228  
TELEFAX: 612/305-1228  
INFORMATION FOR SEQ ID NO: 15:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 50 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: peptide  
SEQUENCE DESCRIPTION: SEQ ID NO: 15:  
US-09-813-345-15

Query Match 75.0%; Score 57; DB 9; Length 50;  
Best Local Similarity 100.0%; Pred. No. 0.035;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 HOIYOPTDKD 13  
DB 26 HOIYOPTDKD 35

RESULT 6  
US-09-813-345-14  
Sequence 14, Application US/09813345  
Patent No. US20020068814A1  
GENERAL INFORMATION:  
APPLICANT: Smith, Derek D.  
Saha, Shankar  
Abel, Peter W.

TITLE OF INVENTION: PEPTIDE ANTAGONISTS OF CGRP-RECEPTOR  
SUPERFAMILY AND METHODS OF USE

NUMBER OF SEQUENCES: 23  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Muehling, Raasch & Gebhardt, P.A.  
STREET: 119 No. US20020068814A1n Fourth Street  
CITY: Minneapolis  
STATE: MN  
COUNTRY: USA  
ZIP: 55401

COMPUTER READABLE FORM:

MEDIUM TYPE: floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/813,345

FILING DATE: 20-Mar-2001

CLASSIFICATION: <Unknown>

ATTORNEY/AGENT INFORMATION:

NAME: McCormack, Myra H

REGISTRATION NUMBER: 36,602

REFERENCE/DOCKET NUMBER: 180.00020101

TELECOMMUNICATION INFORMATION:

TELEPHONE: 612/305-1228

TELEFAX: 612/305-1228

INFORMATION FOR SEQ ID NO: 14:

SEQUENCE CHARACTERISTICS:

LENGTH: 52 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: peptide

SEQUENCE DESCRIPTION: SEQ ID NO: 14:  
US-09-813-345-14

Query Match 75.0%; Score 57; DB 9; Length 52;  
Best Local Similarity 100.0%; Pred. No. 0.036;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 HOIYOPTDKD 13  
DB 28 HOIYOPTDKD 37

RESULT 7  
US-10-197-954-2

Sequence 2, Application US/10197954

Publication No. US20030119021A1

GENERAL INFORMATION:

APPLICANT: K'ater, Hubert

APPLICANT: Siddiqui, Suhail

APPLICANT: Little, Daniel

TITLE OF INVENTION: Capture Compounds, Collections Thereof  
And Methods For Analyzing The Proteome And Complex

TITLE OF INVENTION: Compositions

FILE REFERENCE: 24743-2305

CURRENT FILING DATE: 2002-07-16

PRIOR FILING DATE: 2001-07-16

PRIOR FILING DATE: 2001-08-21

PRIOR FILING DATE: 2002-03-11

PRIOR FILING DATE: 2002-03-11

```
; NUMBER OF SEQ ID NOS: 149
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 52
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-197-954-2
```

```
Query Match          75.0%; Score 57; DB 14; Length 52;
Best Local Similarity 100.0%; Pred. No. 0.036;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      4 HQIYQFTDKD 13
        |||||
Db      28 HQIYQFTDKD 37
```

```
RESULT 8
US-10-360-101-74
; Sequence 74, Application US/10360101
; Publication No. US2004009550A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Leenhouts, Cornelis J.
; TITLE OF INVENTION: Export and modification of (poly)peptide in the lantibiotic way
; FILE REFERENCE: 2183-5673
; CURRENT APPLICATION NUMBER: US/10/360,101
; CURRENT FILING DATE: 2003-02-07
; PRIOR APPLICATION NUMBER: EP 02077060.8
; PRIOR FILING DATE: 2002-05-24
; NUMBER OF SEQ ID NOS: 309
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 74
; LENGTH: 52
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
```

```
; OTHER INFORMATION: A13,S16-sequence of Adrenomedullin Hypotensive peptide
US-10-360-101-74
```

```
Query Match          75.0%; Score 57; DB 15; Length 52;
Best Local Similarity 100.0%; Pred. No. 0.036;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      4 HQIYQFTDKD 13
        |||||
Db      28 HQIYQFTDKD 37
```

```
RESULT 9
US-10-474-635A-19
; Sequence 19, Application US/10474635A
; Publication No. US20040176567A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Isis Innovation Ltd
; TITLE OF INVENTION: Peptides
; FILE REFERENCE: 480821.00004
; CURRENT APPLICATION NUMBER: US/10/474,635A
; CURRENT FILING DATE: 2003-10-14
; PRIOR APPLICATION NUMBER: GB 0109438.2
; PRIOR FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 19
; LENGTH: 52
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-474-635A-19
```

```
Query Match          75.0%; Score 57; DB 16; Length 52;
Best Local Similarity 100.0%; Pred. No. 0.036;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      4 HQIYQFTDKD 13
        |||||
Db      28 HQIYQFTDKD 37
```

```
RESULT 10
US-10-364-889-6
; Sequence 6, Application US/10364889
; Publication No. US20030224989A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Pabel, Gregory L.
; APPLICANT: Quinn, Kerry
; TITLE OF INVENTION: Compositions and Methods for Treatment of Osteoarthritis
; FILE REFERENCE: 21402-558
; CURRENT APPLICATION NUMBER: US/10/364,889
; CURRENT FILING DATE: 2003-02-12
; PRIOR APPLICATION NUMBER: 60/356,376
; PRIOR FILING DATE: 2002-02-12
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: CuraSeqlet version 0.1
; SEQ ID NO 6
; LENGTH: 185
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-364-889-6
```

```
Query Match          75.0%; Score 57; DB 14; Length 185;
Best Local Similarity 100.0%; Pred. No. 0.14;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      4 HQIYQFTDKD 13
        |||||
Db      122 HQIYQFTDKD 131
```

```
RESULT 11
US-10-372-683-12
; Sequence 12, Application US/10372683
; Publication No. US2004009171A1
; GENERAL INFORMATION:
```

```
; APPLICANT: GERRITSEN, MARY E.
; APPLICANT: PEALE JR., FRANKLIN V.
; APPLICANT: WU, THOMAS D.
; TITLE OF INVENTION: METHODS FOR THE TREATMENT OF CARCINOMA
; FILE REFERENCE: P1928R1P1
; CURRENT APPLICATION NUMBER: US/10/372,683
; CURRENT FILING DATE: 2003-02-21
; PRIOR APPLICATION NUMBER: US 10/271,690
; PRIOR FILING DATE: 2002-10-16
; PRIOR APPLICATION NUMBER: US 60/344,534
; PRIOR FILING DATE: 2001-10-18
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 12
; LENGTH: 185
; TYPE: PRT
; ORGANISM: Homo sapien
US-10-372-683-12
```

```
Query Match          75.0%; Score 57; DB 15; Length 185;
Best Local Similarity 100.0%; Pred. No. 0.14;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      4 HQIYQFTDKD 13
        |||||
Db      122 HQIYQFTDKD 131
```

```
RESULT 12
US-10-675-406A-7
; Sequence 7, Application US/10675406A
; Publication No. US20040121375A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Bayer Pharmaceuticals Corporation
```

```

? APPLICANT: Eveleigh, Deepa
? APPLICANT: Taylor, Ian
? TITLE OF INVENTION: METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING
? TITLE OF INVENTION: CANCER THERAPY
? FILE REFERENCE: 5138
? CURRENT APPLICATION NUMBER: US/10/675,406A
? CURRENT FILING DATE: 2003-09-30
? PRIOR APPLICATION NUMBER: US 60/415,194
? PRIOR FILING DATE: 2002-09-30
? NUMBER OF SEQ ID NOS: 7
? SOFTWARE: PatentIn version 3.2
? SEQ ID NO 7
? LENGTH: 185
? TYPE: DPT
? ORGANISM: Homo sapiens
? US-10-675-406A-7

```

Query Match	75.0%;	Score 57;	DB 16;	Length 185;
Best Local Similarity	100.0%;	Pred. No. 0.14;		
Matches 10;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

QY 4 HQIYQFTDKD 13  
Db 122 HQIYQFTDKD 131

```

RESULT 13
US-10-755-889-148
Sequence 148, Application US/10755889
Publication No. US20040171823a1
GENERAL INFORMATION:
APPLICANT: Bristol-Myers Squibb Company
TITLE OF INVENTION: POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-KB
TITLE OF INVENTION: PATHWAY
FILE REFERENCE: D0284 NP
CURRENT APPLICATION NUMBER: US/10/755, 889
CURRENT FILING DATE: 2004-01-13
PRIOR APPLICATION NUMBER: U.S. 60/440,068
PRIOR FILING DATE: 2003-01-14
PRIOR APPLICATION NUMBER: U.S. 60/469,757
PRIOR FILING DATE: 2003-05-12
NUMBER OF SEQ ID NOS: 823
SOFTWARE: PatentIn version 3.2
SEQ ID NO 148
LENGTH: 185
TYPE: PRT
ORGANISM: Homo sapiens
US-10-755-889-148

```

Query Match 75.0%; Score 57; DB 16; Length 185;  
Best Local Similarity 100.0%; Pred. No. 0.14;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	4	HQIYQFTDKD	13
Db	122	HQIYQFTDKD	131

```

RESULT 14
US-10-425-115-194068
; Sequence 194068, Application US/10425115
; Publication No. US20040214272A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants
; FILE REFERENCE: 38-21(53222) B
; CURRENT APPLICATION NUMBER: US/10/425,115
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 369326

```

```

; SEQ ID NO 194068
; LENGTH: 117
; TYPE: PRT
; ORGANISM: Zea mays
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(117)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: clone ID: MRT4577_108570C.1.pep
US-10-425-115-194068

```

Query Match 59.2%; Score 45; DB 17; Length 117;  
Best Local Similarity 63.6%; Pred. No. 8.9;  
Matches 7; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY	1	YGGHQIQFTD	11
		:	
Db	44	YGGGEQVYNFDD	54

```

RESULT 15
US-10-424-599-207877
: Sequence 207877, Application US/10424599
: Publication No. US20040031072A1
: GENERAL INFORMATION:
: APPLICANT: La Rosa Thomas J
: APPLICANT: Kovallig David K
: APPLICANT: Zhou Yihua
: APPLICANT: Cao Yongwei
: TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
: TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
: FILE REFERENCE: 38-21(53223)B
: CURRENT APPLICATION NUMBER: US/10/424,599
: CURRENT FILING DATE: 2003-04-28
: NUMBER OF SEQ ID NOS: 285684
: SEQ ID NO 207877
: LENGTH: 157
: TYPE: PRT
: ORGANISM: Glycine max
: FEATURE:
: NAME/KEY: unsure
: LOCATION: (1)..(157)
: OTHER INFORMATION: unsure at all Xaa locations
: FEATURE:
: OTHER INFORMATION: Clone ID: PAT_MRT3847_2973C.1 pep
: US-10-424-599-207877

```

Query Match	57.9%	Score 44;	DB 15;	Length 157;
Best Local Similarity	53.8%	Pred. No. 18;		
Matches	7;	Conservative	2;	Mismatches 4; Indels 0; Gaps 0;

```
QY      1 YGGHQIYQFTDKD 13
         |||:|:|
Db      103 YGEHNVTQAREKD 115
```

Search completed: January 5, 2005, 09:15:07  
Job time : 229.864 secs

**This Page Blank (uspic,**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 5, 2005, 08:39:22 ; Search time 14.1818 Seconds

(without alignments)  
88.199 Million cell updates/sec

Title: US-09-931-700-2

Sequence: 1 YGSHQIYQFTDKD 13

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database: PIR 79:\*

1: p1r1:\*

2: p1r2:\*

3: p1r3:\*

4: p1r4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	57	75.0	185	2 JN0684	adrenomedullin pre
2	57	75.0	185	2 JN0766	adrenomedullin pre
3	57	75.0	188	2 S41600	adrenomedullin - p
4	51	67.1	643	2 S76069	hypothetical prote
5	45	59.2	776	2 T02702	hypothetical prote
6	44	57.9	2231	2 D71870	hypothetical prote
7	42	55.3	280	2 H70089	hypothetical prote
8	42	55.3	324	2 A87544	hypothetical prote
9	42	55.3	350	2 T21106	hypothetical prote
10	42	55.3	350	2 T09378	hypothetical prote
11	41	53.9	185	2 C86705	hypothetical prote
12	41	53.9	467	2 T21680	hypothetical prote
13	41	53.9	514	2 D89775	hypothetical prote
14	40	52.6	146	2 G83445	conserved hypochet
15	40	52.6	260	2 H71979	probable type II r
16	40	52.6	275	2 T32005	hypothetical prote
17	39.5	52.0	606	2 T40566	hypothetical prote
18	39	51.3	176	2 B35687	transcription fact
19	39	51.3	310	2 H69986	hypothetical prote
20	39	51.3	444	1 B69130	histidine-tRNA lig
21	39	51.3	705	2 JX0194	prolyl oligopeptid
22	39	51.3	1356	2 S51389	ROM2 protein - Yea
23	38.5	50.7	322	2 T22410	hypothetical prote
24	38	50.0	165	2 F69819	conserved hypochet
25	38	50.0	254	2 B70860	probable enoyl-CoA
26	38	50.0	257	2 A40859	periplasmic fibrin
27	38	50.0	264	2 T23866	hypothetical prote
28	38	50.0	387	2 T28402	ORF MSV241 leucine
29	38	50.0	391	2 H89859	hypothetical prote

30	38	50.0	425	2 S17759	protein kinase, ca
31	38	50.0	532	2 T14335	protein kinase, ca
32	38	50.0	564	2 A96999	pectate lyase rela
33	38	50.0	571	2 S58356	pept protein - Sta
34	38	50.0	586	2 A95167	ABC transporter, A
35	38	50.0	586	2 H98032	hypothetical prote
36	38	50.0	952	2 B84534	hypothetical prote
37	38	50.0	1337	2 T30291	dextranase - Strep
38	37.5	49.3	569	2 JS0101	alpha-amylase (EC
39	37	48.7	105	2 T26838	hypothetical prote
40	37	48.7	164	2 AG0539	probable lipoprote
41	37	48.7	227	2 H82344	rfbT protein VC025
42	37	48.7	250	2 B86817	oxidoreductase ypi
43	37	48.7	253	2 F90507	sugar phosphate nu
44	37	48.7	257	2 B82238	imidazoleglycerol-
45	37	48.7	285	2 T29832	hypothetical prote

#### ALIGNMENTS

RESULT 1  
JN0684  
adrenomedullin precursor - human  
C:Species: Homo sapiens (man)  
C:Date: 03-Feb-1994 #sequence revision 03-Feb-1994 #text\_change 09-Jul-2004  
C:Accession: J02351; JN0684; P0548; JN0476  
R:Ichimaru, T.; Kojima, M.; Kangawa, K.; Hino, J.; Matsuo, H.; Eto, T.  
Biochem. Biophys. Res. Commun. 203, 631-639, 1994  
A:Title: Genomic structure of human adrenomedullin gene.  
A:Reference number: J02351; PMID:94354869; PMID:8074714  
A:Accession: J02351  
A:Molecule type: DNA  
A:Residues: 1185 <ISH>  
A:Cross-references: UNIPROT:P35318; GB:S73906; NID:G455470; PIDN:BA03589.1; PID:G50612  
A:Experimental source: pheochromocytoma  
R:Kitamura, K.; Sakata, T.; Kangawa, K.; Kojima, M.; Matsuo, H.; Eto, T.  
Biochem. Biophys. Res. Commun. 194, 720-725, 1993  
A:Title: Cloning and characterization of cDNA encoding a precursor for human adrenomedu  
A:Reference number: JN0684; PMID:93343928; PMID:7688224  
A:Accession: JN0684  
A:Molecule type: mRNA  
A:Residues: 1-185 <KIT>  
A:Cross-references: GB:D14874; NID:G455470; PIDN:BA03589.1; PID:G50612  
A:Accession: P0548  
A:Molecule type: protein  
A:Residues: 22-41 <KIT>  
R:Kitamura, K.; Kangawa, K.; Kawamoto, M.; Ichiki, Y.; Nakamura, S.; Matsuo, H.; Eto, T.  
Biochem. Biophys. Res. Commun. 192, 553-560, 1993  
A:Title: Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocyto  
A:Reference number: JN0476; PMID:93249425; PMID:8587282  
A:Accession: JN0476  
A:Molecule type: protein  
A:Residues: 95-146 <KIT>  
A:Experimental source: pheochromocytoma  
C:Genetics  
A:Gene: GDB:ADM  
A:Cross-references: GDB:217070; OMIM:103275  
A:Map position: 11pter-11qter  
A:Keywords: amidated carboxyl end; blood pressure control; hormone  
F:1-21/Domain: signal sequence #status predicted <SIG>  
F:22-185/Product: proadrenomedullin #status predicted <PPV>  
F:22-41/Domain: proadrenomedullin amino-terminal 20 peptide #status predicted <PPV>  
F:95-146/Product: adrenomedullin #status experimental <NMT>  
F:147-185/Domain: carboxyl-terminal propeptide #status predicted <CTP>  
F:41/Modified site: amidated carboxyl end (Arg) (amide in mature form from following gl;  
F:110-115/Disulfide bonds: #status experimental  
F:146/Modified site: amidated carboxyl end (Tyr) (amide in mature form from following gl;

Query Match 75.0%; Score 57; DB 2; Length 185;  
Best Local Similarity 100.0%; Pred. No. 0.016;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 HOIYQFTDKD 13  
 |||||  
 Db 122 HOIYQFTDKD 131

## RESULT 2

UN0766

adrenomedullin precursor - rat

C/Species: Rattus norvegicus (Norway rat)

C/Date: 30-Sep-1993 #sequence\_revision 20-Aug-1994 #text\_change 09-Jul-2004

C/Accession: UN0766; E0610

R/Sakata, U.; Shimokubo, T.; Kitamura, K.; Nakamura, S.; Kangawa, K.; Matsuo, H.; Eco, T.

Biochem. Biophys. Res. Commun. 195, 921-927, 1993

A/Title: Molecular cloning and biological activities of rat adrenomedullin, a hypotensive

A/Reference number: UN0766; MUID:93384621; PMID:7690563

A/Accession: UN0766

A/Molecule type: mRNA

A/Residues: 1-185 <SAK>

A/Cross-references: UNIPROT:P43145

A/Accession: P0610

A/Molecule type: protein

A/Residues: 22-41 <SK2>

C/Comment: This precursor contains a unique 20-amino acid sequence designated proadrenom

essure control.

C/Keywords: amidated carboxyl end

F/1-21/Domain: signal sequence #status predicted <SIG>

F/22-185/Product: proadrenomedullin #status predicted <PRU>

F/22-41/Product: proadrenomedullin amino-terminal 20 peptide #status predicted <PAP>

F/94-143/Product: adrenomedullin #status predicted <MAT>

F/41/Modified site: amidated carboxyl end (Arg) (amide in mature form from following gly

F/143/Modified site: amidated carboxyl end (Tyr) (amide in mature form from following gly

Query Match 75.0%; Score 57; DB 2; Length 185;

Best Local Similarity 100.0%; Pred. No. 0.016;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 HOIYQFTDKD 13  
 |||||  
 Db 119 HOIYQFTDKD 128

## RESULT 3

S41600

adrenomedullin - pig

C/Species: Sus scrofa domestica (domestic pig)

C/Date: 19-Mar-1997 #sequence\_revision 19-Mar-1997 #text\_change 09-Jul-2004

C/Accession: S41600

R/Kitamura, K.; Kangawa, K.; Kojima, M.; Ichiki, Y.; Matsuo, H.; Eco, T.

FEBS Lett. 338, 306-310, 1994

A/Title: Complete amino acid sequence of porcine adrenomedullin and cloning of cDNA encod

A/Reference number: S41600; MUID:94139945; PMID:8043068

A/Accession: S41600

A/Status: preliminary

A/Molecule type: mRNA

A/Residues: 1-188 <KIT>

A/Cross-references: UNIPROT:P53366; GB:D14875; NID:g439721; PIDN:BA03590.1; PID:g496379

Query Match 75.0%; Score 57; DB 2; Length 188;

Best Local Similarity 100.0%; Pred. No. 0.017;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 HOIYQFTDKD 13  
 |||||  
 Db 122 HOIYQFTDKD 131

Query Match 75.0%; Score 57; DB 2; Length 188;

Best Local Similarity 100.0%; Pred. No. 0.017;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 HOIYQFTDKD 13  
 |||||  
 Db 122 HOIYQFTDKD 131

## RESULT 4

S76069

hypothetical protein - Synecocystis sp. (strain PCC 6803)

C/Species: Synecocystis sp.

A/Variety: PCC 6803

C/Date: 25-Apr-1997 #sequence\_revision 25-Apr-1997 #text\_change 09-Jul-2004

C/Accession: S76069

R/Kaneko, T.; Sato, S.; Kotani, H.; Tanaka, A.; Asamizu, E.; Nakamura, Y.; Miyajima, N.;

O.; K.; Okumura, S.; Shimpo, S.; Takeuchi, C.; Wada, T.; Watanabe, A.; Yamada, M.; Yasuda

DNA Res. 3, 109-136, 1996

A/Title: Sequence analysis of the genome of the unicellular cyanobacterium Synecocystis

A/Reference number: S74322; MUID:97061201; PMID:8905231

A/Accession: S76069

A/Status: preliminary

A/Molecule type: DNA

A/Residues: 1-643 <KAN>

A/Cross-references: UNIPROT:Q5549; EMBL:D63999; GB:AB001339; NID:g1001396; PIDN:BA11004

A/Note: the nucleotide sequence was submitted to the EMBL Data Library, June 1996

Query Match 67.1%; Score 51; DB 2; Length 643;

Best Local Similarity 72.7%; Pred. No. 0.69;

Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 3 GGHQYQFTDKD 13  
 |||||  
 Db 447 GGHQYQFTDKD 457

Query Match 67.1%; Score 51; DB 2; Length 643;

Best Local Similarity 72.7%; Pred. No. 0.69;

Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 3 GGHQYQFTDKD 13  
 |||||  
 Db 447 GGHQYQFTDKD 457

Query Match 67.1%; Score 51; DB 2; Length 643;

Best Local Similarity 72.7%; Pred. No. 0.69;

Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 3 GGHQYQFTDKD 13  
 |||||  
 Db 447 GGHQYQFTDKD 457

Query Match 67.1%; Score 51; DB 2; Length 643;

Best Local Similarity 72.7%; Pred. No. 0.69;

Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 3 GGHQYQFTDKD 13  
 |||||  
 Db 447 GGHQYQFTDKD 457

Query Match 67.1%; Score 51; DB 2; Length 643;

Best Local Similarity 72.7%; Pred. No. 0.69;

Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 3 GGHQYQFTDKD 13  
 |||||  
 Db 447 GGHQYQFTDKD 457

Query Match 67.1%; Score 51; DB 2; Length 643;

Best Local Similarity 72.7%; Pred. No. 0.69;

Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 3 GGHQYQFTDKD 13  
 |||||  
 Db 447 GGHQYQFTDKD 457

Query Match 67.1%; Score 51; DB 2; Length 643;

Best Local Similarity 72.7%; Pred. No. 0.69;

Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 3 GGHQYQFTDKD 13  
 |||||  
 Db 447 GGHQYQFTDKD 457

Query Match 67.1%; Score 51; DB 2; Length 643;

Best Local Similarity 72.7%; Pred. No. 0.69;

Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 3 GGHQYQFTDKD 13  
 |||||  
 Db 447 GGHQYQFTDKD 457

Query Match 67.1%; Score 51; DB 2; Length 643;

Best Local Similarity 72.7%; Pred. No. 0.69;

Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

R; Alm, R.A.; Ling, L.S.L.; Moir, D.T.; King, B.L.; Brown, E.D.; Doig, P.C.; Smith, D.R.; Ives, C.; Gibson, R.; Merberg, D.; Mills, S.D.; Jiang, Q.; Taylor, D.E.; Vovis, G.F.; Nature 397, 176-180, 1999

A;Title: Genomic sequence comparison of two unrelated isolates of the human gastric path

A;Reference number: A71800; MUID:99120557; PMID:9923682

A;Accession: D71870

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-2231 <ARN>

A;Cross-references: UNIPROT:Q9ZKX7; GB:AE001522; GB:AE001439; NID:g4155505; PIDN:AD0650

A;Experimental source: strain J99

C;Genetics:

Query Match 57.9%; Score 44; DB 2; Length 2231;  
Best Local Similarity 53.8%; Pred. No. 43;  
Matches 7; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 YGGHQIYQFTDKD 13  
|||:|:|:|:|:  
Db 620 YGNHKIYSNDKE 632

# RESULT 7

## hypothetical protein yycI - Bacillus subtilis

C;Species: Bacillus subtilis

C;Date: 05-Dec-1997 #sequence\_revision 05-Dec-1997 #text\_change 09-Jul-2004

C;Accession: H70089

R;Kunst, F.; Ogasawara, N.; Moszer, I.; Albertini, A.M.; Alloni, G.; Azevedo, V.; Berte

C.; Bron, S.; Brouillet, S.; Brusch, C.V.; Caldwell, B.; Capuano, V.; Carter, N.M.; Ch

A.; Ehlich, S.D.; Emerson, P.T.; Entian, K.D.; Errington, J.; Fabret, C.; Ferrari, E.

Nature 390, 249-256, 1997

A;Authors: Follmer, C.; Fritz, C.; Fujita, M.; Fujita, Y.; Fuma, S.; Gallizi, A.; Gall

lech, J.; Harwood, C.R.; Hentat, A.; Hilbert, H.; Holsteppel, S.; Hosono, S.; Hullo, M.F.

Koester, P.; Koningsstein, G.; Krogh, S.; Kumano, M.; Kurita, K.; Lapidus, A.; Lardinois,

A;Authors: Lamber, J.; Lazarevic, V.; Lee, S.M.; Levine, A.; Liu, H.; Masuda, S.; Maue

Y, M.; Ogawa, K.; Ogawa, A.; Oudega, B.; Park, S.H.; Parro, V.; Pohl, T.M.; Portetell

Rieger, M.; Rivolta, C.; Rocha, E.; Roche, B.; Rose, M.; Sadate, Y.; Sato, T.; Scanlon,

A;Authors: Schleich, S.; Schroeter, R.; Scottone, F.; Sekiguchi, J.; Sekowska, A.; Ser

akeuchi, M.; Tamakoshi, A.; Tanaka, T.; Terbeta, P.; Tognoni, A.; Tosato, V.; Uchiyama,

T.; Winters, P.; Wipat, A.; Yamamoto, H.; Yamane, K.; Yasumoto, K.; Yata, K.; Yoshida, K

A;Authors: Yoshikawa, H.F.; Zunsstein, E.; Yoshikawa, H.; Danchin, A.

A;Title: The complete genome sequence of the Gram-positive bacterium Bacillus subtilis.

A;Reference number: A69580; MUID:98044033; PMID:9384377

A;Accession: H70089

A;Status: preliminary; nucleic acid sequence not shown; translation not shown

A;Molecule type: DNA

A;Residues: 1-280 <KUN>

A;Cross-references: UNIPROT:Q45612; GB:Z99124; GB:AL009126; NID:g2636442; PIDN:CAB16075.

A;Experimental source: strain 168

C;Genetics:

A;Gene: yycI

C;Superfamily: Bacillus subtilis hypothetical protein yycI

Query Match 55.3%; Score 42; DB 2; Length 280;  
Best Local Similarity 72.7%; Pred. No. 11;  
Matches 8; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 YGGHQIYQFTDKD 11  
|||:|:|:|:|:  
Db 152 YEGHYIYQKTD 162

# RESULT 8

## hypothetical protein CC2378 (imported) - Caulobacter crescentus

C;Species: Caulobacter crescentus

C;Date: 20-Apr-2001 #sequence\_revision 20-Apr-2001 #text\_change 09-Jul-2004

C;Accession: A87544

R;Nierman, W.C.; Felblyum, T.V.; Paulsen, I.T.; Nelson, K.E.; Bisen, J.; Heidelberg, J.

B.; Laub, M.T.; DeBoy, R.T.; Dodson, R.J.; Durkin, A.S.; Gwinn, M.L.; Haft, D.H.; Kol

n, J.; Ermolaeva, M.; White, O.; Salzberg, S.L.; Shapiro, L.; Venter, J.C.; Fraser, C.M.

Proc. Natl. Acad. Sci. U.S.A. 98, 4136-4141, 2001

A;Title: Complete Genome Sequence of Caulobacter crescentus.

A;Reference number: A87249; MUID:21173698; PMID:11259647

A;Accession: A87544

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-324 <STO>

A;Cross-references: UNIPROT:Q9A5R9; GB:AE005673; NID:g13423911; PIDN:AAK24349.1; GSPDB:

C;Genetics:

C;Superfamily: Escherichia coli UDPglucose 4-epimerase; UDPglucose 4-epimerase homology

Query Match 55.3%; Score 42; DB 2; Length 324;  
Best Local Similarity 50.0%; Pred. No. 12;  
Matches 6; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 2 GGHQIYQFTDKD 13  
|||:|:|:|:|:  
Db 244 GGHQIYQFTDKD 255

# RESULT 9

## hypothetical protein F19B6.3 - Caenorhabditis elegans

C;Species: Caenorhabditis elegans

C;Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 09-Jul-2004

C;Accession: T21106

R;Thomas, K.

Submitted to the EMBL Data Library, February 1996

A;Reference number: Z19375

A;Accession: T21106

A;Status: preliminary; translated from GB/EMBL/DDbJ

A;Molecule type: DNA

A;Residues: 1-350 <ML>

A;Cross-references: UNIPROT:Q19582; EMBL:Z69635; NID:g1200023; PIDN:CAA93458.1; GSPDB:G

A;Experimental source: clone F19B6

C;Genetics:

A;Gene: CESP.F19B6.3

A;Map position: 4

A;Intons: 180/3; 274/2

Query Match 55.3%; Score 42; DB 2; Length 350;  
Best Local Similarity 46.2%; Pred. No. 13;  
Matches 6; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 YGGHQIYQFTDKD 13  
|||:|:|:|:|:  
Db 20 YNGRKIFDFTDRD 32

# RESULT 10

## hypothetical protein F23K16.250 - Arabidopsis thaliana

C;Species: Arabidopsis thaliana (mouse-ear cress)

C;Date: 11-Jun-1999 #sequence\_revision 11-Jun-1999 #text\_change 09-Jul-2004

C;Accession: T09378; T04999

R;Bevan, M.; Murphy, G.; Ridley, P.; Hudson, S.; Bancroft, I.; Mewes, H.W.; Mayer, K.F.

Submitted to the Protein Sequence Database, June 1999

A;Reference number: Z16652

A;Accession: T09378

A;Molecule type: DNA

A;Residues: 1-563 <BEV>

A;Cross-references: UNIPROT:Q9SV96; EMBL:AL078620; GSPDB:GN00062; ATSP:F23K16.250

A;Experimental source: cultivar Columbia; BAC clone F23K16

R;Bevan, M.; Montfort, A.; Casacuberta, E.; Pulgomech, P.; Hohenseel, J.; Mewes, H.W.;

Submitted to the Protein Sequence Database, April 1998

A;Reference number: Z15394

A;Accession: T04999

A;Molecule type: DNA

A;Residues: 444-563 <BE2>

A;Cross-references: EMBL:AL022605

A;Experimental source: cultivar Columbia; BAC clone T19P19

C;Genetics:

A;Gene: ATSP:F23K16.250  
A;Map position: 4  
A;Intons: 118/3; 502/3  
A;Note: T19P19.10

Query Match 55.3%; Score 42; DB 2; Length 563;  
Best Local Similarity 58.3%; Pred. No. 22;  
Matches 7; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2 GGHQIYQFTDKD 13  
|||:|:|  
Db 491 GGNQTRFQDKD 502

## RESULT 11

hypothetical protein ygdA [imported] - Lactococcus lactis subsp. lactis (strain IL1403)  
C;Species: Lactococcus lactis subsp. lactis  
C;Date: 23-Mar-2001 #sequence\_revision 23-Mar-2001 #text\_change 09-Jul-2004  
C;Accession: C86705  
R;Bolojin, A.; Winkler, P.; Mauger, S.; Jallion, O.; Malarme, K.; Weissenbach, J.; Ehrlich  
Genome Res. 11, 731-753, 2001  
A;Title: The complete genome sequence of the lactic acid bacterium Lactococcus lactis s  
A;Reference number: A86825; MUID:21235186; PMID:11337471  
A;Accession: C86705  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-185 <STO>  
A;Cross-references: UNIPROT:Q9CH88; GB:AE05176; PID:G12723547; PIDN:AAK04741.1; GSPDB:G  
A;Experimental source: strain IL1403  
C;Genetics:  
A;Gene: ygdA

Query Match 53.9%; Score 41; DB 2; Length 185;  
Best Local Similarity 63.6%; Pred. No. 10;  
Matches 7; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 3 GGHQIYQFTDKD 13  
|||:|:|  
Db 154 GHDFYVTTDAD 164

## RESULT 12

T21690  
hypothetical protein F33A8.4 - Caenorhabditis elegans  
C;Species: Caenorhabditis elegans  
C;Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 09-Jul-2004  
C;Accession: T21690  
R;Matthews, L.  
submitted to the EMBL Data Library, November 1996  
A;Reference number: Z19459  
A;Accession: T21690  
A;Status: preliminary; translated from GB/EMBL/DBJ  
A;Molecule type: DNA  
A;Residues: 1-467 <MTL>  
A;Cross-references: UNIPROT:O62214; EMBL:Z81525; PIDN:CAB04258.1; GSPDB:GN00020; CESP:F3  
A;Experimental source: clone F33A8  
C;Genetics:  
A;Gene: CESP:F33A8.4  
A;Map position: 2  
A;Intons: 29/3; 159/2; 212/3; 243/3; 266/3; 365/3  
C;Superfamily: Caenorhabditis elegans hypothetical protein F33A8.4

Query Match 53.9%; Score 41; DB 2; Length 467;  
Best Local Similarity 50.0%; Pred. No. 27;  
Matches 6; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1 YGGHIOYQFTDK 12  
|||:|:|  
Db 368 YEGHKLIOHSEK 379

## RESULT 13

D89775  
hypothetical protein [imported] - Staphylococcus aureus (strain N315)  
C;Species: Staphylococcus aureus  
C;Date: 10-May-2001 #sequence\_revision 10-May-2001 #text\_change 09-Jul-2004  
C;Accession: D89775

R;Kuroda, M.; Ohta, T.; Uchiyama, I.; Baba, T.; Yuzawa, H.; Kobayashi, I.; Cui, L.; Ogur  
ma, A.; Mizutani-Ui, Y.; Kobayashi, N.; Sawano, T.; Inoue, R.; Kato, C.; Sekimizu, K.;  
C.; Shibata, T.; Hattori, M.; Ogasawara, N.; Hayashi, H.; Hiratake, K.  
Lancet 357, 1225-1240, 2001

A;Title: Whole genome sequencing of methicillin-resistant Staphylococcus aureus.  
A;Reference number: A89758; MUID:21311952; PMID:11418146  
A;Accession: D89775  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-514 <KUR>

A;Cross-references: UNIPROT:Q99X71; GB:BA000018; PID:G13700060; PIDN:BA841359.1; GSPDB:G  
A;Experimental source: strain N315  
C;Genetics:  
A;Gene: SA0139

Query Match 53.9%; Score 41; DB 2; Length 514;  
Best Local Similarity 66.7%; Pred. No. 30;  
Matches 8; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 2 GGHQIYQFTDKD 13  
|||:|:|  
Db 449 GGRQIQFSSKD 460

## RESULT 14

G83445  
conserved hypothetical protein PA1607 [imported] - Pseudomonas aeruginosa (strain PA01)  
C;Species: Pseudomonas aeruginosa  
C;Date: 15-Sep-2000 #sequence\_revision 15-Sep-2000 #text\_change 09-Jul-2004  
C;Accession: G83445  
R;Stover, C.K.; Pham, X.Q.; Erwin, A.L.; Mizoguchi, S.D.; Warren, P.; Hickey, M.J.; B  
adman, S.; Yuan, Y.; Brody, L.L.; Coulter, S.N.; Folger, K.R.; Kas, A.; Lapidis, K.; Lam,  
.; Lory, S.; Olson, M.V.  
Nature 406, 959-964, 2000  
A;Title: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic path  
A;Reference number: A82950; MUID:20437337; PMID:10984043  
A;Accession: G83445  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-146 <STO>  
A;Cross-references: UNIPROT:Q913B4; GB:AE004588; GB:AE004091; NID:G9447563; PIDN:AA0495  
A;Experimental source: strain PA01  
C;Genetics:  
A;Gene: PA1607

Query Match 52.6%; Score 40; DB 2; Length 146;  
Best Local Similarity 63.6%; Pred. No. 12;  
Matches 7; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 2 GGHQIYQFTDK 12  
|||:|:|  
Db 75 GSHQYRRLDK 85

## RESULT 15

H71979  
probable type II restriction enzyme - Helicobacter pylori (strain J99)  
C;Species: Helicobacter pylori  
A;Variety: strain J99  
C;Date: 12-Feb-1999 #sequence\_revision 12-Feb-1999 #text\_change 09-Jul-2004  
C;Accession: H71979  
R;Alm, R.A.; Ling, L.S.; Moir, D.T.; King, B.L.; Brown, E.D.; Dolg, P.C.; Smith, D.R.;  
Ives, C.; Gibson, R.; Merberg, D.; Miller, S.D.; Jiang, Q.; Taylor, D.E.; Vovis, G.F.;  
Nature 397, 176-180, 1999  
A;Title: Genomic sequence comparison of two unrelated isolates of the human gastric path  
A;Reference number: A71800; MUID:99120557; PMID:9923682  
A;Accession: H71979  
A;Status: preliminary



A;Molecule type: DNA  
A;Residues: 1-260 <ARN>  
A;Cross-references: UNIPROT:Q9ZNI4; GB:AE001444; GB:AE001439; NID:g4154549; PIDN:AAD0562  
A;Experimental source: strain J99  
C;Genetics:  
A;Gene: jhp0046

Query Match 52.6%; Score 40; DB 2; Length 260;  
Best Local Similarity 63.6%; Pred. No. 22;  
Matches 7; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 YGGHQIYQFTD 11  
:|||||  
Db 194 FGCHQNAQFND 204

Search completed: January 5, 2005, 08:44:39  
Job time : 16.1818 secs

**This Page Blank (uspto)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 5, 2005, 08:39:22 ; Search time 75.0455 Seconds  
(without alignments)  
99.671 Million cell updates/sec

Title: US-09-931-700-2  
Perfect score: 76  
Sequence: 1 YGGHQYQFTDKD 13

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1825181 seqs, 575374646 residues

Total number of hits satisfying chosen parameters: 1825181

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database : UniProt\_02: \*  
1: uniprot\_sprot: \*  
2: uniprot\_trembl: \*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	57	75.0	27	Q9TRZ6	Q9TRZ6 sus scrofa
2	57	75.0	185	ADML_HUMAN	P5318 ractus horv
3	57	75.0	185	ADML_RAT	P33145 ractus horv
4	57	75.0	185	AAH3548	AAH3548 homo sapi
5	57	75.0	185	AAH61775	AAH61775 ractus no
6	57	75.0	188	ADML_PIG	P53366 sus scrofa
7	52	68.4	188	ADML_BOVIN	Q62827 bos taurus
8	52	68.4	188	ADML_CANFA	Q77559 canis famli
9	52	68.4	188	Q9SKF0	Q9SKF0 bos taurus
10	51	67.1	184	ADML_MOUSE	P97297 mus musculu
11	51	67.1	184	AAH52665	AAH52665 mus muscu
12	51	67.1	643	Q55549	Q55549 bynechocyst
13	45.5	59.9	388	Q24544	Q24544 drosophila
14	45.5	59.9	488	Q81NM4	Q81NM4 drosophila
15	45.5	59.9	488	AAH13464	AAH13464 drosophila
16	45.5	59.9	537	Q81NM6	Q81NM6 drosophila
17	45.5	59.9	980	ADML_PIG	Q24546 drosophila
18	45.5	59.9	981	Q86BA0	Q86BA0 drosophila
19	45.5	59.9	981	AAO41538	AAO41538 drosophila
20	45	59.2	776	Q81050	Q81050 arabidopsis
21	45	59.2	823	Q6R865	Q6R865 arabidopsis
22	45	59.2	823	AAH99487	AAH99487 arabidops
23	44	57.9	514	Q9X5R9	Q9X5R9 streptomyce
24	44	57.9	833	Q7Z9M4	Q7Z9M4 trichoderma
25	44	57.9	2231	Q9ZKK7	Q9ZKK7 helicobacte
26	43.5	57.2	611	Q7Q0R2	Q7Q0R2 anopheles g
27	43.5	57.2	611	Q7Q9C9	Q7Q9C9 anopheles g
28	42	55.3	173	Q8MXJ0	Q8MXJ0 caenorhabdi
29	42	55.3	184	Q9EMQ4	Q9EMQ4 streptomyce
30	42	55.3	280	Q45612	Q45612 bacillus su
31	42	55.3	324	Q9A5R9	Q9A5R9 caulobacter

32	42	55.3	326	Q8RCV8	Q8RCV8 thermoaer
33	42	55.3	350	Q19582	Q19582 caenorhabdi
34	42	55.3	563	Q9SV96	Q9SV96 arabidopsis
35	42	55.3	1206	Q9UT2	Q9UT2 schizosacch
36	41	53.9	185	Q9L474	Q9L474 lactococcus
37	41	53.9	185	Q9CHS8	Q9CHS8 lactococcus
38	41	53.9	245	Q7VLT4	Q7VLT4 prochloroco
39	41	53.9	330	Q7N9F6	Q7N9F6 prochlorabu
40	41	53.9	392	Q88XD7	Q88XD7 lactobacilli
41	41	53.9	467	Q62214	Q62214 caenorhabdi
42	41	53.9	478	Q7US57	Q7US57 rhodospirell
43	41	53.9	514	Q6GCY0	Q6GCY0 staphylococ
44	41	53.9	514	Q6GKG1	Q6GKG1 staphylococ
45	41	53.9	514	Q8NYQ7	Q8NYQ7 staphylococ

## ALIGNMENTS

RESULT 1	PRELIMINARY;	PRT;	27 AA.
ID Q9TRZ6			
AC Q9TRZ6;			
DT 01-MAY-2000 (TREMBLrel. 13, Created)			
DT 01-MAY-2000 (TREMBLrel. 13, Last sequence update)			
DT 01-JUN-2003 (TREMBLrel. 24, Last annotation update)			
DE ADRENOMEDULLIN.			
OS Sus scrofa (pig).			
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC Mammalia; Eutheria; Cetartiodactyla; Suidae; Sus.			
OX NCBI_Taxid=9823;			
RN [1]			
RP SEQUENCE FROM N.A.			
RX MEDLINE=96157714; PubMed=8576091;			
RA Ichiki Y., Kitamura K., Kawaguchi M., Matsuo H., Eco T.;			
RT "Distribution and characterization of immunoreactive adrenomedullin in			
RT porcine tissue, and isolation of adrenomedullin [26-52] and			
RT adrenomedullin-[34-52] from porcine duodenum.";			
RL J. Biochem. 118:765-770 (1995).			
DR GO; GO:0005576; C:extracellular; IEA.			
DR GO; GO:0005179; F:hormone activity; IEA.			
DR InterPro; IPR001710; Adrenomedullin.			
DR Pfam; PF02039; Adrenomedullin; 1.			
DR PRINTS; PRO0801; ADRENOMEDULLIN.			
SQ SEQUENCE 27 AA; 3063 MW; B8DC7FA18B8B3D90 CRC64;			
Query Match	75.0%;	Score 57;	DB 2;
Best local similarity	100.0%;	Pred. No. 0.0084;	
Matches	10;	Conservative	0; Mismatches 0; Indels 0; Gaps 0;
QY 4 HQIYQFTDKD 13			
DB 3 HQIYQFTDKD 12			
RESULT 2			
ID ADML_HUMAN			
AC P5318;			
DT 01-FEB-1994 (Rel. 28, Created)			
DT 01-FEB-1994 (Rel. 28, Last sequence update)			
DT 05-JUL-2004 (Rel. 44, Last annotation update)			
DE ADM precursor [Contains: Adrenomedullin (AM); Proadrenomedullin N-20			
DE terminal peptide (ProADM-N20) (ProADM N-terminal 20 peptide) (PAMP)].			
GN Name=ADM; Synonyms=AM;			
OS Homo sapiens (Human).			
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.			
OX NCBI_Taxid=9606;			
RN [1]			
RP SEQUENCE FROM N.A.			
RC TISSUE=Phenochromocytoma;			
RX MEDLINE=93343928; PubMed=7688224;			

RA Kitamura K., Sakata J., Kangawa K., Kojima M., Matsuo H., Eto T.,  
 RT "Cloning and characterization of cDNA encoding a precursor for human  
 RT adrenomedullin.";  
 RL Biochem. Biophys. Res. Commun. 194:720-725(1993).  
 [2]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Liver;  
 RX MEDLINE=94354869; PubMed=8074714;  
 RA Ishihara T., Kojima M., Kangawa K., Hino J., Matsuo H.,  
 RA Kitamura K., Eto T., Matsuo H.,  
 RT "Genomic structure of human adrenomedullin gene.";  
 RL Biochem. Biophys. Res. Commun. 203:631-639(1994).  
 [3]  
 RN SEQUENCE FROM N.A.  
 RC TISSUE=Kidney;  
 RX MEDLINE=2238257; PubMed=12477932; DOI=10.1073/pnas.242603899;  
 RA Straubeberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 RA Kraemer R.D., Collins F.S., Wagner L., Stenmen C.W., Schuler G.D.,  
 RA Altschul S.F., Zeeberg B., Buettow K.H., Schaefer C.F., Bhat N.K.,  
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heile F.,  
 RA Datchenko L., Marusik K., Farmer A.A., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
 RA Brownstein M.J., Udell T.B., Toshiyuki S., Carninci P., Prange C.,  
 RA Kana S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,  
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gumaratne P.H.,  
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Huliy S.W.,  
 RA Villalón D.K., Muzny D.M., Sodergren B.J., Lu X., Gibbs R.A.,  
 RA Whiting J., Helton E., Kettner M., Madan A., Rodriguez S., Sanchez A.,  
 RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 RA Buttefield Y.S.N., Krzywinski M.I., Skalka U., Smallus D.E.,  
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,  
 RT "Generation and initial analysis of more than 15,000 full-length human  
 RT and mouse cDNA sequences.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
 [4]  
 RN SEQUENCE OF 95-146.  
 RC TISSUE=Pheochromocytoma;  
 RX MEDLINE=93249425; PubMed=8387282;  
 RA Kitamura K., Kangawa K., Kawamoto M., Ichiki Y., Nakamura S.,  
 RA Matsuo H., Eto T.,  
 RT "Adrenomedullin: a novel hypotensive peptide isolated from human  
 RT pheochromocytoma.";  
 RL Biochem. Biophys. Res. Commun. 192:553-560(1993).  
 [5]  
 RN REVIEW.  
 RX MEDLINE=98240137; PubMed=9578982;  
 RA Samson W.K.,  
 RT "Proadrenomedullin-derived peptides.";  
 RL Front. Neuroendocrinol. 19:100-127(1998).  
 [6]  
 RN REVIEW.  
 RX MEDLINE=20053666; PubMed=1058445;  
 RA Champion H.C., Nussdorfer G.G., Kadowitz P.J.,  
 RT "Structure-activity relationships of adrenomedullin in the circulation  
 RT and adrenal gland.";  
 RL Regul. Pept. 85:1-8(1999).  
 CC -1- FUNCTION: AM and PAMP are potent hypotensive and vasodilator  
 CC agents. Numerous actions have been reported most related to the  
 CC physiologic control of fluid and electrolyte homeostasis. In the  
 CC kidney, am is diuretic and natriuretic, and both am and pamp  
 CC inhibit aldosterone secretion by direct adrenal actions. In  
 CC pituitary gland, both peptides at physiologically relevant doses  
 CC inhibit basal ACTH secretion. Both peptides appear to act in brain  
 CC and pituitary gland to facilitate the loss of plasma volume,  
 CC actions which complement their hypotensive effects in blood  
 CC vessels.  
 CC -1- SUBCELLULAR LOCATION: Secreted.  
 CC -1- TISSUE SPECIFICITY: Highest levels found in pheochromocytoma and  
 CC adrenal medulla. Also found in lung, ventricle and kidney tissues.  
 CC -1- SIMILARITY: Belongs to the adrenomedullin family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR EMBL; D14874; BAA0589.1; -  
 DR EMBL; S73906; AAC60642.1; -  
 DR EMBL; BC015961; AAH15961.1; -  
 DR EMBL; D43639; BAA07756.1; ALT\_SEQ.  
 DR PIR; JC2351; UN0684.  
 DR Genew; HGNC:259; ADM.  
 DR MIM; 103275; -  
 DR GO; GO:0005615; C:extracellular space; TAS.  
 DR GO; GO:0005625; C:soluble fraction; TAS.  
 DR GO; GO:0005102; F:receptor binding; TAS.  
 DR GO; GO:0006171; P:cAMP biosynthesis; TAS.  
 DR GO; GO:0007267; P:cell-cell signaling; TAS.  
 DR GO; GO:0008015; P:circulation; TAS.  
 DR GO; GO:0007565; P:pregnancy; TAS.  
 DR GO; GO:0006701; P:progesterone biosynthesis; TAS.  
 DR GO; GO:0009611; P:response to wounding; TAS.  
 DR GO; GO:0007165; P:signal transduction; TAS.  
 DR InterPro; IPR001710; Adrenomedullin.  
 DR Pfam; PF02039; Adrenomedullin; 1.  
 DR PRINTS; PRO0801; ADRENOMEDULLIN.  
 KW Annotation; Cleavage on pair of basic residues;  
 KW Direct protein sequencing; Hormone; Polymorphism; Signal.  
 FT SIGNAL 1 21 Proadrenomedullin N-20 terminal peptide.  
 FT PEPTIDE 22 41  
 FT PROPEP 45 92  
 FT PROPEP 95 146 Adrenomedullin.  
 FT PROPEP 148 185 PreproAM C-terminal fragment.  
 FT DISULFID 110 115  
 FT MOD\_RES 41 41 Arginine amide (G-42 provides amide  
 FT MOD\_RES 146 146 Tyrosine amide (G-147 provides amide  
 FT VARIANT 50 50 S->R (in dbSNP:5005).  
 FT  
 FT  
 SQ SEQUENCE 185 AA; 20420 MW; 64C7D2A0B4654DFE CRC64;  
 Query Match 75.0%; Score 57; DB 1; Length 185;  
 Best Local Similarity 100.0%; Pred. No. 0.065; Mismatches 0; Indels 0; Gaps 0;  
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 4 HQYQFTDKD 13  
 Db 122 HQYQFTDKD 131

RESULT 3  
 ADML RAT  
 ID ADML RAT STANDARD; PRT; 185 AA.  
 AC P43145;  
 DT 01-NOV-1995 (Rel. 32, Created)  
 DT 01-NOV-1995 (Rel. 32, Last sequence update)  
 DT 05-JUL-2004 (Rel. 44, Last annotation update)  
 DE ADM precursor [Contents: Adrenomedullin (ADM); Proadrenomedullin N-20  
 DE terminal peptide (ProAM-N20) (ProAM N-terminal 20 peptide) (PAMP)].  
 GN Name=Adm;  
 OS Rattus norvegicus (Rat).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
 OX NCBI\_TaxID=10116;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RP STRAIN=Sprague-Dawley; TISSUE=Adrenal gland;  
 RX MEDLINE=93384621; PubMed=7690563;  
 RA Sakata J., Shinokuba T., Kitamura K., Nakamura S., Kangawa K.,  
 RA Matsuo H., Eto T.,

RT "Molecular cloning and biological activities of rat adrenomedullin, a  
RT hypotensive peptide.";  
RL Biochem. Biophys. Res. Commun. 195:921-927(1993).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC MEDLINE=6102137; PubMed=5524787;  
RA Wang X., Yue T.L., Barone F.C., White R.F., Clark R.K., Willette R.N.,  
RA Sulphatio A.C., Aiyar N.V., Ruffolo R.R. Jr., Feuerstein G.Z.;  
RT "Discovery of adrenomedullin in rat ischemic cortex and evidence for  
RT its role in exacerbating focal brain ischemic damage.";  
RL Proc. Natl. Acad. Sci. U.S.A. 92:11480-11484(1995).  
CC -1- FUNCTION: AM and PAMP are potent hypotensive and vasodilator  
CC agents.  
CC -1- SUBCELLULAR LOCATION: Secreted.  
CC -1- TISSUE SPECIFICITY: Expressed in adrenal glands, lung, kidney,  
CC heart, spleen, duodenum and submandibular glands.  
CC -1- SIMILARITY: Belongs to the adrenomedullin family.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.ebi.ac.uk/announcements/>  
CC or send an email to [license@ebi.ac.uk](mailto:license@ebi.ac.uk)).  
CC -----  
DR EMBL; D15069; BAA03665.1; -;  
DR EMBL; U15419; AAB60519.1; -;  
DR PIR; JN0766; JN0766.  
DR RGD; 2047; Adm.  
DR InterPro: IPR001710; Adrenomedullin.  
DR Pfam; PF02039; Adrenomedullin.  
DR PRINTS; PR00801; ADRENOMEDULLIN.  
KW Amidation; cleavage on pair of basic residues; Hormone; Signal.  
FT SIGNAL 1 21  
FT PROPEP 22 41 Proadrenomedullin N-20 terminal peptide.  
FT PROPEP 45 91 By similarity.  
FT PROPEP 94 143 Adrenomedullin.  
FT PROPEP 149 185 PreproAM C-terminal fragment (By  
FT similarity).  
FT DISULFID 107 112 Arginine amide (G-42 provides amide  
FT MOD\_RES 41 41 By similarity.  
FT MOD\_RES 143 143 Tyrosine amide (G-144 provides amide  
FT MOD\_RES 143 143 Tyrosine amide (G-144 provides amide  
FT MOD\_RES 143 143 Tyrosine amide (G-144 provides amide  
SQ SEQUENCE 185 AA; 20636 MW; 35CAD9A9DD19A835 CRC64;  
Query Match 75.0%; Score 57; DB 1; Length 185;  
Best Local Similarity 100.0%; Pred. No. 0.065;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 4 HQIYQFTDKD 13  
Db 119 HQIYQFTDKD 128  
RESULT 4  
AAP35548 PRELIMINARY; PRT; 185 AA.  
ID AAP35548  
AC AAP35548  
DT 02-MAR-2004 (TREMBlrel. 27, Created)  
DT 02-MAR-2004 (TREMBlrel. 27, Last sequence update)  
DT 02-MAR-2004 (TREMBlrel. 27, Last annotation update)  
DE Adrenomedullin.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
OC NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Kainine N., Chen X., Rolfe A., Hallack A., Hines L., Eisenstein S.,  
RA Koundinya M., Raphael J., Moreira D., Kelley T., Labber J., Lin Y.,

RA Phelan M., Farmer A.;  
RT "Cloning of human full-length cDNA in BD Creator(TM) System Donor  
RT vector.";  
RL Submitted (MAY-2003) to the EMBL/GenBank/DBJ databases.  
DR EMBL; BT006902; AAP35548.1; -;  
SQ SEQUENCE 185 AA; 20420 MW; 64C7D2A0B4654DFE CRC64;  
Query Match 75.0%; Score 57; DB 2; Length 185;  
Best Local Similarity 100.0%; Pred. No. 0.065;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 4 HQIYQFTDKD 13  
Db 122 HQIYQFTDKD 131  
RESULT 5  
AAP61775 PRELIMINARY; PRT; 185 AA.  
ID AAP61775  
AC AAP61775  
DT 02-MAR-2004 (TREMBlrel. 27, Created)  
DT 02-MAR-2004 (TREMBlrel. 27, Last sequence update)  
DT 02-MAR-2004 (TREMBlrel. 27, Last annotation update)  
DE Adrenomedullin.  
OS Rattus norvegicus (Rat).  
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
OC NCBI\_TaxID=10116;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Prostate;  
RX MEDLINE=22388257; PubMed=12477932;  
RA Strauberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
RA Klausner R.D., Collins F.S., Wagner L., Shemen C.M., Schuler G.D.,  
RA Altschul S.F., Zeeberg B., Bueter K.H., Schaefer C.F., Bhat N.K.,  
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heile F.,  
RA Diachenko L., Marsina K., Farmer A.A., Rubin G.M., Hong L.,  
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
RA Brownstein M.J., Udell T.B., Toshiyuki S., Carninci P., Prange C.,  
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,  
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
RA Richards S., Morley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
RA Fahy J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,  
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
RA Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,  
RA Krzywinski M.I., Skalska U., Smallus D.E., Schnerch A., Schein J.E.,  
RA Jones S.J., Marra M.A.;  
RT "Generation and initial analysis of more than 15,000 full-length human  
RT and mouse cDNA sequences.";  
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Prostate;  
RA Strauberg R.;  
RL Submitted (NOV-2003) to the EMBL/GenBank/DBJ databases.  
DR EMBL; BC061775; AAP61775.1; -;  
SQ SEQUENCE 185 AA; 20636 MW; 35CAD9A9DD19A835 CRC64;  
Query Match 75.0%; Score 57; DB 2; Length 185;  
Best Local Similarity 100.0%; Pred. No. 0.065;  
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 4 HQIYQFTDKD 13  
Db 119 HQIYQFTDKD 128  
RESULT 6  
ADML\_PIG STANDARD; PRT; 188 AA.  
ID ADML\_PIG  
AC P53366;

```

DT 01-OCT-1996 (Rel. 34, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE ADM precursor [Contains: Adrenomedullin (AM); Proadrenomedullin N-20
DE terminal peptide (ProAM-N20) (ProAM N-terminal 20 peptide) (PAMP)].
GN Name=ADM; Synonyms=AM;
OS Sus scrofa (Pig).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Suidae; Sus.
OX NCBI_TaxID=9823;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Adrenal medulla;
RX MEDLINE=94139945; PubMed=8043068;
RA Kitamura K., Kangawa K., Kojima M., Ichiki Y., Matsuo H., Eto T.;
RT "Complete amino acid sequence of porcine adrenomedullin and cloning of
RT cDNA encoding its precursor.";
RL FEBS Lett. 338:306-310(1994).
RN [2]
RP SEQUENCE OF 22-41.
RC TISSUE=Adrenal medulla;
RX MEDLINE=94357274; PubMed=8076689;
RA Kitamura K., Kangawa K., Ishiyama Y., Washimine H., Ichiki Y.,
RA Kawamoto M., Minamino N., Matsuo H., Eto T.;
RT "Identification and hypotensive activity of proadrenomedullin N-
RT terminal 20 peptide (PAMP).";
RL FEBS Lett. 351:35-37(1994).
CC -1- FUNCTION: AM and PAMP are potent hypotensive and vasodilator
CC agents.
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- TISSUE SPECIFICITY: Highly expressed in adrenal glands, lung and
CC kidney.
CC -1- SIMILARITY: Belongs to the adrenomedullin family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; D14875; BAA03590.1; -.
DR PIR; S41600; S41600.
DR InterPro; IPR001710; Adrenomedullin.
DR InterPro; IPR011038; Calycin.
DR Pfam; PF02039; Adrenomedullin; 1.
DR PRINTS; PR00801; ADRENOMEDULLIN.
KW Amidation; Cleavage on pair of basic residues;
KW Direct protein sequencing; Hormone; Signal.
FT SIGNAL 1 21
FT PEPTIDE 22 41 Proadrenomedullin N-20 terminal peptide.
FT PROPEP 45 92
FT PEPTIDE 95 146 Adrenomedullin.
FT PROPEP 153 188 PreproAM C-terminal fragment (By
FT similarity).
FT DISULFID 110 115 Arginine amide (G-42 provides amide
FT MOD_RES 41 41 Tyrosine amide (G-147 provides amide
FT MOD_RES 146 146 Tyrosine amide (G-147 provides amide
FT group).
SQ SEQUENCE 188 AA; 20893 MW; 717949460F5660A61 CRC64;
Query Match 75.0%; Score 57; DB 1; Length 188;
Best Local Similarity 100.0%; Pred. No. 0.066; Mismatches 0;
Matches 10; Conservative 0; Indels 0; Gaps 0;
QY 4 HQIYQFTDKD 13
DB 122 HQIYQFTDKD 131
RESULT 7

```

```

ADML_BOVIN
ID ADML_BOVIN STANDARD; PRT; 188 AA.
AC 062827;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE ADM precursor [Contains: Adrenomedullin (AM); Proadrenomedullin N-20
DE terminal peptide (ProAM-N20) (ProAM N-terminal 20 peptide) (PAMP)].
GN Name=ADM;
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovinae; Bos.
OX NCBI_TaxID=9913;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Aorta;
RX MEDLINE=98244567; PubMed=9585168;
RA Barker S., Wood E., Clark A.J.L., Corder R.;
RT "Cloning of bovine preproadrenomedullin and inhibition of its basal
RT expression in vascular endothelial cells by staurosporine.";
RL Life Sci. 62:1407-1415(1998).
CC -1- FUNCTION: Hypotensive peptide. May function as a hormone in
CC circulation control (By similarity).
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- SIMILARITY: Belongs to the adrenomedullin family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AJ001613; CA04866.1; -.
DR InterPro; IPR001710; Adrenomedullin.
DR Pfam; PF02039; Adrenomedullin; 1.
DR PRINTS; PR00801; ADRENOMEDULLIN.
KW Amidation; Cleavage on pair of basic residues; Hormone; Signal.
FT SIGNAL 1 21
FT PEPTIDE 22 41 Proadrenomedullin N-20 terminal peptide.
FT PROPEP 45 92
FT PEPTIDE 95 146 Adrenomedullin.
FT PROPEP 148 188 PreproAM C-terminal fragment (By
FT similarity).
FT DISULFID 110 115 Arginine amide (G-42 provides amide
FT MOD_RES 41 41 Tyrosine amide (G-147 provides amide
FT MOD_RES 146 146 Tyrosine amide (G-147 provides amide
FT group).
SQ SEQUENCE 188 AA; 20981 MW; 3002E79AB3B6612C CRC64;
Query Match 68.4%; Score 52; DB 1; Length 188;
Best Local Similarity 90.0%; Pred. No. 0.52;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 4 HQIYQFTDKD 13
DB 122 HQIYQFTDKD 131
RESULT 8
ADML_CANPA
ID ADML_CANPA STANDARD; PRT; 188 AA.
AC 077559; Q9TVQ9;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE ADM precursor [Contains: Adrenomedullin (AM); Proadrenomedullin N-20
DE terminal peptide (ProAM-N20) (ProAM N-terminal 20 peptide) (PAMP)].
GN Name=ADM;
OS Canis familiaris (Dog).

```

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Carnivora; Pisces; Canidae; Canis.  
 OX NCBI\_TaxID=9615;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Imoto I., Jougaaki M.;  
 RT "Cloning of cDNA encoding canine adrenomedullin."  
 RL Submitted (JAN-1999) to the EMBL/GenBank/DBJ databases.  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=99002704; PubMed=9786655;  
 RA Ono Y., Kojima M., Okada K., Kangawa K.;  
 RT "cDNA cloning of canine adrenomedullin and its gene expression in the  
 heart and blood vessels in endotoxin shock."  
 RL Shock 10:243-247 (1998)  
 CC -!- FUNCTION: AM and PAMP are potent hypotensive and vasodilator  
 agents.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- SIMILARITY: Belongs to the adrenomedullin family.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 the European Bioinformatics Institute. There are no restrictions on its  
 use by non-profit institutions as long as its content is in no way  
 modified and this statement is not removed. Usage by and for commercial  
 entities requires a license agreement (See <http://www.1sb-sib.ch/announce/>  
 or send an email to [license@1sb-sib.ch](mailto:license@1sb-sib.ch)).  
 CC -----  
 CC DR EMBL; AF045773; AAD05423.1; -.  
 DR EMBL; U96127; AAD09957.1; -.  
 DR InterPro; IPR001710; Adrenomedullin.  
 DR Pfam; PF02039; Adrenomedullin; 1.  
 DR PRINTS; PRO0801; ADRENOMEDULLIN.  
 DR Annotation; Cleavage on pair of basic residues; Hormone; Signal.  
 KW SIGNAL 1 21 By similarity.  
 FT PEPTIDE 22 41 Proadrenomedullin N-20 terminal peptide.  
 FT PROPEP 45 92 By similarity.  
 FT PEPTIDE 95 146 Adrenomedullin.  
 FT PROPEP 148 188 PreproAM C-terminal fragment (By  
 similarity).  
 FT DISUFID 110 115 By similarity.  
 FT MOD\_RES 41 41 Arginine amide (G-42 provides amide  
 group) (By similarity).  
 FT MOD\_RES 146 146 Tyrosine amide (G-147 provides amide  
 group) (By similarity).  
 FT CONFLICT 130 130 N -> K (in Ref. 2).  
 FT SEQUENCE 188 AA; 20929 MW; 809D6A64F98F5578 CRC64;  
 SQ  
 Query Match 68.4%; Score 52; DB 1; Length 188;  
 Best Local Similarity 90.0%; Pred. No. 0.52;  
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 4 HQIYQPTDKD 13  
 Db 122 HQIYQPTDKD 131  
 RESULT 9  
 Q95KPO PRELIMINARY; PRT; 188 AA.  
 AC Q95KPO;  
 DT 01-DEC-2001 (TREMURel. 19, Created)  
 DT 01-DEC-2001 (TREMURel. 19, Last sequence update)  
 DT 01-MAR-2004 (TREMURel. 26, Last annotation update)  
 DE Adrenomedullin.  
 DE Name=PBAM-2;  
 OS Bos taurus (Bovine).  
 OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;  
 OX NCBI\_TaxID=9913;  
 OX [1]  
 RP SEQUENCE FROM N.A.

RX MEDLINE=21630318; PubMed=11754956;  
 RA Kitamura K., Matsui E., Kato J., Katoh F., Kita T., Tsuji T.,  
 RA Kangawa K., Eto T.;  
 RT "Adrenomedullin (11-26): a novel endogenous hypertensive peptide  
 RT isolated from bovine adrenal medulla."  
 RL Peptides 22:1713-1718 (2001).  
 DR EMBL; AB055107; BAB62176.1; -.  
 DR GO; GO:0005576; Extracellular; IEA.  
 DR GO; GO:0005179; Hormone activity; IEA.  
 DR InterPro; IPR001710; Adrenomedullin.  
 DR Pfam; PF02039; Adrenomedullin; 1.  
 DR PRINTS; PRO0801; ADRENOMEDULLIN.  
 SQ SEQUENCE 188 AA; 20963 MW; 6102E9A756DCA86 CRC64;  
 Query Match 68.4%; Score 52; DB 2; Length 188;  
 Best Local Similarity 90.0%; Pred. No. 0.52;  
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 4 HQIYQPTDKD 13  
 Db 122 HQIYQPTDKD 131  
 RESULT 10  
 ADML MOUSE STANDARD; PRT; 184 AA.  
 AC P97257; P97453;  
 DT 16-OCT-2001 (Rel. 40, Created)  
 DT 16-OCT-2001 (Rel. 40, Last sequence update)  
 DT 05-JUL-2004 (Rel. 44, Last annotation update)  
 DE ADM precursor (Contains: Adrenomedullin (AM); Proadrenomedullin N-20  
 DE terminal peptide (ProAM-N20) (ProAM N-terminal 20 peptide) (PAMP)).  
 GN Name=Adm.  
 OS Mus musculus (Mouse).  
 OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=129/Sv;  
 RX MEDLINE=97092892; PubMed=8938454;  
 RA Okazaki T., Ogawa Y., Tamura N., Mori Y., Ise N., Aoki T.,  
 RA Rochelle J.M., Takeko M.M., Seldin M.F., Nakao K.;  
 RT "Genomic organization, expression, and chromosomal mapping of the  
 RT mouse adrenomedullin gene."  
 RL Genomics 37:395-399 (1996).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J;  
 RX MEDLINE=99046755; PubMed=9808778;  
 RA Yotsumoto S., Shimada T., Cui C.Y., Nakashima H., Fujiwara H.,  
 RA Ko M.S.H.;  
 RT "Expression of adrenomedullin, a hypotensive peptide, in the  
 RT trophoblast giant cells at the embryo implantation site in mouse."  
 RL Dev. Biol. 203:264-275 (1998).  
 CC -!- FUNCTION: AM and PAMP are potent hypotensive and vasodilator  
 agents.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- SIMILARITY: Belongs to the adrenomedullin family.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 the European Bioinformatics Institute. There are no restrictions on its  
 use by non-profit institutions as long as its content is in no way  
 modified and this statement is not removed. Usage by and for commercial  
 entities requires a license agreement (See <http://www.1sb-sib.ch/announce/>  
 or send an email to [license@1sb-sib.ch](mailto:license@1sb-sib.ch)).  
 CC -----  
 CC DR EMBL; D78349; BA011367.1; -.  
 DR EMBL; U77630; AAB36535.1; -.  
 DR MGD; MGI:108058; Adm.  
 DR InterPro; IPR001710; Adrenomedullin.  
 DR Pfam; PF02039; Adrenomedullin; 1.

DR PRINTS; PRO0801; ADRENOMEDULLIN.  
 KW Amidation; Cleavage on pair of basic residues; Hormone; Signal.  
 FT SIGNAL 1 21 By similarity.  
 FT PEPTIDE 22 41 Proadrenomedullin N-20 terminal peptide.  
 FT PROPEP 45 92 By similarity.  
 FT PEPTIDE 95 144 Adrenomedullin.  
 FT PROPEP 151 184 ProPOM C-terminal fragment (By similarity).  
 FT DISULFID 108 113 Arginine amide (G-42 provides amide  
 FT MOD\_RES 41 41 group) (By similarity).  
 FT MOD\_RES 144 144 Tyrosine amide (G-145 provides amide  
 FT group) (By similarity).  
 FT CONFLICT 173 173 A -> G (in Ref. 2).  
 SQ SEQUENCE 184 AA; 20764 MW; C88C9045A79C898 CRC64;

Query Match 67.1%; Score 51; DB 1; Length 184;  
 Best Local Similarity 90.0%; Pred. No. 0.77;  
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4 HQIYQFTDKD 13  
 Db 120 HQIYQFTDKD 129

RESULT 11  
 AAHS2665 PRELIMINARY; PRT; 184 AA.  
 ID AAHS2665;  
 AC AAHS2665;  
 DT 02-MAR-2004 (TrEMBLrel. 27, Created)  
 DT 02-MAR-2004 (TrEMBLrel. 27, Last sequence update)  
 DT 02-MAR-2004 (TrEMBLrel. 27, Last annotation update)  
 DE Adrenomedullin.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 OC NCBI\_TaxId=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=Egg;  
 RX MEDLINE=22388257; PubMed=12477932;  
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
 RA Altschul S.F., Zeeberg B., Buetow K.H., Scheffer C.F., Bhat N.K.,  
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
 RA Diatchenko L., Marusik K., Farmer A.A., Rubin G.W., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldo M.P., Casavant T.L., Scheetz T.E.,  
 RA Brownstein M.J., Ueda T.B., Tomihata S., Carninci P., Frange C.,  
 RA Rana S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mulhally S.J.,  
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hultk S.W.,  
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,  
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,  
 RA Krzywinski M.I., Skalska U., Smalins D.E., Schnerch A., Schein J.E.,  
 RA Jones S.J., Marra M.A.;  
 RT "Generation and initial analysis of more than 15,000 full-length human  
 and mouse cDNA sequences";  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=Egg;  
 RA Strausberg R.;  
 RU Submitted (May-2003) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; BC052665; AAHS2665.1; -;  
 SQ SEQUENCE 184 AA; 20750 MW; C88C9903C479C898 CRC64;

Query Match 67.1%; Score 51; DB 2; Length 184;  
 Best Local Similarity 90.0%; Pred. No. 0.77;  
 Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4 HQIYQFTDKD 13  
 Db 120 HQIYQFTDKD 129

RESULT 12  
 Q55549 PRELIMINARY; PRT; 643 AA.  
 ID Q55549;  
 AC Q55549;  
 DT 01-NOV-1996 (TrEMBLrel. 01, Created)  
 DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)  
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
 DE S1r0168 protein.  
 OS OrderedLocustNames=s1r0168;  
 GN Synecocystis sp. (strain PCC 6803).  
 OC Bacteria; Cyanobacteria; Chroococcales; Synecocystis.  
 OC NCBI\_TaxId=1148;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=PCC6803;  
 RX MEDLINE=97061201; PubMed=8905231;  
 RA Kaneko T., Sato S., Kotani H., Tanaka A., Asamizu E., Nakamura Y.,  
 RA Miyajima N., Hiroseawa M., Sugita M., Sasamoto S., Kimura T.,  
 RA Hosouchi T., Matsuno A., Muraki A., Nakazaki N., Kuro K., Okumura S.,  
 RA Shimp S., Takeuchi C., Wada T., Watanabe A., Yamada M., Yasuda M.,  
 RA Tabata S.;  
 RT "Sequence analysis of the genome of the unicellular cyanobacterium  
 RT Synecocystis sp. strain PCC6803. II. Sequence determination of the  
 RT entire genome and assignment of potential protein-coding regions.";  
 RL DNA Res. 3:109-136(1996).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=96127529; PubMed=8590279;  
 RA Kaneko T., Tanaka A., Sato S., Kotani H., Sazuka T., Miyajima N.,  
 RA Sugita M., Tabata S.;  
 RT "Sequence analysis of the genome of the unicellular cyanobacterium  
 RT Synecocystis sp. strain PCC6803. I. Sequence features in the 1 Mb  
 RT region from map positions 64k to 92k of the genome.";  
 RL DNA Res. 2:153-166(1995).  
 DR EMBL; D63999; BAA10047.1; -;  
 DR PIR; S76069; S76069.  
 KW Complete proteome.  
 SQ SEQUENCE 643 AA; 68369 MW; 1EB9001D3332B411 CRC64;

Query Match 67.1%; Score 51; DB 2; Length 643;  
 Best Local Similarity 72.7%; Pred. No. 2.9;  
 Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 3 GHQIYQFTDKD 13  
 Db 447 GHQIYQFTDKD 457

RESULT 13  
 Q24544 PRELIMINARY; PRT; 388 AA.  
 ID Q24544;  
 AC Q24544;  
 DT 01-NOV-1996 (TrEMBLrel. 01, Created)  
 DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)  
 DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
 DE Homologous to synapsin II (fragment).  
 GN Name=Syn; Synonyms=SYN2;  
 OS Drosophila melanogaster (Fruit fly).  
 OC Neoptera; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
 OC Eukaryota; Metazoa; Arthropoda; Insecta; Pterygota;  
 OC Ephydroidea; Drosophilidae; Drosophila.  
 OC NCBI\_TaxId=7227;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=wildtype 'Berlin'; TISSUE=Head;  
 RX MEDLINE=96209149; PubMed=8627354;  
 RA Klages B.R., Heimbeck G., Godenschwege T.A., Hofbauer A.,  
 RA Pflugfelder G.O., Reifegerste R., Reisch D., Schupp M., Buchner S.,



RA Buchner.E.;  
RT "Invertebrate synaptrins: a single gene codes for several isoforms in  
RL Drosophila.",  
RN J. Neurosci. 16:3154-3165 (1996).  
[2]  
RP SEQUENCE FROM N.A.  
RC STRAIN-Wildtype 'Berlin'; TISSUE=Head;  
RA Klages B.R.;  
RL Submitted (JAN-1996) to the EMBL/GenBank/DBJ databases.  
DR EMBL; X95454; CAA64724.1; -  
DR FlyBase; FBgn0004575; Syn.  
DR GO; GO:0008021; C:synaptic vesicle; IEA.  
DR GO; GO:0007269; P:neurotransmitter secretion; IEA.  
DR InterPro; IPR001359; Synapsin.  
DR Pfam; PF02750; Synapsin\_C; 1.  
DR Pfam; PF02078; Synapsin\_N; 1.  
DR PRINTS; PR01368; SYNAPSIN.  
DR NON TER  
SQ SEQUENCE 388 AA; 42887 MW; 583B24E6456CBF40 CRC64;  
Query Match 59.9%; Score 45.5; DB 2; Length 388;  
Best Local Similarity 52.6%; Pred. No. 17;  
Matches 10; Conservative 0; Mismatches 2; Indels 7; Gaps 1;  
CY 1 YGS-----HQIYPTDX 12  
DB 81 YGSVPSTNSLSTHYFQDK 99  
RESULT 14  
Q8INM4 PRELIMINARY; PRT; 488 AA.  
AC Q8INM4  
DT 01-MAR-2003 (TREMBlrel. 23, Created)  
DT 01-MAR-2003 (TREMBlrel. 23, Last sequence update)  
DT 01-MAR-2004 (TREMBlrel. 26, Last annotation update)  
DE CG3985-PC  
GN Name=Syn; ORFName=CG3985;  
OS Drosophila melanogaster (Fruit fly).  
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;  
OC Ephydroidea; Drosophilidae; Drosophila.  
OX NCBI\_TaxID=7227;  
[1]  
RN SEQUENCE FROM N.A.  
RX MEDLINE=20196006; PubMed=10731132;  
RA Adams M.D., Celuker S.E., Holt R.A., Evans C.A., Gocayne J.D.,  
R Aumanides P.G., Scherer S.E., Li P.W., Hoikins R.A., Galie R.F.,  
R George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,  
R Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,  
R Brindon R.C., Rogers Y.H., Blazek R.G., Champe M., Pfeiffer B.D.,  
R Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Gabor G.L.,  
R Abril J.F., Aghayani A., An H.J., Andrews-Pfankuch C., Baldwin D.,  
R Ballew R.M., Banu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,  
R Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,  
R Borokova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,  
R Butts K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,  
R Chertis J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,  
R de Pallos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,  
R Dodson K., Doup L.R., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,  
R Durbin K.J., Evangelista C.C., Ferrara C., Ferreira S., Fleischmann W.,  
R Foele C., Gaboriellian A.E., Garg N.S., Gelbart W.M., Glaeser K.,  
R Glodok A., Gong P., Gorrell J.H., Gu Z., Guan P., Harris M.,  
R Harris N.L., Harvey D., Heiman T.J., Hernandez J.B., Houck J.,  
R Hostin D., Houston K.A., Howland T.J., Hernandez J.B., Hwang C.,  
R Jaitai M., Kalush P., Karpen G.H., Ke Z., Kennison J.A., Kechum K.A.,  
R Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,  
R Laeko P.E., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,  
R Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson J.,  
R Mekulov G., Mlehnina N.V., Moberly C., Morris J., Moshrefi A.,  
R Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,  
R Nelson D.R., Nelson K.A., Nixon K., Nuskern D.R., Pacled J.M.,  
R Palazzolo W., Plattman G.S., Pan S., Pollard J., Puri V., Reese M.G.,

RA Rehner K., Remington K., Saunders R.D., Scheeler F., Shen H.,  
RA Shue B.C., Sliden-Klimos I., Simpson M., Skupski M.P., Smith T.,  
RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,  
RA Svitskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,  
RA Wang Z.Y., Wassarman D.A., Weinstein G.M., Weissbach J.,  
RA Williams S.M., Woodger, Morley K.C., Wu D., Yang S., Yao Q.A., Ye J.,  
RA Yeh R.P., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,  
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,  
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.,  
RL "The genome sequence of *Drosophila melanogaster*,"  
RL Science 287:2185-2195(2000).  
[2]  
RP SEQUENCE FROM N.A.  
RP MEDLINE=22426065; PubMed=12537568;  
RA Celniker S.E., Wheeler D.A., Krommiller B., Carlson J.W., Halpern A.,  
RA Patel S., Adams M., Champe M., Dugan S.P., Fritze B., Hodgson A.,  
RA George R.A., Hoskins R.A., Laverly T., Muzny D.M., Nelson C.R.,  
RA Pacle J.M., Park S., Pfeiffer B.D., Richards S., Sodergren E.J.,  
RA Svitskas R., Taber P.E., Wan K., Stapleton M., Sutton G.G., Venter C.,  
RA Weinstein G., Scherer S.E., Myers E.W., Gibbs R.A., Rubin G.M.,  
RT "Finishing a whole-genome shotgun: release 3 of the *Drosophila*  
RT melanogaster euchromatic genome sequence,"  
RL Genome Biol. 3:RESEARCH0079-RESEARCH0079(2002).  
[3]  
RP SEQUENCE FROM N.A.  
RP MEDLINE=22426070; PubMed=12537573;  
RA Kaulin J.S., Bergman C.M., Krommiller B., Carlson J., Svitskas R.,  
RA Patel S., Fritze B., Wheeler D.A., Lewis S.E., Rubin G.M.,  
RA Ashburner M., Celniker S.E.,  
RT "The transposable elements of the *Drosophila melanogaster* euchromatin:  
RT a genomic perspective,"  
RL Genome Biol. 3:RESEARCH0084-RESEARCH0084(2002).  
[4]  
RP SEQUENCE FROM N.A.  
RP MEDLINE=22426099; PubMed=12537572;  
RA Miura S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,  
RA Hradecky P., Huang Y., Kaulin J.S., Millburn G.H., Prochuk S.B.,  
RA Smith C.D., Tupy J.U., Whitfield E.J., Beyrekaratoglu U., Berman B.P.,  
RA Beltracchi J., Celniker S.E., de Grey A.D., Drysdale R.A.,  
RA Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.O.,  
RA Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,  
RA Lewis S.E.,  
RT "Annotation of the *Drosophila melanogaster* euchromatic genome: a  
RT systematic review,"  
RL Genome Biol. 3:RESEARCH0083-RESEARCH0083(2002).  
[5]  
RP SEQUENCE FROM N.A.  
RP FLYBASE;  
RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.  
[6]  
RP SEQUENCE FROM N.A.  
RP FLYBASE;  
RL Submitted (MAR-2004) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AB003686; AAI13464.2; --  
DR HSPB; P17599; IATX.  
DR FLYBASE; FBGN0004575; Syn.  
DR GO; GO:0008021; C:synaptic vesicle; IEA.  
DR GO; GO:0007269; P:neurotransmitter secretion; IEA.  
DR InterPro; IPR001359; Synapsin.  
DR Pfam; PF02750; Synapsin\_C; 1.  
DR Pfam; PF02078; Synapsin\_N; 1.  
DR PRINTS; PR01368; SYNAPSIN.  
SQ SEQUENCE 488 AA; 52962 MW; 452EDPAD4C26241E CRC64;

Query Match 59.9%; Score 45.5; DB 2; Length 488;  
Best Local Similarity 52.6%; Pred. No. 21;  
Matches 10; Conservative 0; Mismatches 2; Indels 7; Gaps 1;

1 YG-----HQIQFTDK 12  
||| ||| ||| |||  
Db 181 YGVGPSINSLHSITGFQDK 199

```

RESULT 15
ID AAN13464 PRELIMINARY; PRT; 488 AA.
AC AAN13464;
DT 01-APR-2004 (TrEMBLrel. 27, Created)
DT 01-APR-2004 (TrEMBLrel. 27, Last sequence update)
DT 01-APR-2004 (TrEMBLrel. 27, Last annotation update)
DE CG3985-PC.
GN SYN OR CG3985.
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_Taxid=7227;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20196006; PubMed=10731132;
RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA George R.A., Lewis S.B., Richards S., Ashburner M., Henderson S.N.,
RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA Brandon R.C., Rogers Y.H., Bialek R.G., Champe M., Pfeiffer B.D.,
RA Wan K.H., Doyle C., Baxter B.G., Helt G., Nelson C.R., Gaber G.L.,
RA Abt J.F., Agbayani A., An H.J., Andrews-Plankoch C., Baldwin D.,
RA Bailly R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brotcher P.,
RA Burris K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA dePablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,
RA Foslter C., Gabrielian A.E., Gary N.S., Gelbart W.M., Glasser K.,
RA Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Honck J.,
RA Hostin D., Houston K.A., Howland T.J., Wei M.H., Ibegwan C.,
RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kenison J.A., Ketchum K.A.,
RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
RA Laske P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
RA Liu X., Martel B., McIntosh T.C., McLeod M.P., McPherson D.,
RA Merkulov G., Mlehnina N.V., Mobarry C., Morris J., Moshrefi A.,
RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA Nelson D.R., Nelson K.A., Nixon K., Nuskeirn D.R., Pacleb J.M.,
RA Palazolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA Reinert K., Remington K., Saunders R.D., Scheeler F., Shen H.,
RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,
RA Spier B., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA Wang Z.Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,
RA Williams S.M., Woodage J., Worley K.C., Wu D., Yang S., Yao Q.A., Ye J.,
RA Yeh R.F., Zaveri J.S., Zhan M., Zhang K.C., Zhao Q., Zheng L.,
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.,
RT "The genome sequence of Drosophila melanogaster.",
RN Science 287:2185-2195(2000).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=22426065; PubMed=12537568;
RA Celniker S.E., Wheeler D.A., Kronmiller B., Carlson J.W., Halpern A.,
RA Patel S., Adams M., Champe M., Dugan S.P., Frise E., Hodgson A.,
RA George R.A., Hoskins R.A., Laverly T., Muzny D.M., Nelson C.R.,
RA Pacleb J.M., Park S., Pfeiffer B.D., Richards S., Sodergren E.J.,
RA Svirskas R., Taber P.E., Wan K., Stapleton M., Sutton G.G., Venter C.,
RA Weinstock G., Scherer S.B., Myers E.W., Gibbs R.A., Rubin G.M.,
RT "Finishing a whole-genome shotgun: release 3 of the Drosophila
RT melanogaster euchromatic genome sequence.",
RN Genome Biol. 3:RESEARCH0079-RESEARCH0079(2002).
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=22426069; PubMed=12537572;
RA Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochownik S.B.,
RA Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,
RA Bettencourt B.R., Celniker S.E., de Grey A.D., Drysdale R.A.,
RA Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA Lewis S.B.,
RT "Annotation of the Drosophila melanogaster euchromatic genome: a
RT systematic review.",
RN Genome Biol. 3:RESEARCH0083-RESEARCH0083(2002).
RN [4]
RP SEQUENCE FROM N.A.
RX MEDLINE=22426070; PubMed=12537573;
RA Kaminker J.S., Bergman C.M., Kronmiller B., Carlson J., Svirskas R.,
RA Patel S., Frise E., Wheeler D.A., Lewis S.B., Rubin G.M.,
RA Ashburner M., Celniker S.B.,
RT "The transposable elements of the Drosophila melanogaster euchromatin:
RT a genomic perspective.",
RN Genome Biol. 3:RESEARCH0084-RESEARCH0084(2002).
RN [5]
RP SEQUENCE FROM N.A.
RA FlyBase;
RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
RN [6]
RP SEQUENCE FROM N.A.
RA FlyBase;
RL Submitted (MAR-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; AE003686; AAN13464.2; -.
SQ SEQUENCE 488 AA; 52962 MW; 452RDAD4C26241B CRC64;

Query Match 59.9%; Score 45.5; DB 2; Length 488;
Best Local Similarity 52.6%; Pred. No. 21;
Matches 10; Conservative 0; Mismatches 2; Indels 7; Gaps 1;

QY 1 YCG-----HOIYQPTDK 12
DB 181 YGGVPSINSLSHYQGRDK 199

```

Search completed: January 5, 2005, 08:43:46  
Job time : 78.0455 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 5, 2005, 08:39:23 ; Search time 159.932 Seconds  
(without alignments)  
69.533 Million cell updates/sec

Title: US-09-931-700-3

Perfect score: 163  
Sequence: 1 TVQKLAHQYQFTDQKDNVAPRSKISPGCY 31

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2002273 seqs, 358729299 residues

Total number of hits satisfying chosen parameters: 2002273

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database :

A\_Geneseq\_23Sep04:\*

1: geneseqp1980s:\*

2: geneseqp1980s:\*

3: geneseqp2000s:\*

4: geneseqp2001s:\*

5: geneseqp2002s:\*

6: geneseqp2003as:\*

7: geneseqp2003bs:\*

8: geneseqp2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	163	100.0	31	2 AAW25160	AAW25160 Human pre
2	163	100.0	31	4 AAB91762	AAB91762 Adrenomed
3	163	100.0	31	4 AAE09827	AAE09827 Human adr
4	163	100.0	31	7 ADC25153	ADC25153 Human ang
5	163	100.0	31	8 ADP18403	ADP18403 Neurogene
6	163	100.0	31	4 AAB91759	AAB91759 Adrenomed
7	163	100.0	31	4 AAB75110	AAB75110 Human adr
8	163	100.0	31	4 AAB09818	AAB09818 Human adr
9	163	100.0	31	4 AABP55104	AABP55104 Human ang
10	163	100.0	31	7 ADC25152	ADC25152 Human ang
11	163	100.0	31	7 ADG91993	ADG91993 Human mat
12	163	100.0	31	8 ADL91994	ADL91994 Adrenomed
13	163	100.0	31	8 ADM94034	ADM94034 Human AM
14	163	100.0	31	8 ADM93278	ADM93278 Exemplary
15	163	100.0	31	8 ADM98309	ADM98309 Mature hu
16	163	100.0	31	8 ADP18429	ADP18429 Neurogene
17	163	100.0	31	8 ADP18402	ADP18402 Neurogene
18	163	100.0	31	4 AAB75111	AAB75111 Glycine e
19	163	100.0	31	4 AAB75112	AAB75112 Glycine e
20	163	100.0	31	6 AABU1865	AABU1865 Universal
21	163	100.0	31	4 AAB75113	AAB75113 Linker pe
22	163	100.0	31	8 ADP55556	ADP55556 Active hu
23	163	100.0	120	4 AAB75123	AAB75123 USP4(1-56
24	163	100.0	120	4 AAB75122	AAB75122 USP4(1-57
25	163	100.0	120	6 AABU1866	AABU1866 Universal

#### ALIGNMENTS

26	163	100.0	120	6 AABU18670	AABU18670 Universal
27	163	100.0	147	4 AAB75124	AAB75124 USP4(1-84
28	163	100.0	147	6 AABU18671	AABU18671 Universal
29	163	100.0	170	4 AAB75114	AAB75114 Thiorodox
30	163	100.0	185	4 AAB60344	AAB60344 Human adr
31	163	100.0	185	4 AAB49697	AAB49697 Human adr
32	163	100.0	185	6 AAB72347	AAB72347 Adrenomed
33	163	100.0	185	7 ADA27595	ADA27595 Human adr
34	163	100.0	185	8 ADP55557	ADP55557 Human adr
35	163	100.0	185	8 ADN10849	ADN10849 Human adr
36	163	100.0	185	8 ADM98308	ADM98308 Human pre
37	163	100.0	185	8 ADP19855	ADP19855 Human pre
38	163	100.0	185	8 ADP12587	ADP12587 Protein e
39	163	100.0	185	8 AD036937	AD036937 Human pro
40	163	100.0	186	7 ADP18582	ADP18582 Human dis
41	163	100.0	206	6 AABU18668	AABU18668 Universal
42	161	98.8	31	7 ADB51624	ADB51624 Adrenomed
43	157	96.3	52	7 AAB51615	AAB51615 Adrenomed
44	157	96.3	188	4 AAB60345	AAB60345 Porcine a
45	157	96.3	188	4 AAB49698	AAB49698 Porcine a

RESULT 1  
AAW25160 standard; peptide; 31 AA.

XX	AAW25160;	
XX	08-DEC-1997 (first entry)	
XX	Human preproadrenomedullin derived immunogen, P072.	
XX	Adrenomedullin; antibody; detection; diagnosis; cancer; renal; bone;	
XX	skin; blood related; disease; type II diabetes; preclampsia;	
XX	neurotransmission; regulation; allergy; mast cell degranulation;	
XX	antibacterial; antifungal; wound repair.	
XX	Homo_sapiens.	
XX		
XX	Key	Location/Qualifiers
XX	Peptide	1..31
XX	Modified-site	31
XX		/note= "amidated"
XX	W09707214-A1.	
XX	27-FEB-1997.	
XX	16-AUG-1996;	96MO-US013286.
XX	18-AUG-1995;	95US-0002514P.
XX	30-AUG-1995;	95US-0002936P.
XX	PR 12-MAR-1996;	96US-0013172P.
XX	(USSH ) US DEPT HEALTH & HUMAN SERVICES.	
XX	Cutcliffe F, Martinez A, Miller MJ, Unsworth EJ, Hook W, Walsh T;	
XX	Gray K, Macri C;	
XX	WPI; 1997-165298/15.	
XX	Human adrenomedullin peptide(s), P070, P071, P072 and PAMP-20 - used in	
XX	the diagnosis and treatment of type II diabetes and cancer.	
XX	Claim 1; Page 43; 106pp; English.	
XX	Human adrenomedullin (AM) peptides P070, P071, P072 and PAMP-20 were used	
XX	for the production of anti-AM antibodies (Ab). P070 represents preproAM	
XX	amino acids (aa) 34-41 with the sequence Tyr-Tyr attached at the N-	

CC terminus, POT1 represents preproAM aa 122-131 with the sequence Tyr-Gly-  
 CC Gly attached at the N-terminus, POT2 represents preproAM aa 116-146 and  
 CC PAMP-20 represents the proAM N-terminus. The Ab are useful for the  
 CC prevention and/or treatment of cancers, e.g. adrenal, nervous system,  
 CC lung, colon, ovarian and breast cancer by inhibiting cell growth. They  
 CC are also useful for regulating insulin secretion and blood glucose  
 CC metabolism and therefore for treating and/or preventing diabetes type II.  
 CC They may be used for the diagnosis or treatment of conditions relating to  
 CC pregnancy e.g. preclampsia. The Ab are also useful for the following:  
 CC (i) regulating neurotransmission or neuron growth in areas of the central  
 CC nervous system; (ii) lessening or inhibiting mast cell degranulation and  
 CC hence reducing the effects of an allergic response; (iii) inhibiting or  
 CC preventing bacterial and fungal growth (to treat infection); (iv)  
 CC facilitating wound healing; and (v) promoting organ and bone development

XX SQ Sequence 31 AA;

Query Match 100.0%; Score 163; DB 2; Length 31;  
 Best Local Similarity 100.0%; Pred. No. 3.6e-18;  
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVQKLAHQIYQFTDKDKNVAPRSKISPOGY 31  
 DB 1 TVQKLAHQIYQFTDKDKNVAPRSKISPOGY 31

RESULT 2

AAB91762 standard; peptide; 31 AA.

XX AAB91762;

DT 22-JUN-2001 (first entry)

XX Adrenomedullin peptide (AM) SEQ ID NO:938.

KW Protection; endogenous therapeutic peptide; peptidase; conjugation;  
 KM blood component; modification; succinimideyl; maleimide group; amino;  
 KM hydroxyl; thiol; hormone; growth factor; neurotransmitter.

OS Homo sapiens.  
 OS Synthetic.

XX WO200063900-A2.

XX 23-NOV-2000.

PF 17-MAY-2000; 2000MO-US013576.

XX 17-MAY-1999; 99US-0134406P.

PR 10-SEP-1999; 99US-0153406P.

PR 15-OCT-1999; 99US-0159783P.

XX (CONJ-) CONJUCHEM INC.

PI Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibaudau K;

XX WPI; 2001-112059/12.

PT Modifying and attaching therapeutic peptides to albumin prevents  
 PT peptidase degradation, useful for increasing length of in vivo activity.

XX Disclosure; Page 499-500; 733pp; English.

CC The present invention describes a modified therapeutic peptide (1)  
 CC comprising a therapeutically active amino acid region (III) and a  
 CC reactive group (II) (e.g. succinimideyl and maleimide groups) attached to  
 CC a less therapeutically active amino acid region (IV), which covalently  
 CC bonds with amino/hydroxyl/thiol groups on blood components to form a  
 CC peptidase stabilised therapeutic peptide composed of 3-50 amino acids.  
 CC (1) are useful for modifying therapeutic peptides e.g. hormones, growth  
 CC factors and neurotransmitters, to protect them from peptidase activity in  
 CC vivo for the treatment of various disorders. Endogenous therapeutic

CC peptides are not suitable as drug candidates as they require frequent  
 CC administration due to rapid degradation by peptidases in the body.  
 CC Modifying and attaching therapeutic peptides to albumin prevents or  
 CC reduces the action of peptidases to increase length of activity (half  
 CC life) and specificity as bonding to large molecules decreases  
 CC intracellular uptake and interference with physiological processes.  
 CC AAB90829 to AAB92441 represent peptides which can be used in the  
 CC exemplification of the present invention

XX SQ Sequence 31 AA;

Query Match 100.0%; Score 163; DB 4; Length 31;  
 Best Local Similarity 100.0%; Pred. No. 3.6e-18;  
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVQKLAHQIYQFTDKDKNVAPRSKISPOGY 31  
 DB 1 TVQKLAHQIYQFTDKDKNVAPRSKISPOGY 31

RESULT 3

AAB90827 standard; peptide; 31 AA.

XX AAB90827;

DT 29-NOV-2001 (first entry)

XX Human adrenomedullin peptide #2.

KW Human; vasoactive peptide; calcitonin gene related peptide; CGRP;  
 KM CGRP-receptor identification; adrenomedullin.

OS Homo sapiens.

PH Key Location/Qualifiers  
 FT Modified-site 31  
 FT "C-terminal amide"

PN US6268474-B1.

XX 31-JUL-2001.

PF 30-APR-1998; 98US-00070504.

PR 30-APR-1998; 98US-00070504.

XX (UYCR-) UNIV CREIGHTON.

PI Smith DD, Saha S, Abel PW;

DR WPI; 2001-564216/63.

PT Vasoactive peptides useful for inhibiting calcitonin gene related peptide  
 PT receptor activity.

XX Claim 5; Col 6; 24pp; English.

CC The invention relates to antagonists of the vasoactive peptide calcitonin  
 CC gene related peptide (CGRP) and other members of the CGRP superfamily.  
 CC The invention also relates to amino the terminal modifications of  
 CC peptides to improve their ability to bind to a member of the CGRP-  
 CC receptor super-family. CGRP antagonists are used for inhibiting CGRP  
 CC activity which can be used in vitro e.g. in assays to identify and/or  
 CC isolate CGRP receptors or with intact cells either in vitro or in vivo to  
 CC inhibit the effect of CGRP binding to its receptor. The present sequence  
 CC is human adrenomedullin peptide

XX SQ Sequence 31 AA;

Query Match 100.0%; Score 163; DB 4; Length 31;  
 Best Local Similarity 100.0%; Pred. No. 3.6e-18;  
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TVOKLAHQIYQFTDKDKNVAPRSKISPOGY 31  
Db 1 TVOKLAHQIYQFTDKDKNVAPRSKISPOGY 31

## RESULT 4

ID ADC25153 standard; peptide; 31 AA.

AC ADC25153;

DT 18-DEC-2003 (first entry)

DE Human angiogenesis inhibiting peptide #SEQ ID 2.

KW Cytostatic; gene therapy; cancer; stomach; colon; pulmonary; ovarian;  
KM liver; pancreatic; human.

OS Homo sapiens.

PN WO2003078460-A1.

PD 25-SEP-2003.

PF 19-MAR-2003; 2003WO-JP003344.

PR 19-MAR-2002; 2002JP-00075575.

PA (HOKK-) HOKKAIDO TECHNOLOGY LICENSING OFFICE CO.

PI Kobayashi M;

DR WPI; 2003-767505/72.

PT Peptides with effect on inhibiting angiogenesis in cancer cells and  
inhibiting proliferation of cancer cells, and encoded polynucleotides,  
PT applicable in drug compositions for treating cancer.

PS Example 2, SEQ ID NO 2; 41pp; Japanese.

XX The invention relates to peptides comprising an amino acid sequence  
CC derived from a fully defined 52 amino acid sequence (S1) given in the  
CC specification. Peptides may be created by deletion of some amino acids  
CC from the N-terminal of S1. The peptides are applicable in drug  
CC compositions for treating cancer e.g. stomach cancer, colon cancer,  
CC pulmonary cancer, ovarian cancer, liver cancer or pancreatic cancer. The  
CC current sequence represents an angiogenesis inhibiting peptide of the  
CC invention.

SO Sequence 31 AA;

Query Match 100.0%; Score 163; DB 7; Length 31;

Best Local Similarity 100.0%; Pred. No. 3, 6e-18;

Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TVOKLAHQIYQFTDKDKNVAPRSKISPOGY 31  
Db 1 TVOKLAHQIYQFTDKDKNVAPRSKISPOGY 31

## RESULT 5

ID ADP18403 standard; peptide; 31 AA.

AC ADP18403;

DT 26-AUG-2004 (first entry)

DE Neurogenesis modulation-related peptide Segid17.

KW neurogenesis modulation; neural tissue; central nervous system disorder;  
KM neurodegenerative; ischaemic; learning and memory disorder;

KM neurological trauma; nootropic; neuroprotective; CNS-Gen;  
KM cerebroprotective; vasotropic; anticonvulsant; antiparkinsonian;  
KM haemostatic; hypertensive; muscular-Gen; ophthalmological;  
KM antiinflammatory; analgesic; antidiabetic; neurogenesis modulator;  
KM neural stem cell; progenitor cell;  
KM neural tissue G-protein coupled receptor activator; neurogenesis inducer;  
KM intracellular neural CaMP enhancer; intracellular neural CaMP stimulator;  
KM intracellular neural Ca 2+ enhancer; Parkinson's disease;  
KM Parkinson's disorder; Huntington's disease; Alzheimer's disease;  
KM multiple sclerosis; amyotrophic lateral sclerosis; Shy-Drager syndrome;  
KM progressive supranuclear palsy; Lewy body disease; spinal ischaemia;  
KM ischaemic stroke; cerebral infarction; spinal cord injury;  
KM cancer-related brain; spinal cord injury; multi-infarct dementia;  
KM geriatric dementia; CaMP level; embryonic tissue; human.

XX Homo sapiens.

PN WO2004045592-A2.

PD 03-JUN-2004.

PF 20-NOV-2003; 2003WO-IB005311.

PR 20-NOV-2002; 2002US-0427912P.

PA (NEUR-) NEURONOVA AB.

PI (BERT/) BERTILSSON G.

DR (ERLA/) ERLANDSSON R.

PT (FRIS/) FRISSEN J.

PA (HAEG/) HAEGESTRAND A.

PA (HEID/) HEIDRICH J.

PA (HAEG/) HAEGBLAD J.

PA (JANS/) JANSSEN K.

PA (KORT/) KORTESMAA J.

PA (LUND/) LUNDQUIST P.

PA (LUND/) LUNDH H.

PA (MCGU/) MCGUIRE J.

PA (MERC/) MERCER A.

PA (NJBG/) NJBERG K.

PA (OSSO/) OSSOINAK A.

PA (PATR/) PATRONE C.

PA (ROEN/) ROENHOLM H.

PA (ZACH/) ZACHRISSON O.

PA (WIKS/) WIKSTROM L.

XX Bertilsson G, Eriandsson R, Frisen J, Haegestrang A, Heidrich J;

PI Hellerroem K, Haegblad J, Jansson K, Kortessmaa J, Lindquist P;

PI Lundh H, McGuire J, Mercer A, Njberg K, Ossoinak A, Patrone C;

PI Roenholm H, Zachrisson O, Wikstrom L;

DR WPI; 2004-449666/42.

PT Use of agent(s) that elevate intracellular cyclic adenosine monophosphate  
or intracellular calcium levels in neural tissue for modulating  
PT neurogenesis to treat central nervous system disorder.

PS Disclosure; SEQ ID NO 17; 77pp; English.

XX This invention relates to a novel method of modulating neurogenesis in  
CC the neural tissue of a patient exhibiting symptom(s) of a central nervous  
CC system disorder, such as neurodegenerative, ischemic or learning and  
CC memory disorder or neurological trauma. The method involves at least one  
CC agent (A) that elevates intracellular cyclic adenosine monophosphate  
CC (CaMP) levels or at least one agent (B) that elevates intracellular Ca 2+  
CC levels in the neural tissue, which is administered where (A) modulates  
CC production of compounds with a nootropic, neuroprotective, CNS-Gen,  
CC cerebroprotective, vasotropic, anticonvulsant, antiparkinsonian,  
CC haemostatic, hypertensive, muscular-Gen, ophthalmological,  
CC antiinflammatory, analgesic or antidiabetic activity. These compounds may  
CC act as neurogenesis modulators, neural stem or progenitor cell  
CC proliferation, differentiation and/or migration modulators, neural tissue

CC G-protein coupled receptor activators, neurogenesis inducers,  
 CC intracellular neural CAMP enhancers, intracellular neural CAMP  
 CC stimulators or intracellular neural Ca<sup>2+</sup> enhancers. The invention is  
 CC useful for modulating neurogenesis in neural tissue of a patient  
 CC exhibiting at least one symptom of central nervous system disorder, such  
 CC as Parkinson's disease and Parkinson's disorders, Huntington's disease,  
 CC Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis,  
 CC Shy-Drager syndrome, progressive supranuclear palsy, Lewy body disease,  
 CC spinal ischemia, ischemic stroke, cerebral infarction, spinal cord  
 CC injury, cancer-related brain and spinal cord injury, multi-infarct  
 CC dementia and geriatric dementia; for increasing the intracellular levels  
 CC of or stimulating CAMP levels in a cell (preferably a cell from a neural  
 CC tissue); and for in vitro modulation of neurogenesis. The agent modulates  
 CC neurogenesis in neural tissue by modulating proliferation,  
 CC differentiation, migration or survival of neural stem cells or progenitor  
 CC cells in the tissue; by maintaining or increasing the amount or  
 CC percentage of doublecortin positive cells in the neural tissue relative  
 CC to a patient not dosed with the agent or by activation of a G-protein  
 CC coupled receptor in the neural tissue. The method results in elevation of  
 CC CAMP levels of the neural stem cells by over 20% compared to untreated  
 CC tissue. The in vivo induction of neurogenesis allows treatment of  
 CC disorders caused by cell loss, injury or disease by endogenous  
 CC replacement and obviates the need for transplanting foreign cells into a  
 CC patient. Neurogenesis can also be induced by administration of the  
 CC neurogenesis-modulating agent directly into a desired site, which avoids  
 CC unnecessary systemic administration and possible side effects and further  
 CC provides an alternative to the use of drugs and the controversial use of  
 CC large quantities of embryonic tissue for treatment of Parkinson's  
 CC disease. The present sequence is that of a polypeptide which has been  
 CC shown to have the ability to increase intracellular CAMP levels and which  
 CC is related to the method of the invention.

XX  
 SQ Sequence 31 AA;

Query Match 100.0%; Score 163; DB 8; Length 31;  
 Best Local Similarity 100.0%; Pred. No. 3.6e-18;  
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TVOKLAHQIYQFTDKDKDNVAPRSKISPOGY 31  
 |||||  
 DB 1 TVOKLAHQIYQFTDKDKDNVAPRSKISPOGY 31

RESULT 6  
 AAB91759  
 ID AAB91759 standard; peptide; 52 AA.

XX  
 AC AAB91759;

XX  
 DT 22-JUN-2001 (first entry)

XX  
 DE Adrenomedullin peptide (AM) SEQ ID NO:935.

XX  
 KW Protection; endogenous therapeutic peptide; peptidase; conjugation;  
 KW blood component; modification; succinimide; maleimido group; amino;  
 KW hydroxyl; thiol; hormone; growth factor; neurotransmitter.

XX  
 OS Homo sapiens.

OS  
 Synthetic.

XX  
 PN WO200069900-A2.

XX  
 PD 23-NOV-2000.

XX  
 PF 17-MAY-2000; 2000WO-US013576.

XX  
 PR 17-MAY-1999; 99US-0134406P.

XX  
 PR 10-SEP-1999; 99US-0153406P.

XX  
 PR 15-OCT-1999; 99US-0159783P.

XX  
 PA (CONJ-) CONJUCHEM INC.

XX  
 PI Bridon DP, Ezrin AM, Milner PG, Holmes DL, Thibaudau K;

XX  
 DX WPI; 2001-112059/12.  
 XX  
 PT Modifying and attaching therapeutic peptides to albumin prevents  
 PT peptidase degradation, useful for increasing length of in vivo activity.  
 XX  
 PS Disclosure; Page 498; 733pp; English.

XX  
 CC The present invention describes a modified therapeutic peptide (I)  
 CC comprising a therapeutically active amino acid region (II) and a  
 CC reactive group (III) (e.g. succinimide and maleimido groups) attached to  
 CC a less therapeutically active amino acid region (IV), which covalently  
 CC bonds with amino/hydroxyl/thiol groups on blood components to form a  
 CC peptidease stabilized therapeutic peptide composed of 3-50 amino acids.  
 CC (I) are useful for modifying therapeutic peptides e.g. hormones, growth  
 CC factors and neurotransmitters, to protect them from peptidase activity in  
 CC vivo for the treatment of various disorders. Endogenous therapeutic  
 CC peptides are not suitable as drug candidates as they require frequent  
 CC administration due to rapid degradation by peptidases in the body.  
 CC Modifying and attaching therapeutic peptides to albumin prevents or  
 CC reduces the action of peptidases to increase length of activity (half  
 CC life) and specificity as bonding to large molecules decreases  
 CC intracellular uptake and interference with physiological processes.  
 CC AAB90829 to AAB92441 represent peptides which can be used in the  
 CC exemplification of the present invention

XX  
 SQ Sequence 52 AA;

Query Match 100.0%; Score 163; DB 4; Length 52;  
 Best Local Similarity 100.0%; Pred. No. 6.6e-18;  
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TVOKLAHQIYQFTDKDKDNVAPRSKISPOGY 31  
 |||||  
 DB 22 TVOKLAHQIYQFTDKDKDNVAPRSKISPOGY 52

RESULT 7  
 AAB75110  
 ID AAB75110 standard; protein; 52 AA.

XX  
 AC AAB75110;

XX  
 DT 31-JUL-2001 (first entry)

XX  
 DE Human adrenomedullin (AM) protein.

XX  
 KW Adrenomedullin; glycine extended adrenomedullin; AM; AM-gly;  
 KW adrenomedullin precursor; fusion protein; pharmaceutical; diagnostic.

XX  
 OS Homo sapiens.

XX  
 PN WO200127310-A1.

XX  
 PD 19-APR-2001.

XX  
 PF 10-OCT-2000; 2000WO-JP007023.

XX  
 PR 15-OCT-1999; 99JP-00294147.

XX  
 PA (SHIO ) SHIONOGI & CO LTD.

XX  
 PI Takimoto A, Mitsuuda Y, Nakayama T, Mitsuuhima K;

XX  
 DR WPI; 2001-282044/29.

XX  
 DR N-PSDB; AAB19806.

XX  
 PT Producing adrenomedullin useful for pharmaceutical and diagnostic  
 PT application comprises producing fused adrenomedullin precursor using a  
 PT recombinant host.

XX  
 PS Disclosure; Page 45; 75pp; Japanese.

CC The present invention describes a method (M1) for producing  
 CC adrenomedullin precursor. The method comprises: (a) producing the fused  
 CC protein using a recombinant host cell; (b) restricted digestion of the  
 CC fused protein by a protease followed by collection of sediment; and (c)  
 CC dissolving the sediment and extracting adrenomedullin precursor. The  
 CC method can be used for the production of adrenomedullin precursor for  
 CC pharmaceutical and diagnostic applications. AAH19806 to AAH19866 and  
 CC AAB7510 to AAB7514 represent sequences which are used in the  
 CC exemplification of the present invention

XX Sequence 52 AA;

Query Match 100.0%; Score 163; DB 4; Length 52;  
 Best Local Similarity 100.0%; Pred. No. 6, 6e-18;  
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVQKLAHQIYQFTDKDNVAPRSKISPGGY 31  
 DB 22 TVQKLAHQIYQFTDKDNVAPRSKISPGGY 52

RESULT 8

AAE09818 ID AAE09818 standard; peptide; 52 AA.

XX AAE09818;

AC 29-NOV-2001 (first entry)

XX Human adrenomedullin peptide #1.

XX Human; vasoactive peptide; calcitonin gene related peptide; CGRP;

KM CGRP-receptor identification; adrenomedullin.

XX Homo sapiens.

XX US6268474-B1.

XX 31-JUL-2001.

XX 30-APR-1998; 98US-00070504.

XX 30-APR-1998; 98US-00070504.

XX (UYCR-) UNIV CREIGHTON.

XX Smith DD, Saha S, Abel PW;

XX WPI; 2001-564216/63.

XX Vasoactive peptides useful for inhibiting calcitonin gene related peptide  
 PT receptor activity.

XX Claim 5; Col 25-26; 24pp; English.

XX The invention relates to antagonists of the vasoactive peptide calcitonin  
 CC gene related peptide (CGRP) and other members of the CGRP superfamily.  
 CC The invention also relates to amino the terminal modifications of  
 CC peptides to improve their ability to bind to a member of the CGRP-  
 CC receptor super-family. CGRP antagonists are used for inhibiting CGRP  
 CC activity which can be used in vitro e.g. in assays to identify and/or  
 CC isolate CGRP receptors or with intact cells either in vitro or in vivo to  
 CC inhibit the effect of CGRP binding to its receptor. The present sequence  
 CC is human adrenomedullin peptide

XX Sequence 52 AA;

Query Match 100.0%; Score 163; DB 4; Length 52;  
 Best Local Similarity 100.0%; Pred. No. 6, 6e-18;  
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVQKLAHQIYQFTDKDNVAPRSKISPGGY 31  
 DE |||||

DB 22 TVQKLAHQIYQFTDKDNVAPRSKISPGGY 52

RESULT 9

ABP55104 ID ABP55104 standard; peptide; 52 AA.

XX ABP55104;

AC 07-FEB-2003 (first entry)

XX Human adrenomedullin.

XX Adrenomedullin; human; protein engineering; solubility; aggregation;

KM hypotensive; vasodilator; cyclic.

XX Homo sapiens.

XX Key Location/Qualifiers

XX Disulfide-bond 16..21

XX WO200283734-A2.

XX 24-OCT-2002.

XX 17-APR-2002; 2002WO-GB001778.

XX 17-APR-2001; 2001GB-00009438.

XX (ISIS-) ISIS INNOVATION LTD.

XX Zurdo J, Dobson CM;

XX WPI; 2003-046916/04.

XX New modified human calcitonin peptide having reduced aggregation, useful  
 PT for the treatment of Paget's disease, hypercalcemia and/or osteoporosis.

XX Example; Page 21; 35pp; English.

XX The present sequence is that of human adrenomedullin, a potent  
 CC hypotensive and vasodilator. The invention provides modified calcitonin  
 CC and related peptides, such as adrenomedullin, that have at least 70%  
 CC identity to the native form but are modified such that the tendency of  
 CC the peptide to aggregate is reduced. Preferred regions for modification  
 CC include those for which the peptide is polymorphic amongst different  
 CC species, which increase the propensity of the peptide to form local  
 CC interactions of the alpha-helical type, or which reduce the number of  
 CC hydrophobic residues or increase the net charge of the peptide. When  
 CC aggregation is reduced or prevented, lower doses of the drug can be used.  
 CC Side-effects and undesired responses are minimised by retaining high  
 CC sequence identity to the human peptide

XX Sequence 52 AA;

Query Match 100.0%; Score 163; DB 6; Length 52;  
 Best Local Similarity 100.0%; Pred. No. 6, 6e-18;  
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVQKLAHQIYQFTDKDNVAPRSKISPGGY 31  
 DB 22 TVQKLAHQIYQFTDKDNVAPRSKISPGGY 52

RESULT 10

ADC25152 ID ADC25152 standard; peptide; 52 AA.

XX ADC25152;

XX 18-DEC-2003 (first entry)

XX Human angiogenesis inhibiting peptide #SEQ ID 1.

XX Cytostatic; gene therapy; cancer; stomach; colon; pulmonary; ovarian;  
KW liver; pancreatic; human.  
XX  
OS Homo sapiens.  
XX WO2003078460-A1.  
XX PN  
XX 25-SEP-2003.  
XX PD  
XX PF 19-MAR-2003; 2003WO-JP003344.  
XX XX  
PR 19-MAR-2002; 2002JP-00075575.  
XX  
XX (HOKK-) HOKKAIDO TECHNOLOGY LICENSING OFFICE CO.  
XX PA  
XX Kobayashi M;  
XX PI  
XX WPI, 2003-767505/72.  
XX DR  
XX Peptides with effect on inhibiting angiogenesis in cancer cells and  
PT inhibiting proliferation of cancer cells, and encoded polynucleotides,  
PT applicable in drug compositions for treating cancer.  
XX PS  
XX Claim 1; SEQ ID NO 1; 41pp; Japanese.  
XX  
XX The invention relates to peptides comprising an amino acid sequence  
CC derived from a fully defined 52 amino acid sequence (S1) given in the  
CC specification. Peptides may be created by deletion of some amino acids  
CC from the N-terminal of S1. The peptides are applicable in drug  
CC compositions for treating cancer e.g. stomach cancer, colon cancer,  
CC pulmonary cancer, ovarian cancer, liver cancer or pancreatic cancer. The  
CC current sequence represents an angiogenesis inhibiting peptide of the  
CC invention.  
XX  
SQ Sequence 52 AA;  
XX  
Query Match 100.0%; Score 163; DB 7; Length 52;  
Best Local Similarity 100.0%; Pred. No. 6.6e-18;  
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPOGY 31  
DB 22 TVQKLAHQIYQFTDKDKDNVAPRSKISPOGY 52  
RESULT 11  
ADG91993  
ID ADG91993 standard; protein; 52 AA.  
XX  
XX ADG91993;  
XX DT  
XX 11-MAR-2004 (first entry)  
XX  
DE Human mature adrenomedullin protein.  
XX  
XX neuroleptic; antisense therapy; gene therapy; adrenomedullin agonist;  
KW schizoprenia; gene expression; decidal protein induced by progesterone;  
KW DBPP; adrenomedullin; cold shock domain protein A; csda; antisense;  
KW siRNA; ribozyme; triple helix formation.  
XX  
XX Homo sapiens.  
XX OS  
XX WO2003078658-A2.  
XX PN  
XX 25-SEP-2003.  
XX PD  
XX PF 19-MAR-2003; 2003WO-EP002875.  
XX XX  
PR 20-MAR-2002; 2002US-0366001P.  
XX  
XX (NOVS ) NOVARTIS AG.  
XX (NOVS ) NOVARTIS PHARMA GMBH.  
XX PA

XX Buxton FP, Carpenter WT, Roberts RC, Tamminga CA;  
PI WPI, 2003-767532/72.  
XX  
XX DR  
XX PT Screening for schizoprenia in a population utilizing genes encoding the  
PT decidal protein induced by progesterone, adrenomedullin and/or cold  
PT shock domain protein A, useful in diagnosing, preventing and/or treating  
PT schizoprenia.  
XX  
XX PS Disclosure; SEQ ID NO 1; 41pp; English.  
XX  
XX The invention relates to a method of screening for schizoprenia in a  
CC population comprising determining the magnitude of expression, in members  
CC of the population, of at least one gene selected from the gene encoding  
CC decidal protein induced by progesterone (DBPP), the gene encoding  
CC adrenomedullin and the gene encoding cold shock domain protein A (csda)  
CC in a sample, and comparing the magnitude of expression to a baseline of  
CC expression of the gene, where increased gene expression indicates the  
CC presence of schizoprenia. An antisense molecule, siRNA, ribozyme or  
CC nucleic acid molecule promoting triple helix formation that specifically  
CC inhibit the expression of DBPP, csda or adrenomedullin genes, is useful  
CC for the manufacture of a medicament for the treatment of schizoprenia.  
CC An antibody that specifically binds an epitope of DBPP, csda or  
CC adrenomedullin is also useful for the manufacture of a medicament for the  
CC treatment of schizoprenia. This sequence represents the mature  
CC adrenomedullin protein.  
XX  
SQ Sequence 52 AA;  
XX  
Query Match 100.0%; Score 163; DB 7; Length 52;  
Best Local Similarity 100.0%; Pred. No. 6.6e-18;  
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPOGY 31  
DB 22 TVQKLAHQIYQFTDKDKDNVAPRSKISPOGY 52  
RESULT 12  
ADL91994  
ID ADL91994 standard; protein; 52 AA.  
XX  
XX ADL91994;  
XX DT  
XX 20-MAY-2004 (first entry)  
XX  
DE Adrenomedullin hypotensive peptide A13, S16-sequence.  
XX  
XX harvesting; recombinant; host cell; N-terminal leader peptide;  
KW pre-peptide; lantibiotic; post-translational modification;  
KW pharmaceuticals; vaccine; immunogenic.  
XX  
XX Unidentified.  
XX  
XX Key Location/Qualifiers  
XX FH  
XX Modified-site 16  
FT /note="This residue forms a thioether bond with residue  
FT 21 to form a lanthionine ring"  
FT Modified-site 21  
FT /note="This residue forms a thioether bond with residue  
FT 16 to form a lanthionine ring"  
XX  
XX WO2003099862-A1.  
XX PN  
XX 04-DEC-2003.  
XX PD  
XX PF 26-MAY-2003; 2003WO-NL000389.  
XX XX  
PR 24-MAY-2002; 2002EP-00077060.  
XX 07-FEB-2003; 2003US-00360101.  
XX  
XX (NANO-) APPLIED NANOSYSTEMS BV.  
XX PA



XX Moll GN, Leenhouts CJ, Kuipers OP, Driessen AJW;  
XX WPI; 2004-042770/04.  
DR  
XX Harvesting a desired polypeptide produced by a recombinant host cell, for  
XX producing pharmaceuticals, comprises selecting a recombinant nucleic acid  
PT comprising nucleic acid fragments encoding a leader peptide and the  
PT polypeptide.  
XX  
PS Claim 4; Page 44; 109pp; English.  
XX  
XX The invention relates to a novel method for harvesting a (poly)peptide  
CC produced by a recombinant host cell. The novel method involves selecting  
CC a cell comprising a first nucleic acid encoding a leader peptide and a  
CC second nucleic acid fragment encoding the desired (poly)peptide. The  
CC first and second fragments are within the same open reading frame of the  
CC first nucleic acid and the leader peptide is functionally equivalent to  
CC an N-terminal leader peptide found with the pre-peptide of a lantibiotic.  
CC The host cells and nucleic acids are useful for producing, harvesting and  
CC post-translational modification of polypeptides. The polypeptides may be  
CC used in the production of pharmaceuticals, e.g. as antigen for vaccine or  
CC immunogenic composition. This sequence represents a polypeptide relating  
CC to the novel method of the invention.  
XX  
SQ Sequence 52 AA;  
Query Match 100.0%; Score 163; DB 8; Length 52;  
Best Local Similarity 100.0%; Pred. No. 6,6e-18;  
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
CY 1 TVQKLAHQIYQFTDKDKNVAPRSKISPGY 31  
DB 22 TVQKLAHQIYQFTDKDKNVAPRSKISPGY 52  
RESULT 13  
ADM94034  
ID ADM94034 standard; peptide; 52 AA.  
XX  
AC ADM94034;  
XX  
DT 17-JUN-2004 (first entry)  
XX  
DE Human AM peptide, a CRSP homologue.  
XX  
KM calcitonin receptor stimulating peptide; CRSP; cAMP activity;  
KM skeletal disorder; cancer; hypertension; restenosis; analgesic;  
KM appetite suppressant; diuretic; vasotrophic; cyostatic; diuretic;  
KM osteopathic; anorectic; hypotensive; human; AM.  
XX  
OS Homo sapiens.  
XX  
XX Key Location/Qualifiers  
FH Disulfide-bond 16. 21  
FT Modified-site 52  
FT /note= "C-terminal amide"  
FT  
PN WO2003102180-A1.  
XX  
XX 11-DEC-2003.  
XX  
XX 28-MAY-2003; 2003WO-JP006641.  
XX  
XX 04-JUN-2002; 2002JP-00162797.  
XX  
XX (NISC-) JAPAN SCI & TECHNOLOGY CORP.  
XX (NINA-) JAPAN NAT CARDIOVASCULAR.  
XX Minamino N, Katafuchi T;  
XX WPI; 2004-043113/04.  
XX

PT Calcitonin receptor stimulating peptides promoting cAMP production in  
PT cells for treatment of cancer, skeletal disorders and hypertension and as  
PT appetite suppressants and analgesics.  
XX  
XX Disclosure; Fig 2; 62pp; Japanese.  
PS  
XX  
XX This invention relates to novel calcitonin receptor stimulating peptides  
CC (CRSPs) that are expressed in the central nervous system and act on the  
CC calcitonin receptor to promote the production of cAMP within a cell.  
CC Specifically, it refers to CRSPs that can stimulate concentration  
CC dependent sodium ion uptake and furthermore act to inhibit calcium ion  
CC uptake by the cell. The present invention describes mutant peptides  
CC derived from the CRSPs that have additions, deletions and/or  
CC substitutions of one or more amino acids, yet that retain similar  
CC activity and are useful for developing drug compositions and  
CC pharmaceutically acceptable carriers to treat and/or prevent skeletal  
CC disorders, cancer, hypertension and restenosis. Furthermore, CRSPs can  
CC also be used as analgesics, appetite suppressants and diuretics such that  
CC exhibit vasotrophic, cyostatic, diuretic, osteopathic, anorectic and  
CC hypotensive activities. This peptide sequence is a human AM peptide that  
CC has cAMP activity, given in an exemplification of the invention.  
XX  
SQ Sequence 52 AA;  
Query Match 100.0%; Score 163; DB 8; Length 52;  
Best Local Similarity 100.0%; Pred. No. 6,6e-18;  
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
CY 1 TVQKLAHQIYQFTDKDKNVAPRSKISPGY 31  
DB 22 TVQKLAHQIYQFTDKDKNVAPRSKISPGY 52  
RESULT 14  
ADN03278  
ID ADN03278 standard; peptide; 52 AA.  
XX  
AC ADN03278;  
XX  
DT 17-JUN-2004 (first entry)  
XX  
DE Exemplary peptide ligand for proteome analysis #2.  
XX  
KM Peptide ligand; proteome; capture compound; mass spectrometry;  
KM protein separation;  
KM matrix assisted laser desorption ionisation-time of flight; MALDI-TOF.  
XX  
OS Unidentified.  
XX  
PN US2003119021-A1.  
XX  
XX 26-JUN-2003.  
XX  
XX 16-JUL-2002; 2002US-00197954.  
XX  
XX 16-JUL-2001; 2001US-0306019P.  
XX 21-AUG-2001; 2001US-0314123P.  
XX 11-MAR-2002; 2002US-0363433P.  
XX  
XX (KOST/) KOSTER H.  
XX (SIDD/) SIDDIGI S.  
XX (LIT/) LITTLE D P.  
XX  
XX Koster H, Siddig S, Little DP;  
XX WPI; 2004-059185/06.  
XX  
XX Collection of capture compounds capable of binding to biomolecules to  
XX form complexes that are stable under mass spectrometry conditions, useful  
XX for analysis of biomolecules, especially proteins.  
XX  
XX Disclosure; SEQ ID NO 2; 165pp; English.  
XX

CC The invention relates to a collection of capture compounds capable of  
 CC binding to biomolecules to form complexes that are stable under mass  
 CC spectrometry conditions. The formulae for the capture compounds comprises  
 CC sets of compounds of formula (I)-(III) given in the specification. Also  
 CC included are analysis of biomolecules (by contacting a composition  
 CC comprising a biomolecule with the above collection and identifying or  
 CC detecting bound biomolecules), separating protein conformers (by  
 CC contacting a composition comprising a biomolecule with the above  
 CC collection, separating the members of the collection and identifying  
 CC bound proteins), reducing diversity of a complex mixture of biomolecules  
 CC (by contacting the mixture with the above collection and separating each  
 CC set of complexes of capture compounds with biomolecules from the other  
 CC sets) and identifying phenotype-specific biomolecules (by sorting cells  
 CC from a single subject into sets according to a phenotype, contacting  
 CC mixtures of biomolecules from each set with the above collection and  
 CC comparing the patterns of biomolecule binding from each set). The  
 CC collection of capture compounds is useful for the analysis of  
 CC biomolecules, especially proteins (e.g. analysis of a proteome), using  
 CC mass spectrometry, especially matrix assisted laser desorption/ionisation  
 CC -time of flight (MALDI-TOF) mass spectrometry. The present sequence is an  
 CC exemplary peptide ligand which may be incorporated into a capture  
 CC compound of the invention.

CC Sequence 52 AA;

Query Match 100.0%; Score 163; DB 8; Length 52;  
 Best Local Similarity 100.0%; Pred. No. 6.6e-18;  
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGGY 31  
 |||||  
 DB 22 TVQKLAHQIYQFTDKDKDNVAPRSKISPGGY 52

RESULT 15

ID ADM98309 standard; protein; 52 AA.

XX ADM98309;

DT 15-JUL-2004 (first entry)

DE Mature human adrenomedullin protein SegID 3.

XX AM(11-22): vasoconstriction; human; adrenomedullin; AM; vasoregulatory;  
 KM blood pressure; vasodilator; vasodilatory shock; septic shock;  
 KM haemorrhagic shock; vasotropic; hypotensive; immunosuppressive;  
 KM antibacterial.

XX Homo sapiens.

PN WO2004032708-A2.

PD 22-APR-2004.

PF 03-OCT-2003; 2003WO-US031400.

PR 04-OCT-2002; 2002US-0416291P.

XX (USSH ) US DEPT HEALTH & HUMAN SERVICES.

PI Cuttitta F, Martinez A, Stetler-Stevenson WG, Unsworth EJ;

PI Saavedra JM;

DR WPI; 2004-340778/31.

PT New AM(11-22) peptides, useful for inducing vasoconstriction,  
 PT for treating septic shock, vasodilatory shock or hemorrhagic shock, or  
 PT for reducing blood pressure.

PS Disclosure; SEQ ID NO 3; 40pp; English.

CC This invention relates to a novel peptide AM(11-22) useful for treating

CC shock, or in a pharmaceutical composition for inducing vasoconstriction.  
 CC Specifically, AM(11-22) is a short peptide derived from human  
 CC adrenomedullin (AM), which is a vasoregulatory compound that influences  
 CC blood pressure. The present invention describes screening assays to  
 CC identify compounds including antibodies, small molecule inhibitors or  
 CC peptides that modulate AM(11-22)-mediated vasoconstriction and as such  
 CC represent novel vasodilators or vasoconstrictors. Accordingly, AM(11-22)  
 CC can be used therapeutically in a pharmaceutical composition to inhibit  
 CC blood flow following traumatic or surgical injury, as well as for  
 CC vasodilatory, septic or haemorrhagic shock, and thus exhibits vasotropic,  
 CC hypotensive, immunosuppressive and antibacterial activities. This  
 CC polypeptide sequence is the mature human adrenomedullin protein of the  
 CC invention.

CC Sequence 52 AA;

Query Match 100.0%; Score 163; DB 8; Length 52;  
 Best Local Similarity 100.0%; Pred. No. 6.6e-18;  
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGGY 31  
 |||||  
 DB 22 TVQKLAHQIYQFTDKDKDNVAPRSKISPGGY 52

Search completed: January 5, 2005, 08:49:13  
 Job time : 159.932 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 5, 2005, 08:44:46 ; Search time 548.136 Seconds  
(without alignments)  
20.344 Million cell updates/sec

Title: US-09-931-700-3

Perfect score: 163  
Sequence: 1 TVQKLAHQYQFTDKDKDNVAPRSKISPCGY 31

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1599051 seqs, 359727711 residues

Total number of hits satisfying chosen parameters: 1599051

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :

Published Applications AA:\*

- 1: /cgn2\_6/ptodata/2/pubppaa/US07\_PUBCOMB.pep:\*
- 2: /cgn2\_6/ptodata/2/pubppaa/PCT\_NEW\_PUB.pep:\*
- 3: /cgn2\_6/ptodata/2/pubppaa/US06\_NEW\_PUB.pep:\*
- 4: /cgn2\_6/ptodata/2/pubppaa/US06\_PUBCOMB.pep:\*
- 5: /cgn2\_6/ptodata/2/pubppaa/US07\_NEW\_PUB.pep:\*
- 6: /cgn2\_6/ptodata/2/pubppaa/PCTUS\_PUBCOMB.pep:\*
- 7: /cgn2\_6/ptodata/2/pubppaa/US08\_NEW\_PUB.pep:\*
- 8: /cgn2\_6/ptodata/2/pubppaa/US08\_PUBCOMB.pep:\*
- 9: /cgn2\_6/ptodata/2/pubppaa/US09\_PUBCOMB.pep:\*
- 10: /cgn2\_6/ptodata/2/pubppaa/US09C\_PUBCOMB.pep:\*
- 11: /cgn2\_6/ptodata/2/pubppaa/US09C\_NEW\_PUB.pep:\*
- 12: /cgn2\_6/ptodata/2/pubppaa/US09\_NEW\_PUB.pep:\*
- 13: /cgn2\_6/ptodata/2/pubppaa/US10\_PUBCOMB.pep:\*
- 14: /cgn2\_6/ptodata/2/pubppaa/US10C\_PUBCOMB.pep:\*
- 15: /cgn2\_6/ptodata/2/pubppaa/US10C\_PUBCOMB.pep:\*
- 16: /cgn2\_6/ptodata/2/pubppaa/US10C\_PUBCOMB.pep:\*
- 17: /cgn2\_6/ptodata/2/pubppaa/US10C\_PUBCOMB.pep:\*
- 18: /cgn2\_6/ptodata/2/pubppaa/US11\_NEW\_PUB.pep:\*
- 19: /cgn2\_6/ptodata/2/pubppaa/US60\_NEW\_PUB.pep:\*
- 20: /cgn2\_6/ptodata/2/pubppaa/US60\_PUBCOMB.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	163	100.0	31	US-09-931-700-3	Sequence 3, Appl1
2	163	100.0	31	US-09-931-700-14	Sequence 14, Appl1
3	163	100.0	31	US-09-813-345-23	Sequence 23, Appl1
4	163	100.0	52	US-09-813-345-14	Sequence 14, Appl1
5	163	100.0	52	US-10-197-954-2	Sequence 2, Appl1
6	163	100.0	52	US-10-360-101-74	Sequence 74, Appl1
7	163	100.0	52	US-10-474-635A-19	Sequence 19, Appl1
8	163	100.0	185	US-10-364-889-6	Sequence 6, Appl1
9	163	100.0	185	US-10-372-683-12	Sequence 12, Appl1
10	163	100.0	185	US-10-675-406A-7	Sequence 7, Appl1
11	163	100.0	185	US-10-755-889-148	Sequence 148, Appl1
12	148	90.8	50	US-09-813-345-15	Sequence 15, Appl1
13	57	35.0	13	US-09-931-700-2	Sequence 2, Appl1

14	53	32.5	67	US-10-437-963-124471	Sequence 124471,
15	51	31.3	44	US-10-424-599-274214	Sequence 274214,
16	51	31.3	437	US-10-389-566-1910	Sequence 1910, Ap
17	50	30.7	425	US-10-389-566-1493	Sequence 1493, Ap
18	50	30.7	860	US-10-389-566-2131	Sequence 2131, Ap
19	49.5	30.4	352	US-10-739-930-5546	Sequence 5546, Ap
20	49	30.1	78	US-10-767-701-35785	Sequence 35785, A
21	48	30.1	397	US-10-696-616-42	Sequence 42, Appl1
22	48	29.4	66	US-10-424-599-208178	Sequence 208178,
23	48	29.4	119	US-10-424-599-259144	Sequence 259144,
24	48	29.4	168	US-10-425-115-346792	Sequence 346792,
25	48	29.4	328	US-10-282-122A-77837	Sequence 77837, A
26	48	29.4	380	US-10-437-963-195045	Sequence 195045,
27	48	29.4	478	US-10-427-631-31	Sequence 31, Appl1
28	48	29.4	467	US-10-437-963-107189	Sequence 107189,
29	48	29.4	1745	US-09-795-061-4	Sequence 4, Appl1
30	48	29.4	1745	US-10-723-860-2660	Sequence 2660, Ap
31	47.5	29.1	984	US-10-128-714-3547	Sequence 3547, Ap
32	47.5	29.1	1058	US-10-128-714-8547	Sequence 8547, Ap
33	47	28.8	33	US-09-864-761-43882	Sequence 43882, A
34	47	28.8	81	US-10-425-115-309562	Sequence 309562,
35	47	28.8	103	US-10-437-963-169347	Sequence 169347,
36	47	28.8	327	US-09-925-298-570	Sequence 570, App
37	47	28.8	327	US-10-102-806-570	Sequence 570, App
38	47	28.8	341	US-10-425-115-251952	Sequence 251952,
39	47	28.8	480	US-10-424-599-224233	Sequence 224233,
40	47	28.8	590	US-10-437-963-139304	Sequence 139304,
41	47	28.8	706	US-10-739-930-7483	Sequence 7483, Ap
42	47	28.8	1268	US-10-231-956A-494	Sequence 494, App
43	47	28.8	1268	US-10-741-601-524	Sequence 524, App
44	47	28.8	1268	US-10-741-601-525	Sequence 525, App
45	47	28.8	1268	US-10-741-601-526	Sequence 526, App

#### ALIGNMENTS

RESULT 1  
US-09-931-700-3  
Sequence 3, Application US/09931700  
Patent No. US20020055615A1  
GENERAL INFORMATION:  
APPLICANT: CUTTITTA, FRANK  
APPLICANT: MARTINEZ, ALFREDO  
APPLICANT: MILLER, MAE JEAN  
APPLICANT: UNSWORTH, EDWARD J.  
APPLICANT: HOOK, WILLIAM  
APPLICANT: WALSH, THOMAS  
APPLICANT: GREY, KAREN  
TITLE OF INVENTION: Functional Role of Adrenomedullin (Am) and the  
TITLE OF INVENTION: Gene-Related Product (GAMP) in Human Pathology and  
FILE OF INVENTION: Physiology  
FILE REFERENCE: 2026-4202054  
CURRENT APPLICATION NUMBER: US/09/931,700  
CURRENT FILING DATE: 2001-08-16  
PRIOR APPLICATION NUMBER: 09/011,922  
PRIOR FILING DATE: 1998-02-17  
PRIOR APPLICATION NUMBER: PCT/US96/13286  
PRIOR FILING DATE: 1996-08-16  
PRIOR APPLICATION NUMBER: US/60/013,172  
PRIOR FILING DATE: 1996-03-12  
PRIOR APPLICATION NUMBER: US60/002,936  
PRIOR FILING DATE: 1995-08-30  
PRIOR APPLICATION NUMBER: US/60/002,514  
PRIOR FILING DATE: 1995-08-18  
NUMBER OF SEQ ID NOS: 17  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 3  
LENGTH: 31  
TYPE: PRT  
ORGANISM: Artificial Sequence  
FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Peptide, P072,  
OTHER INFORMATION: PreproAM (amino acids 116-146)  
US-09-931-700-3

Query Match 100.0%; Score 163; DB 9; Length 31;  
Best Local Similarity 100.0%; Pred. No. 2.3e-16;

Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGGY 31  
DB 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGGY 31

RESULT 2  
US-09-931-700-14

Sequence 14, Application US/09931700  
Patent No. US20020055615A1

GENERAL INFORMATION:

APPLICANT: CUTTITTA, FRANK

APPLICANT: MARTINEZ, ALFREDO

APPLICANT: MILLER, MAE JEAN

APPLICANT: UNSWORTH, EDWARD J.

APPLICANT: HOOK, WILLIAM

APPLICANT: WALSH, THOMAS

APPLICANT: GREY, KAREN

APPLICANT: MACRI, CHARLES

TITLE OF INVENTION: Functional Role of Adrenomedullin (AM) and the  
TITLE OF INVENTION: Gene-Related Product (PAMP) in Human Pathology and

TITLE OF INVENTION: Physiology

FILE REFERENCE: 2026-4202US4

CURRENT APPLICATION NUMBER: US/09/931,700

CURRENT FILING DATE: 2001-08-16

PRIOR APPLICATION NUMBER: 09/011,922

PRIOR FILING DATE: 1998-02-17

PRIOR APPLICATION NUMBER: PCT/US96/13286

PRIOR FILING DATE: 1996-08-16

PRIOR APPLICATION NUMBER: US/60/013,172

PRIOR FILING DATE: 1996-03-12

PRIOR APPLICATION NUMBER: US60/002,936

PRIOR FILING DATE: 1995-08-30

PRIOR APPLICATION NUMBER: US/60/002,514

PRIOR FILING DATE: 1995-08-18

NUMBER OF SEQ ID NOS: 17

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 14

LENGTH: 31

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURES:

OTHER INFORMATION: Description of Artificial Sequence: Peptide,  
OTHER INFORMATION: Synthetic homolog of AM (P072), Structural amino  
OTHER INFORMATION: acid sequence representing two-thirds of the  
OTHER INFORMATION: intact AM peptide

US-09-931-700-14

Query Match 100.0%; Score 163; DB 9; Length 31;  
Best Local Similarity 100.0%; Pred. No. 2.3e-16;

Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGGY 31  
DB 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGGY 31

RESULT 3  
US-09-813-345-23

Sequence 23, Application US/09813345  
Patent No. US20020068814A1

GENERAL INFORMATION:

APPLICANT: Smith, Derek D.

Saba, Shankar

Abel, Peter W.

TITLE OF INVENTION: PEPTIDE ANTAGONISTS OF CGRP-RECEPTOR

SUPERFAMILY AND METHODS OF USE

NUMBER OF SEQUENCES: 23

CORRESPONDENCE ADDRESS:

ADDRESSER: Muehling, Raasch & Gebhardt, P.A.

STREET: 119 No. US20020068814A1ch Fourth Street

CITY: Minneapolis

STATE: MN

COUNTRY: USA

ZIP: 55401

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/813,345

FILING DATE: 20-Mar-2001

CLASSIFICATION: <Unknown>

ATTORNEY/AGENT INFORMATION:

NAME: McCormack, Myra H

REGISTRATION NUMBER: 36,602

REFERENCE/DOCKET NUMBER: 180.00020101

TELECOMMUNICATION INFORMATION:

TELEPHONE: 612/305-1220

TELEFAX: 612/305-1228

INFORMATION FOR SEQ ID NO: 23:

SEQUENCE CHARACTERISTICS:

LENGTH: 31 amino acids

TYPE: amino acid

STRANDEDNESS: Single

MOLECULE TYPE: peptide

TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 23:

US-09-813-345-23

Query Match 100.0%; Score 163; DB 9; Length 31;  
Best Local Similarity 100.0%; Pred. No. 2.3e-16;

Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGGY 31  
DB 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGGY 31

RESULT 4  
US-09-813-345-14

Sequence 14, Application US/09813345  
Patent No. US20020068814A1

GENERAL INFORMATION:

APPLICANT: Smith, Derek D.

Saba, Shankar

Abel, Peter W.

TITLE OF INVENTION: PEPTIDE ANTAGONISTS OF CGRP-RECEPTOR

SUPERFAMILY AND METHODS OF USE

NUMBER OF SEQUENCES: 23

CORRESPONDENCE ADDRESS:

ADDRESSER: Muehling, Raasch & Gebhardt, P.A.

STREET: 119 No. US20020068814A1ch Fourth Street

CITY: Minneapolis

STATE: MN

COUNTRY: USA

ZIP: 55401

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/813,345

FILING DATE: 20-Mar-2001

CLASSIFICATION: <Unknown>

ATTORNEY/AGENT INFORMATION:

NAME: McCormack, Myra H

```
/
/   REGISTRATION NUMBER: 36,602
/   REFERENCE/DOCKET NUMBER: 180.00020101
/   TELECOMMUNICATION INFORMATION:
/   TELEPHONE: 612/305-1220
/   TELEFAX: 612/305-1228
/   INFORMATION FOR SEQ ID NO: 14:
/   SEQUENCE CHARACTERISTICS:
/       LENGTH: 52 amino acids
/       TYPE: amino acid
/       STRANDEDNESS: single
/       TOPOLOGY: linear
/   MOLECULE TYPE: peptide
/   SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-813-345-14

Query Match      100.0%; Score 163; DB 9; Length 52;
Best Local Similarity 100.0%; Pred. No. 4,1e-16;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGGY 31
Db 22 TVQKLAHQIYQFTDKDKDNVAPRSKISPGGY 52

RESULT 5
US-10-197-954-2
/   Sequence 2, Application US/10197954
/   Publication No. US20030119021A1
/   GENERAL INFORMATION:
/   APPLICANT: K'ater, Hubert
/   APPLICANT: Siddiqi, Subaib
/   APPLICANT: Little, Daniel
/   TITLE OF INVENTION: Capture Compounds, Collections Thereof
/   TITLE OF INVENTION: And Methods For Analyzing The Proteome And Complex
/   FILE REFERENCE: 24743-2305
/   CURRENT APPLICATION NUMBER: US/10/197,954
/   CURRENT FILING DATE: 2002-07-16
/   PRIOR APPLICATION NUMBER: 60/306,019
/   PRIOR FILING DATE: 2001-07-16
/   PRIOR APPLICATION NUMBER: 60/314,123
/   PRIOR FILING DATE: 2001-08-21
/   PRIOR APPLICATION NUMBER: 60/363,433
/   PRIOR FILING DATE: 2002-03-11
/   NUMBER OF SEQ ID NOS: 149
/   SOFTWARE: FastSeq for Windows Version 4.0
/   SEQ ID NO 2
/   LENGTH: 52
/   TYPE: PRT
/   ORGANISM: Homo Sapien
US-10-197-954-2

Query Match      100.0%; Score 163; DB 14; Length 52;
Best Local Similarity 100.0%; Pred. No. 4,1e-16;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGGY 31
Db 22 TVQKLAHQIYQFTDKDKDNVAPRSKISPGGY 52

RESULT 6
US-10-360-101-74
/   Sequence 74, Application US/10360101
/   Publication No. US20040009550A1
/   GENERAL INFORMATION:
/   APPLICANT: Moll, Gert N.
/   APPLICANT: Leenhout, Cornelia J.
/   TITLE OF INVENTION: Export and modification of (poly)peptide in the lantibiotic way
/   FILE REFERENCE: 2183-5673
/   CURRENT APPLICATION NUMBER: US/10/360,101
/   CURRENT FILING DATE: 2003-02-07
/   PRIOR APPLICATION NUMBER: EP 02077060.8
```

```
/   PRIOR FILING DATE: 2002-05-24
/   NUMBER OF SEQ ID NOS: 309
/   SOFTWARE: PatentIn version 3.1
/   SEQ ID NO 74
/   LENGTH: 52
/   TYPE: PRT
/   ORGANISM: Artificial Sequence
/   FEATURE:
/   OTHER INFORMATION: A13,S16-sequence of Adrenomedullin Hypotensive peptide
US-10-360-101-74

Query Match      100.0%; Score 163; DB 15; Length 52;
Best Local Similarity 100.0%; Pred. No. 4,1e-16;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGGY 31
Db 22 TVQKLAHQIYQFTDKDKDNVAPRSKISPGGY 52

RESULT 7
US-10-474-635A-19
/   Sequence 19, Application US/10474635A
/   Publication No. US20040176567A1
/   GENERAL INFORMATION:
/   APPLICANT: Isis Innovation Ltd
/   TITLE OF INVENTION: Peptides
/   FILE REFERENCE: 480821.00004
/   CURRENT APPLICATION NUMBER: US/10/474,635A
/   CURRENT FILING DATE: 2003-10-14
/   PRIOR APPLICATION NUMBER: GB 0109438.2
/   PRIOR FILING DATE: 2001-04-17
/   NUMBER OF SEQ ID NOS: 22
/   SOFTWARE: PatentIn version 3.1
/   SEQ ID NO 19
/   LENGTH: 52
/   TYPE: PRT
/   ORGANISM: Homo sapiens
US-10-474-635A-19

Query Match      100.0%; Score 163; DB 16; Length 52;
Best Local Similarity 100.0%; Pred. No. 4,1e-16;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGGY 31
Db 22 TVQKLAHQIYQFTDKDKDNVAPRSKISPGGY 52

RESULT 8
US-10-364-889-6
/   Sequence 6, Application US/10364889
/   Publication No. US20030224989A1
/   GENERAL INFORMATION:
/   APPLICANT: Pabel, Gregory L.
/   APPLICANT: Quinn, Kerry
/   TITLE OF INVENTION: Compositions and Methods for Treatment of Osteoarthritis
/   FILE REFERENCE: 21402-558
/   CURRENT APPLICATION NUMBER: US/10/364,889
/   CURRENT FILING DATE: 2003-02-12
/   PRIOR APPLICATION NUMBER: 60/356,376
/   PRIOR FILING DATE: 2002-02-12
/   NUMBER OF SEQ ID NOS: 8
/   SOFTWARE: CuraSeqList version 0.1
/   SEQ ID NO 6
/   LENGTH: 185
/   TYPE: PRT
/   ORGANISM: Homo sapiens
US-10-364-889-6

Query Match      100.0%; Score 163; DB 14; Length 185;
Best Local Similarity 100.0%; Pred. No. 1,8e-15;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

OY      1  TVOKLAHQYQFTDNDKDNVAFRSKISPOGY 31
Db      116 TVOKLAHQYQFTDNDKDNVAFRSKISPOGY 146

RESULT 9
US-10-372-683-12
; Sequence 12, Application US/10372683
; Publication No. US20040009171A1
; GENERAL INFORMATION:
; APPLICANT: GERRITSEN, MARY E.
; APPLICANT: PEALE JR., FRANKLIN V.
; APPLICANT: WU, THOMAS D.
; TITLE OF INVENTION: METHODS FOR THE TREATMENT OF CARCINOMA
; FILE REFERENCE: P1928R1P1
; CURRENT APPLICATION NUMBER: US/10/372,683
; CURRENT FILING DATE: 2003-02-21
; PRIOR APPLICATION NUMBER: US 10/271,690
; PRIOR FILING DATE: 2002-10-16
; PRIOR APPLICATION NUMBER: US 60/344,534
; PRIOR FILING DATE: 2001-10-18
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 12
; LENGTH: 185
; TYPE: PRT
; ORGANISM: Homo sapien
US-10-372-683-12

```

Query Match	100.0%	Score 163	DB 15	Length 185;
Best Local Similarity	100.0%	Pred. No. 1.8e-15;		
Matches 31, Conservative	0	Mismatches 0;	Indels 0;	Gaps 0;

```
QY      1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGCY 31
        |||||
Db       116 TVQKLAHQIYQFTDKDKDNVAPRSKISPGCY 146
```

```

RESULT 10
US-10-675-406A-7
; Sequence 7, Application US/10675406A
; Publication No. US20040121375A1
; GENERAL INFORMATION:
; APPLICANT: Bayer Pharmaceuticals Corporation
; APPLICANT: Baveleigh, Deepa
; APPLICANT: Taylor, Ian
; TITLE OF INVENTION: METHODS FOR PREDICTION AND PROGNOSIS OF CANCER, AND MONITORING
; TITLE OF INVENTION: CANCER THERAPY
; FILE REFERENCE: 5138
; CURRENT APPLICATION NUMBER: US/10/675,406A
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/415,194
; PRIOR FILING DATE: 2002-09-30
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-675-406A-7

```

Query Match	100.0%	Score 163	DB 16	Length 185
Best Local Similarity	100.0%	Pred. No. 1.8e-15		
Matches 31, Conservative	0	Mismatches 0	Indels 0	Gaps 0

**Dy**     1 TVQKLAHQIYQFTDKDNDNAPRSKISPGYG 31  
**Db**    116 TVQKLAHQIYQFTDKDNDNAPRSKISPGYG 146

RESULT 11  
US-10-755-889-148  
; Sequence 148, Application US/10755889

```

? Publication No. US20040171823A1
? GENERAL INFORMATION:
? APPLICANT: Bristol-Myers Squibb Company
? TITLE OF INVENTION: POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-KB
? TITLE OF INVENTION: PATHWAY
? FILE REFERENCE: D0284 NP
? CURRENT APPLICATION NUMBER: US/10/755,889
? CURRENT FILING DATE: 2004-01-13
? PRIOR APPLICATION NUMBER: U.S. 60/440,068
? PRIOR FILING DATE: 2003-01-14
? PRIOR APPLICATION NUMBER: U.S. 60/469,757
? PRIOR FILING DATE: 2003-05-12
? NUMBER OF SEQ ID NOS: 823
? SOFTWARE: PatentIn version 3.2
? SEQ ID NO 148
? LENGTH: 185
? TYPE: PRT
? ORGANISM: Homo sapiens
US-10-755-889-148

```

Query Match	100.0%;	Score 163;	DB 16;	Length 185;
Best Local Similarity	100.0%;	Pred. No. 1.8e-15;		
Matches	31;	Conservative	0;	Mismatches
			0;	Indels
				Gaps

```

QY      1 TVQGLAHQIYQFTDKDKDNVAPRSKISPGY  31
          |||||
Db      116 TVQGLAHQIYQFTDKDKDNVAPRSKISPGY  146

```

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```

Query Match 90.8%; Score 148; DB 9; Length 50;  
Best Local Similarity 87.1%; Pred. No. 5,9e-14;  
Matches 27; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1 TVOKLAHQIYQFTDKDKNVAPRSKISPGY 31  
Db 20 TMQKLAHQIYQFTDKDKNVAPRSKISPGY 50

## RESULT 13

US-09-931-700-2  
Sequence 2, Application US/09931700  
Patent No. US20020055615A1

GENERAL INFORMATION:

APPLICANT: CUTTITTA, FRANK

APPLICANT: MARTINEZ, ALFREDO

APPLICANT: MILLER, MAE JEAN

APPLICANT: UNSWORTH, EDWARD J.

APPLICANT: HOOK, WILLIAM

APPLICANT: WALSH, THOMAS

APPLICANT: GREY, KAREN

APPLICANT: MACRI, CHARLES

TITLE OF INVENTION: Functional Role of Adrenomedullin (AM) and the

TITLE OF INVENTION: Gene-Related Product (PAMP) in Human Pathology and

FILE REFERENCE: 2026-4202US4

CURRENT APPLICATION NUMBER: US/09/931,700

CURRENT FILING DATE: 2001-08-16

PRIOR APPLICATION NUMBER: 09/011,922

PRIOR FILING DATE: 1998-02-17

PRIOR APPLICATION NUMBER: PCT/US96/13286

PRIOR FILING DATE: 1996-08-16

PRIOR APPLICATION NUMBER: US/60/013,172

PRIOR FILING DATE: 1996-03-12

PRIOR APPLICATION NUMBER: US60/002,936

PRIOR FILING DATE: 1995-08-30

PRIOR APPLICATION NUMBER: US/60/002,514

PRIOR FILING DATE: 1995-08-18

NUMBER OF SEQ ID NOS: 17

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 2

LENGTH: 13

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE: Description of Artificial Sequence: Peptide,

OTHER INFORMATION: P071, YG3-PreproAM (amino acids 122-131)

US-09-931-700-2

Query Match 35.0%; Score 57; DB 9; Length 13;

Best Local Similarity 100.0%; Pred. No. 0.2;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 HQIYQFTDKD 16

Db 4 HQIYQFTDKD 13

RESULT 14

US-10-437-963-124471

Sequence 124471, Application US/10437963

Publication No. US20040123343A1

GENERAL INFORMATION:

APPLICANT: La Rosa, Thomas J.

APPLICANT: KOVALIC, David K.

APPLICANT: Zhou, Yihua

APPLICANT: Cao, Yongwei

APPLICANT: Wu, Wei

APPLICANT: Boukharov, Andrey A.

APPLICANT: Barbasuk, Brad

APPLICANT: Li, Ping

TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With

TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement

FILE REFERENCE: 38-21(53221)B  
CURRENT APPLICATION NUMBER: US/10/437,963  
CURRENT FILING DATE: 2003-05-14  
NUMBER OF SEQ ID NOS: 204966  
SEQ ID NO 124471

LENGTH: 67

TYPE: PRT

ORGANISM: Oryza sativa

FEATURE: OTHER INFORMATION: Clone ID: PAT\_MRT4530\_27206C.1.pep

US-10-437-963-124471

Query Match 32.5%; Score 53; DB 16; Length 67;

Best Local Similarity 41.7%; Pred. No. 5.1;

Matches 10; Conservative 7; Mismatches 7; Indels 0; Gaps 0;

Qy 8 QIYQFTDKDKNVAPRSKISPGY 31

Db 26 KLFWFLTPPRNIVAPRSFIAPQGF 49

RESULT 15

US-10-424-599-274214

Sequence 274214, Application US/10424599

Publication No. US20040031072A1

GENERAL INFORMATION:

APPLICANT: La Rosa, Thomas J

APPLICANT: KOVALIC, David K

APPLICANT: Zhou, Yihua

APPLICANT: Cao, Yongwei

TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With

TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement

FILE REFERENCE: 38-21(53223)B

CURRENT APPLICATION NUMBER: US/10/424,599

CURRENT FILING DATE: 2003-04-28

NUMBER OF SEQ ID NOS: 285684

SEQ ID NO 274214

LENGTH: 44

TYPE: PRT

ORGANISM: Glycine max

FEATURE: OTHER INFORMATION: Clone ID: PAT\_MRT3847\_89637C.1.pep

US-10-424-599-274214

Query Match 31.3%; Score 51; DB 15; Length 44;

Best Local Similarity 39.3%; Pred. No. 6.2;

Matches 11; Conservative 5; Mismatches 12; Indels 0; Gaps 0;

Qy 1 TVOKLAHQIYQFTDKDKNVAPRSKISPGY 28

Db 8 TFQKIYHQFLKSTNKEMAKCAPTNVCSF 35

Search completed: January 5, 2005, 09:15:07

Job time: 548.136 secs

**This Page Blank (uspto)**



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: January 5, 2005, 08:39:22 ; Search time 33.6182 Seconds  
(without alignments)  
88.199 Million cell updates/sec

Title: US-09-931-700-3

Perfect score: 163  
Sequence: 1 TVQKLHAIQVFTDKDNVAPRSKISPGCY 31

Scoring table: BIOSUM62  
Gapop 10.0, Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Database :

PIR 79:\*  
1: PIR1:\*  
2: PIR2:\*  
3: PIR3:\*  
4: PIR4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	163	100.0	185	2 JN0684	adrenomedullin pre
2	157	96.3	188	2 S41600	adrenomedullin - p
3	148	90.8	185	2 JN0766	adrenomedullin pre
4	58.5	35.9	189	2 A85489	hypothetical prote
5	58.5	35.9	189	2 A89638	hypothetical prote
6	58	35.6	430	2 T14536	S-locus-specific g
7	56	34.4	431	2 T14415	S-locus-specific g
8	54	33.1	373	2 G84107	lipopolysaccharide
9	53	32.5	465	2 T15540	hypothetical prote
10	52	31.9	428	2 T14529	S-locus-specific g
11	51	31.3	428	2 T07814	S-locus-specific g
12	51	31.3	429	2 T14533	S-locus-specific g
13	51	31.3	436	2 A27827	S-locus-specific g
14	51	31.3	857	2 T14471	hypothetical prote
15	50	30.7	90	2 C86279	probable S-recepto
16	50	30.7	427	2 T14424	S-locus-specific g
17	50	30.7	428	2 T14423	S-locus-specific g
18	49	30.1	428	2 T14416	S-locus-specific g
19	49	30.1	428	2 T14530	S-locus-specific g
20	49	30.1	429	2 T14528	S-locus-specific g
21	49	30.1	429	2 T07809	S-receptor kinase
22	49	30.1	431	2 T14418	S-locus-specific g
23	49	30.1	431	2 T07812	S-locus-specific g
24	49	30.1	434	2 S04906	S-locus-specific g
25	48.5	29.8	322	2 T17067	hypothetical prote
26	48	29.4	328	2 AG0363	probable cell divi
27	48	29.4	416	2 JC1343	glycylpeptide N-ter
28	48	29.4	426	2 T07810	S-locus-specific g
29	48	29.4	444	1 BE9130	histidine-trna lig

30	48	29.4	689	2 S39531	exonuclease ABC c
31	48	29.4	856	1 JC2482	S-receptor kinase
32	48	29.4	858	1 JC2481	S-receptor kinase
33	48	29.4	1705	2 P71414	hypothetical prote
34	47.5	29.1	438	2 A50700	DNA primase (EC 2.
35	47	28.8	429	2 T14524	S-locus-specific g
36	47	28.8	545	2 A84938	flagellar M-ring p
37	47	28.8	549	2 T33517	hypothetical prote
38	47	28.8	850	2 T14472	S-receptor kinase
39	47	28.8	858	1 JQ1677	S-receptor kinase
40	47	28.8	1004	2 S51133	transposase Tn4652
41	47	28.8	1268	2 A44125	high density lipop
42	47	28.8	1541	1 S71839	canalicular multidi
43	46.5	28.5	340	2 S41752	UDP-3-O-[3-hydroxy
44	46	28.2	186	2 H90448	hypothetical prote
45	46	28.2	204	2 AD2607	conserved hypochet

#### ALIGNMENTS

##### RESULT 1

JN0684  
adrenomedullin precursor - human  
C:Date: 03-Feb-1994 #sequence revision 03-Feb-1994 #text\_change 09-Jul-2004  
C:Accession: JC2351, JN0684; E05048; JN0476  
R:Shimizu, T.; Kojima, M.; Kangawa, K.; Hino, J.; Matsuo, H.; Eto, T.  
Biochem. Biophys. Res. Commun. 203, 631-639, 1994  
A:Title: Genomic structure of human adrenomedullin gene.  
A:Reference number: JC2351, MUID:94354869; PMID:8074714  
A:Accession: JC2351  
A:Molecule type: DNA  
A:Residues: 1-185 <ISH>  
A:Cross-references: UNIPROT:P35318; GB:573906; NID:9765329; PIDN:AAC60642.1; PID:976533  
R:Experimental source: pheochromocytoma  
A:Kanamura, K.; Sakata, J.; Kangawa, K.; Kojima, M.; Matsuo, H.; Eto, T.  
Biochem. Biophys. Res. Commun. 194, 720-725, 1993  
A:Title: Cloning and characterization of cDNA encoding a precursor for human adrenomedu  
A:Reference number: JN0684; MUID:93343928; PMID:7688224  
A:Accession: JN0684  
A:Molecule type: mRNA  
A:Residues: 1-185 <KIT>  
A:Cross-references: GB:D14874; NID:9455470; PIDN:BA03589.1; PID:9500612  
A:Accession: E05048  
A:Molecule type: protein  
A:Residues: 22-41 <KIT>  
R:Kanamura, K.; Kangawa, K.; Kawamoto, M.; Ichiki, Y.; Nakamura, S.; Matsuo, H.; Eto, T.  
Biochem. Biophys. Res. Commun. 192, 553-560, 1993  
A:Title: Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocyto  
A:Reference number: JN0476; MUID:93249425; PMID:8387282  
A:Accession: JN0476  
A:Molecule type: protein  
A:Residues: 95-146 <KIT>  
A:Experimental source: pheochromocytoma  
C:Genetics:  
A:Gene: GDB:ADM  
A:Cross-references: GDB:217070; OMIM:103275  
A:Map position: 1pter-11pter  
A:Introns: 33/2; 83/2  
C:Keywords: amidated carboxyl end; blood pressure control; hormone  
F:1-21/Domain: signal sequence #status predicted <SIG>  
F:22-185/Product: proadrenomedullin #status predicted <PRU>  
F:22-41/Domain: proadrenomedullin amino-terminal 20 peptide #status predicted <PAP>  
F:95-146/Product: adrenomedullin #status experimental <MAT>  
F:147-185/Domain: carboxyl-terminal propeptide #status predicted <CTP>  
F:41/Modified site: amidated carboxyl end (Arg) (amide in mature form from following gl  
F:110-115/disulfide bonds: #status experimental  
F:146/Modified site: amidated carboxyl end (Tyr) (amide in mature form from following g

Query Match 100.0%; Score 163; DB 2; Length 185;  
Best Local Similarity 100.0%; Pred. No. 2.7e-16;  
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY      1 TVQKLAHQIYQFTDKDKNVAPRSKISPGQY 31
Db      116 TVQKLAHQIYQFTDKDKNVAPRSKISPGQY 146

RESULT 2
S41600
adrenomedullin - pig
C/Species: Sus scrofa domestica (domestic pig)
C/Date: 19-Mar-1997 #sequence_revision 19-Mar-1997 #text_change 09-Jul-2004
C/Accession: S41600
R/Kitamura, K.; Kangawa, K.; Kojima, M.; Ichiki, Y.; Matsuo, H.; Eto, T.
FEBS Lett. 338, 306-310, 1994
A/Title: Complete amino acid sequence of porcine adrenomedullin and cloning of cDNA enc
A/Reference number: S41600; MUID:94139945; PMID:8043068
A/Accession: S41600
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-188 <KIT>
A/Cross-references: UNIPROT:P53366; GB:D14875; NID:G439721; PIDN:BAA03590.1; PID:G496379

Query Match      96.3%; Score 157; DB 2; Length 188;
Best Local Similarity 96.4%; Pred. No. 2e-15;
Matches 30; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1 TVQKLAHQIYQFTDKDKNVAPRSKISPGQY 31
Db      116 TVQKLAHQIYQFTDKDKNVAPRSKISPGQY 146

RESULT 3
JN0766
adrenomedullin precursor - rat
C/Species: Rattus norvegicus (Norway rat)
C/Date: 30-Sep-1993 #sequence_revision 20-Aug-1994 #text_change 09-Jul-2004
C/Accession: JN0766; P0610
R/Sakata, J.; Shimokubo, T.; Kitamura, K.; Nakamura, S.; Kangawa, K.; Matsuo, H.; Eto, T.
Biochem. Biophys. Res. Commun. 195, 921-927, 1993
A/Title: Molecular cloning and biological activities of rat adrenomedullin, a hypotensive
A/Reference number: JN0766; MUID:93384621; PMID:7650563
A/Accession: JN0766
A/Molecule type: mRNA
A/Residues: 1-185 <SAK>
A/Cross-references: UNIPROT:P43145
A/Accession: P0610
A/Molecule type: protein
A/Residues: 22-41 <SN2>
C/Comment: This precursor contains a unique 20-amino acid sequence designated proadrenom
          eadrenomedullin.
C/Keywords: amidated carboxyl end
F/1-21/Domain: signal sequence #status predicted <SIG>
F/22-185/Product: proadrenomedullin #status predicted <PRU>
F/22-41/Product: proadrenomedullin amino-terminal 20 peptide #status predicted <PAp>
F/94-143/Product: adrenomedullin #status predicted <MAT>
F/41/Modified site: amidated carboxyl end (Arg) (amide in mature form from following gly
F/143/Modified site: amidated carboxyl end (Tyr) (amide in mature form from following gly

Query Match      90.8%; Score 148; DB 2; Length 185;
Best Local Similarity 87.1%; Pred. No. 4.2e-14;
Matches 27; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      1 TVQKLAHQIYQFTDKDKNVAPRSKISPGQY 31
Db      113 TVQKLAHQIYQFTDKDKNVAPRSKISPGQY 143

RESULT 4
A85489
hypothetical protein 20078 [imported] - Escherichia coli (strain O157:H7, substrain EDL93
C/Species: Escherichia coli
C/Date: 16-Feb-2001 #sequence_revision 16-Feb-2001 #text_change 09-Jul-2004
C/Accession: A85489

```

```

R/Perna, N.T.; Plunkett III, G.; Burland, V.; Mau, B.; Glasner, J.D.; Rose, D.J.; Mayhew,
Miller, L.; Grobbeck, E.J.; Davis, N.W.; Lim, A.; Dimalanta, E.; Potamousis, K.; Apodaca,
Nature 409, 529-533, 2001
A/Title: Genome sequence of enterohemorrhagic Escherichia coli O157:H7.
A/Reference number: A85489; MUID:21074935; PMID:11206551
A/Accession: A85489
A/Status: preliminary
A/Molecule type: DNA
A/Residues: 1-189 <STO>
A/Cross-references: UNIPROT:O8XA03; GB:AE005174; NID:G12512769; PIDN:AA654373.1; GSPDB:
A/Experimental source: strain O157:H7, substrain EDL933
A/Gene: 20078
C/Superfamily: Escherichia coli yabp protein

Query Match      35.9%; Score 58.5; DB 2; Length 189;
Best Local Similarity 34.4%; Pred. No. 0.52;
Matches 11; Conservative 9; Mismatches 7; Indels 5; Gaps 1;

QY      4 KLAHQIYQFTD-----KDKDNVAPRSKISPGQ 30
Db      95 KLTWMLIKENELKEYAKDPENMAAKASISPEG 126

RESULT 5
A99638
hypothetical protein EC80073 [imported] - Escherichia coli (strain O157:H7, substrain RI
C/Species: Escherichia coli
C/Date: 18-Jul-2001 #sequence_revision 18-Jul-2001 #text_change 09-Jul-2004
C/Accession: A99638
R/Hayashi, T.; Makino, K.; Ohnishi, M.; Kurokawa, K.; Ishii, K.; Yokoyama, K.; Han, C.G.
gaasawara, N.; Yasunaga, T.; Kuhara, S.; Shiba, T.; Hattori, M.; Shingawa, H.
DNA Res. 8, 11-22, 2001
A/Title: Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genc
A/Reference number: A99638; MUID:21156231; PMID:11258796
A/Accession: A99638
A/Status: preliminary
A/Molecule type: DNA
A/Residues: 1-189 <HAV>
A/Cross-references: UNIPROT:O8XA03; GB:BA000007; PIDN:BA833496.1; PID:G13359529; GSPDB:
A/Experimental source: strain O157:H7, substrain RIMD 0509952
A/Gene: EC80073
C/Superfamily: Escherichia coli yabp protein

Query Match      35.9%; Score 58.5; DB 2; Length 189;
Best Local Similarity 34.4%; Pred. No. 0.52;
Matches 11; Conservative 9; Mismatches 7; Indels 5; Gaps 1;

QY      4 KLAHQIYQFTD-----KDKDNVAPRSKISPGQ 30
Db      95 KLTWMLIKENELKEYAKDPENMAAKASISPEG 126

RESULT 6
T14536
S-locus-specific glycoprotein - wild cabbage (fragment)
N/Alternate names: S glycoprotein
C/Species: Brassica oleracea (wild cabbage)
C/Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 09-Jul-2004
C/Accession: T14536
R/Kusaba, M.; Nishio, T.; Satta, Y.; Hinata, K.; Ockendon, D.
Proc. Natl. Acad. Sci. U.S.A. 94, 7673-7678, 1997
A/Title: Striking sequence similarity in inter- and intra-specific comparisons o f class
          echanism.
A/Reference number: Z18078; MUID:97352858; PMID:9207151
A/Accession: T14536
A/Status: preliminary; translated from GB/EMBL/DBJ
A/Molecule type: DNA
A/Residues: 1-430 <KUS>
A/Cross-references: UNIPROT:O23846; EMBL:D85212; NID:G251155; PIDN:BAA21946.1; PID:G235
C/Superfamily: S-locus-specific glycoprotein; S-locus-specific glycoprotein homology
C/Keywords: glycoprotein

```

```

Query Match      35.6%; Score 58; DB 2; Length 430;
Best Local Similarity 25.6%; Pred. No. 1.5;
Matches 10; Conservative 12; Mismatches 7; Indels 10; Gaps 1;

QY          3 OKLAHQIYOPTDKD-----NVAPRSKISPOGY 31
           :|:::| |:::| |:::| |:::| |
DB          230 EKLIVMYNYETENNENBAVYTFRMTNKSIVSRLLTSVEGGY 268

RESULT 7
T14415
S-locus-specific glycoprotein - turnip (fragment)
N.Alternate names: S glycoprotein
C.Species: Brassica rapa (turnip)
C.Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 09-Jul-2004
C.Accession: T14415
R.Kusuba, M.; Mashio, T.; Satra, Y.; Hinata, K.; Ockendon, D.
Proc. Natl. Acad. Sci. U.S.A. 94, 7673-7678, 1997
A.Title: Striking sequence similarity in inter- and intra-specific comparisons o f class
protein.
A.Reference number: Z18078; MUID:97352858; PMID:9207151
A.Accession: T14415
A.Status: preliminary; translated from GB/EMBL/DDBJ
A.Molecule type: DNA
A.Residues: 1-431 <RUS>
A.Cross-references: UNIPROT:O23849; EMBL:D85215; NID:g2351161; PIDN:BAA21949.1; PID:g235
CSuperfamily: S-locus-specific glycoprotein; S-locus-specific glycoprotein homology
C.Keywords: glycoprotein

Query Match      34.4%; Score 56; DB 2; Length 431;
Best Local Similarity 30.8%; Pred. No. 3;
Matches 12; Conservative 8; Mismatches 9; Indels 10; Gaps 1;

QY          3 OKLAHQIYOPTDXKD-----NVAPRSKISPOGY 31
           |||:::| |:::| |:::| |:::| |
DB          232 OKLVWVYNFTENSESDVAYTFRMTNKSIVSRLLTSSEGGY 270

RESULT 8
G84107
lipopolysaccharide biosynthesis BH3663 [Imported] - Bacillus halodurans (strain C-125)
C.Species: Bacillus halodurans
C.Date: 01-Dec-2000 #sequence_revision 01-Dec-2000 #text_change 09-Jul-2004
C.Accession: G84107
R.Takami, H.; Nakasone, K.; Takaki, Y.; Maeno, G.; Sasaki, R.; Maeni, N.; Fujii, F.; Hirai
Nucleic Acids Res. 28, 4317-4331, 2000
A>Title: Complete genome sequence of the alkaliphilic bacterium Bacillus halodurans and
A.Reference number: A83650; MUID:20512582; PMID:11058132
A.Accession: G84107
A>Status: preliminary
A.Molecule type: DNA
A.Residues: 1-373 <STO>
A.Cross-references: UNIPROT:Q9XKR4; GB:AP001519; GB:BA000004; NID:g10176109; PIDN:BAB073
C.Experimental source: strain C-125
C.Genetics:
A.Gene: BH3663

Query Match      33.1%; Score 54; DB 2; Length 373;
Best Local Similarity 48.0%; Pred. No. 5;
Matches 12; Conservative 4; Mismatches 9; Indels 0; Gaps 0;

QY          2 VOKLAHQIYOPTDKDNVA PRSKI 26
           |||||:::| |:::| |:::| |
DB          132 VYKLAHQIVLSRGVKENTLVRRYKI 156

RESULT 9
T15540
hypothetical protein C17C3.1 - Caenorhabditis elegans
C.Species: Caenorhabditis elegans
C.Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 12-Jul-2004
C.Accession: T15540

```

```

R.Du, Z.
submitted to the EMBL Data Library, November 1995
A.Description: The sequence of C. elegans cosmid C17C3.
A.Reference number: Z18356
A.Accession: U15540
A.Status: preliminary; translated from GB/EMBL/DBJ
A.Molecule type: DNA
A.Residues: 1-465 <DUZ>
A.Cross-references: EMBL:U41279; NID:g1086905; PID:g1086919; PIDN:AAB52685.1; GSPDB:GN0
A.Experimental source: errata Bristol N2, clone C17C3
C.Gene: CESP.C17C3.1
A.Map position: 2
A.Introns: 124/2; 138/2; 174/2; 223/1; 369/2
C.Superfamily: acyl-CoA thioesterase II (TEab) with DUF545 domain

Query Match      32.5%; Score 53; DB 2; Length 465;
Best Local Similarity 40.0%; Pred. No. 9;
Matches 8; Conservative 7; Mismatches 5; Indels 0; Gaps 0;

OY      3 OKLAHQIYQFTDKDKDNVAP 22
      ||:::|::|::|::|::|
Db      156 QEIHKEPDTFLKCDSPSP 175

RESULT 10
T14529
S-locus-specific glycoprotein - wild cabbage (fragment)
N.Alternate names: S glycoprotein
C.Species: Brassica oleracea (wild cabbage)
C.Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 09-Jul-2004
C.Accession: T14529
R.Kusaba, M.; Nishio, T.; Saita, Y.; Hinata, K.; Ockendon, D.
Proc. Natl. Acad. Sci. U.S.A. 94, 7673-7678, 1997
A.Title: Striking sequence similarity in inter- and intra-specific comparisons of class
echanism.
A.Reference number: Z18078; MUID:97352858; PMID:9207151
A.Accession: T14529
A.Status: preliminary; translated from GB/EMBL/DBJ
A.Molecule type: DNA
A.Residues: 1-428 <KUS>
A.Cross-references: UNIPROT:O23839; EMBL:D85205; NID:g2351141; PIDN:BA421939.1; PID:g23
C.Superfamily: S-locus-specific glycoprotein; S-locus-specific glycoprotein homology
C.Keywords: glycoprotein

Query Match      31.9%; Score 52; DB 2; Length 428;
Best Local Similarity 28.2%; Pred. No. 11;
Matches 11; Conservative 8; Mismatches 10; Indels 10; Gaps 1;

OY      3 OKLAHQIYQFTDKDKD-----NVARRSKISPOGY 31
      ||:::|::|::|::|::|::|::|::|::|
Db      229 OKLSYMYNPFENSEEVAYTFRTNNSPYRLKVSDDGY 267

RESULT 11
T07814
S-locus-specific glycoprotein S6 - radish (fragment)
C.Species: Raphanus sativus (radish)
C.Date: 14-May-1999 #sequence_revision 14-May-1999 #text_change 09-Jul-2004
C.Accession: T07814
R.Sakamoto, K.; Kusaba, M.; Nishio, T.
Mol. Gen. Genet. 258, 397-403, 1998
A.Title: Polymorphism of the S-locus glycoprotein gene (SLG) and the S-locus related ge
A.Reference number: Z16146; MUID:98311079; PMID:9648745
A.Accession: T07814
A.Status: preliminary; translated from GB/EMBL/DBJ
A.Molecule type: DNA
A.Residues: 1-428 <SAK>
A.Cross-references: UNIPROT:O80351; EMBL:AB009682; NID:g3327849; PIDN:BA41729.1; PID:g
C.Gene: SLG(S6)
A.Gene: SLG(S6)
C.Superfamily: S-locus-specific glycoprotein; S-locus-specific glycoprotein homology
C.Keywords: glycoprotein

```

F/32-426/Domain: S-locus-specific glycoprotein homology <SSG>

## Query Match

Best Local Similarity 31.3%; Score 51; DB 2; Length 428;  
Matches 11; Conservative 8; Mismatches 10; Indels 10; Gaps 1;

QY 3 OKLAHQIYQFTDKD-----NVAPRSKISPOGY 31  
DB 229 OKLSYMYNFTENSEVAVYTFMTNNSIYSRLTISSEGY 267

## RESULT 12

T14533

S-locus-specific glycoprotein - wild cabbage (fragment)

N/Alternate names: S glycoprotein

C/Species: Brassica oleracea (wild cabbage)

C/Date: 20-Sep-1999 #sequence\_revision 20-Sep-1999 #text\_change 09-Jul-2004

C/Accession: T14533

R/Kusaba, M.; Nishio, T.; Satra, Y.; Hinata, K.; Ockendon, D.

Proc. Natl. Acad. Sci. U.S.A. 94, 7673-7678, 1997

A/Title: Striking sequence similarity in inter- and intra-specific comparisons of class

A/Reference number: Z18078; MUID:97352858; PMID:9207151

A/Accession: T14533

A/Status: preliminary; translated from GB/EMBL/DBJ

A/Molecule type: DNA

A/Residues: 1-429 <RUS>

A/Cross-references: UNIPROT:Q03843; EMBL:D85209; NID:g2351149; PIDN:BAA21943.1; PID:g235

C/Superfamily: S-locus-specific glycoprotein; S-locus-specific glycoprotein homology

C/Keywords: glycoprotein

## Query Match

Best Local Similarity 31.3%; Score 51; DB 2; Length 429;  
Matches 13; Conservative 8; Mismatches 7; Indels 12; Gaps 2;

QY 3 OKLAHQIYQFTDKD-----PRSKISPOGY 31  
DB 230 OKLSYMYNFTDSEEVAVTFMTNNSIYSRIQISSEGF 268

## RESULT 13

A27827

S-locus-specific glycoprotein S6 precursor - wild cabbage

C/Species: Brassica oleracea (wild cabbage)

C/Date: 19-May-1989 #sequence\_revision 19-May-1989 #text\_change 09-Jul-2004

C/Accession: A27827

R/Nasrallah, J.B.; Kao, T.H.; Chen, C.H.; Goldberg, M.L.; Nasrallah, M.E.

Nature 326, 617-619, 1987

A/Title: Amino-acid sequence of glycoproteins encoded by three alleles of the S locus of

A/Reference number: A93392

A/Accession: A27827

A/Molecule type: mRNA

A/Residues: 1-436 <NAS>

A/Cross-references: UNIPROT:P07761

C/Superfamily: S-locus-specific glycoprotein; S-locus-specific glycoprotein homology

C/Keywords: glycoprotein

F/1-31/Domain: signal sequence #status predicted <SIG>

F/32-436/Product: S-locus-specific glycoprotein S6 #status predicted <MAT>

F/40-434/Domain: S-locus-specific glycoprotein homology <SSG>

## Query Match

Best Local Similarity 31.3%; Score 51; DB 2; Length 436;  
Matches 10; Conservative 10; Mismatches 9; Indels 10; Gaps 1;

QY 3 OKLAHQIYQFTDKD-----NVAPRSKISPOGY 31  
DB 237 OKLSYMYNFTENSEVAVYTFMTNNSIYSRLTISSEGY 275

## RESULT 14

T14471

probable S-receptor kinase (EC 2.7.1.-) brk29 - wild cabbage

C/Species: Brassica oleracea (wild cabbage)

C/Date: 20-Sep-1999 #sequence\_revision 20-Sep-1999 #text\_change 09-Jul-2004

C/Accession: T14471

R/Kumar, V.; Trick, M.

Plant J. 6, 807-813, 1994

A/Title: Expression of the S-locus receptor kinase multigene family in Brassica oleracea

A/Reference number: Z18108; MUID:95152355; PMID:7849754

A/Accession: T14471

A/Status: preliminary; translated from GB/EMBL/DBJ

A/Molecule type: DNA

A/Residues: 1-857 <KUM>

A/Cross-references: UNIPROT:Q03932; EMBL:Z30211; NID:g459244; PIDN:CAA82930.1; PID:g4592

A/Experimental source: strain aldoglabra; strigma

A/Genetics:

A/Accession: brk29

A/Introns: 438/1; 481/1; 544/3; 615/1; 694/2; 744/3

C/Function:

A/Description: implicated in the self-incompatibility system of Brassica oleracea

C/Superfamily: S-receptor kinase; protein kinase homology; S-locus-specific glycoprotein

C/Keywords: ATP; phosphotransferase; serine/threonine-specific protein kinase; signal tr

F/41-436/Domain: S-locus-specific glycoprotein homology <SSG>

F/526-813/Domain: protein kinase homology <KIN>

Query Match 31.3%; Score 51; DB 2; Length 857;  
Best Local Similarity 28.2%; Pred. No. 35;  
Matches 11; Conservative 8; Mismatches 10; Indels 10; Gaps 1;

QY 3 OKLAHQIYQFTDKD-----NVAPRSKISPOGY 31  
DB 239 OKLSYMYNFTONSEEVAVTFMTNNSIYSRLTISSEGY 277

## RESULT 15

C86279

hypothetical protein F1417.23 [imported] - Arabidopsis thaliana

C/Species: Arabidopsis thaliana (mouse-ear cress)

C/Date: 02-Mar-2001 #sequence\_revision 02-Mar-2001 #text\_change 09-Jul-2004

C/Accession: C86279

R/Theologis, A.; Eckert, J.R.; Palm, C.J.; Federspiel, N.A.; Kaul, S.; White, O.; Alonso,

Chin, C.W.; Chung, M.K.; Conn, L.; Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewar, K.,

ansen, N.F.; Hughes, B.; Hultzer, L.

Nature 408, 816-820, 2000

A/Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, E.; Kim, C.

C.A.; Li, J.H.; Li, Y.; Lin, X.; Liu, S.X.; Liu, Z.A.; Luros, J.S.; Maiti, R.; Marshall,

Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.

A/Authors: Salzberg, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.; Tallon,

ker, M.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.

A/Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.

A/Reference number: A86141; MUID:21016719; PMID:11130712

A/Accession: C86279

A/Status: preliminary

A/Molecule type: DNA

A/Residues: 1-90 <STO>

A/Cross-references: UNIPROT:Q9M9R8; GB:A5005172; NID:g7262688; PIDN:AAF43946.1; GSPDB:G

C/Genetics:

A/Map position: 1

Query Match 30.7%; Score 50; DB 2; Length 90;  
Best Local Similarity 41.9%; Pred. No. 4;  
Matches 13; Conservative 3; Mismatches 15; Indels 0; Gaps 0;

QY 1 TVQKLAHQIYQFTDKD-----NVAPRSKISPOGY 31  
DB 12 TVQTARPTDPTDKIQTVPPSPKTPPGY 42

Search completed: January 5, 2005, 08:44:40  
Job time : 34.8182 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 5, 2005, 08:39:22 : Search time 178.955 Seconds  
(without alignments)  
99.671 Million cell updates/sec

Title: US-09-931-700-3

Perfect score: 163  
Sequence: 1 TVQKLAHQIYQFTDKDXDNVAPRSKISPGQY 31

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1825181 seqs, 575374646 residues

Total number of hits satisfying chosen parameters: 1825181

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Maximum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : UniProt 02:.\*  
1: uniprot\_sprot:.\*  
2: uniprot\_trembl:.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	163	100.0	185	1	ADML_HUMAN
2	163	100.0	185	1	ADML_HUMAN
3	157	96.3	188	1	ADML_PIG
4	152	93.3	188	1	ADML_CANFA
5	148	90.8	185	1	ADML_RAT
6	148	89.6	185	1	AAH61775
7	146	89.6	188	1	ADML_BOVIN
8	146	89.6	188	1	Q9SKD0
9	140	85.9	184	1	ADML_MOUSE
10	140	85.9	184	1	AAH52665
11	138	84.7	27	2	Q9TRR6
12	70	42.9	174	2	Q75XW8
13	70	42.9	174	2	BAD02341
14	66	40.5	171	2	Q6L8K5
15	66	40.5	171	2	BAD19046
16	58.5	35.9	189	2	Q7AHR7
17	58.5	35.9	189	2	Q8XAO3
18	58	35.6	430	2	Q23846
19	56	34.4	367	2	Q9S8B5
20	56	34.4	425	2	Q84KX0
21	56	34.4	431	2	Q23849
22	55	33.7	368	2	Q9S8B2
23	55	33.7	421	2	Q8S9B2
24	55	33.7	436	2	Q84KX4
25	55	33.7	438	2	Q84KX0
26	54	32.8	373	2	Q9K6R4
27	53.5	32.8	168	2	Q75XW7
28	53.5	32.8	168	2	BAD02342
29	53.5	32.8	557	2	Q74JC1
30	53.5	32.8	557	2	AA090009
31	53	32.5	346	2	Q9B1A5

32	53	32.5	357	2	Q9B1A9	Q9B1A9 caenorhabdi
33	53	32.5	431	2	Q84KX5	Q84KX5 brassica ol
34	53	32.5	440	2	Q84KX1	Q84KX1 brassica ol
35	52.5	32.2	159	2	Q75XW6	Q75XW6 fugu rubrip
36	52.5	32.2	159	2	BAD02343	BAD02343 fugu rubr
37	52.5	32.2	269	2	Q6MCI3	Q6MCI3 parachlamy
38	52.5	32.2	269	2	CAI23886	CAI23886 parachlam
39	52	31.9	294	2	Q6SV92	Q6SV92 brassica na
40	52	31.9	294	2	Q6SV94	Q6SV94 brassica na
41	52	31.9	294	2	Q6SV96	Q6SV96 brassica na
42	52	31.9	294	2	Q6SV90	Q6SV90 brassica ca
43	52	31.9	294	2	Q6SV92	Q6SV92 brassica ca
44	52	31.9	294	2	AA09046	AA09046 brassica
45	52	31.9	294	2	AA09048	AA09048 brassica

## ALIGNMENTS

RESULT 1	ADML_HUMAN	STANDARD;	PRT;	185 AA.
ID	ADML_HUMAN	STANDARD;	PRT;	185 AA.
AC	P3518;			
DT	01-FEB-1994 (Rel. 28, Created)			
DT	01-FEB-1994 (Rel. 28, Last sequence update)			
DT	05-JUN-2004 (Rel. 44, Last annotation update)			
DE	ADM precursor (Contains: Adrenomedullin (AM); Proadrenomedullin N-20 terminal peptide (PROM-N20) (PROM-N-terminal 20 peptide) (PAMP)).			
GN	Name=ADM; Synonyms=AM;			
OS	Homo sapiens (Human);			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.			
OX	NCBI_TaxID=9606;			
RN	[1]			
RP	SEQUENCE FROM N.A.			
RC	TISUB=Phenochromocytoma;			
RC	MEDLINE=93343928; PubMed=7688224;			
RA	Kitamura K., Sakata J., Kangawa K., Kojima M., Matsuo H., Eto T.;			
RT	"Cloning and characterization of cDNA encoding a precursor for human			
RL	adrenomedullin.";			
RL	Biochem. Biophys. Res. Commun. 194:720-725 (1993).			
RN	[2]			
RP	SEQUENCE FROM N.A.			
RC	TISUB=Liver;			
RX	MEDLINE=94354869; PubMed=8074714;			
RA	Ishimatsu T., Kojima M., Kangawa K., Hino J., Matsuo H.,			
RT	"Genomic structure of human adrenomedullin gene.";			
RL	Biochem. Biophys. Res. Commun. 203:631-639 (1994).			
RN	[3]			
RP	SEQUENCE FROM N.A.			
RC	TISUB=Kidney;			
RX	MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;			
RA	Straussberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,			
RT	Klausner R.D., Collins F.S., Wagner L., Shennan C.M., Schuler G.D.,			
RL	Altschul S.F., Zeeberg B., Buelow K.H., Schaefer C.P., Bhat N.K.,			
RA	Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,			
RA	Diatlenko L., Marusik A., Farmer A.A., Rubin G.M., Hong L.,			
RA	Capletton M., Soares M.B., Bonaldi M.F., Casavant T.L., Schaefer T.E.,			
RA	Brownstein M.J., Uedlin T.B., Toshiyuki S., Carninci P., Prange C.,			
RA	Raba S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,			
RA	Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,			
RA	Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,			
RA	Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,			
RA	Fahy J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,			
RA	Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,			
RA	Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,			
RA	Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,			
RA	Butterfield Y.S.N., Krzywnicki M.I., Skalska U., Smalls D.E.,			
RA	Schmeich A., Schein J.E., Jones S.J.M., Maria W.A.,			
RT	"Generation and initial analysis of more than 15,000 full-length human			
RT	and mouse cDNA sequences.";			
Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).				

RN [4]  
 RC SEQUENCE OF 95-146.  
 RC TISSUE=Pneochromocytoma;  
 RA MEDLINE=93249425; PubMed=8387282;  
 RA Kitamura K., Kangawa K., Kawamoto M., Ichiki Y., Nakamura S.,  
 RA Matsuo H., Eto T.;  
 RT "Adrenomedullin: a novel hypotensive peptide isolated from human  
 RT pheochromocytoma";  
 RL Biochem. Biophys. Res. Commun. 192:553-560(1993).  
 RL [5]  
 RP REVIEW  
 RX MEDLINE=98240137; PubMed=9578982;  
 RA Samson W.K.;  
 RT "Proadrenomedullin-derived peptides";  
 RL Front. Neuroendocrinol. 19:100-127(1998).  
 RL [6]  
 RP REVIEW  
 RX MEDLINE=20053666; PubMed=10588445;  
 RA Champion H.C., Nussdorfer G.G., Kadowitz P.J.;  
 RT "Structure-activity relationships of adrenomedullin in the circulation  
 RT and adrenal gland";  
 RL Regul. Pept. 85:1-8(1999).  
 CC -1- FUNCTION: AM and PAMP are potent hypotensive and vasodilator  
 CC agents. Numerous actions have been reported most related to the  
 CC physiologic control of fluid and electrolyte homeostasis. In the  
 CC kidney, am is diuretic and natriuretic, and both am and pamp  
 CC inhibit aldosterone secretion by direct adrenal actions. In  
 CC pituitary gland, both peptides at physiologically relevant doses  
 CC inhibit basal ACTH secretion. Both peptides appear to act in brain  
 CC and pituitary gland to facilitate the loss of plasma volume,  
 CC actions which complement their hypotensive effects in blood  
 CC vessels.  
 CC -1- SUBCELLULAR LOCATION: Secreted.  
 CC -1- TISSUE SPECIFICITY: Highest levels found in pheochromocytoma and  
 CC adrenal medulla. Also found in lung, ventricle and kidney tissues.  
 CC -1- SIMILARITY: Belongs to the adrenomedullin family.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL: D14874; BAA03589.1; -;  
 CC EMBL: S73906; AAC60642.1; -;  
 CC EMBL: BC015961; AAH15961.1; -;  
 CC EMBL: D43639; BAA07756.1; ALT\_SEQ.  
 CC PIR: JC2351; JN0684.  
 CC GeneW: HGNC:259; ADM.  
 CC MIM: 103275; -;  
 DR GO: GO:0005615; C:extracellular space; TAS.  
 DR GO: GO:0005625; C:soluble fraction; TAS.  
 DR GO: GO:0005102; F:receptor binding; TAS.  
 DR GO: GO:0006171; P:cAMP biosynthesis; TAS.  
 DR GO: GO:0007267; P:cell-cell signaling; TAS.  
 DR GO: GO:0008015; P:circulation; TAS.  
 DR GO: GO:0007565; P:pregnancy; TAS.  
 DR GO: GO:0006701; P:progesterone biosynthesis; TAS.  
 DR GO: GO:0009611; P:response to wounding; TAS.  
 DR GO: GO:0007165; P:signal transduction; TAS.  
 DR InterPro: IPR001710; Adrenomedullin.  
 DR Pfam: PF02039; Adrenomedullin; 1.  
 DR PRINTS: PR00801; ADRENOMEDULLIN.  
 KW Amidation; Cleavage on pair of basic residues;  
 KW Direct protein sequencing; Hormone; Polymorphism; Signal.  
 FT SIGNAL 1 21 Proadrenomedullin N-20 terminal peptide.  
 FT PEPTIDE 22 41  
 FT PROPEP 45 92  
 FT PEPTIDE 95 146 Adrenomedullin.  
 FT PROPEP 148 185 ProPOM C-terminal fragment.  
 FT DISUFID 110 115

FT MOD\_RES 41 41 Arginine amide (G-42 provides amide  
 FT MOD\_RES 146 146 Tyrosine amide (G-147 provides amide  
 FT VARIANT 50 50 S->R (in dbSNP:5005).  
 FT FT FTId=VAR 014861.  
 SQ SEQUENCE 185 AA; 20420 MW; 64C7D2A0B4654DFE CRC64;  
 Query Match 100.0%; Score 163; DB 1; Length 185;  
 Best Local Similarity 100.0%; Pred. No. 5.2e-15;  
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGY 31  
 Db 116 TVQKLAHQIYQFTDKDKDNVAPRSKISPGY 146  
 RESULT 3  
 ADML\_PIG STANDARD; PRT; 188 AA.  
 AC P53366;  
 DT 01-OCT-1996 (Rel. 34, Created)  
 DT 01-OCT-1996 (Rel. 34, Last sequence update)  
 DT 05-JUN-2004 (Rel. 44, Last annotation update)  
 DE ADM precursor [Contains: Adrenomedullin (AM); Proadrenomedullin N-20  
 DE terminal peptide (ProAM-N20) (ProAM N-terminal 20 peptide) (PAMP)].  
 GN Name=ADM; Synonyms=AM;  
 OS Sus scrofa (Pig).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.  
 OC NCBI\_TaxID=9823;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Adrenal medulla;  
 RA MEDLINE=94139945; PubMed=8043068;  
 RA Kitamura K., Kangawa K., Kojima M., Ichiki Y., Matsuo H., Eto T.;  
 RT "Complete amino acid sequence of porcine adrenomedullin and cloning of  
 RT cDNA encoding its precursor";  
 RL FEBS Lett. 338:306-310(1994).  
 RP [2]  
 RP SEQUENCE OF 22-41.

```

RC TISSUE=Adrenal medulla;
RX MEDLINE=94357274; PubMed=8076689;
RA Kitamura K., Kangawa K., Ishiyama Y., Washimine H., Ichiki Y.,
RA Kawamoto M., Minamoto N., Matsuo H., Eto T.;
RT "Identification and hypotensive activity of proadrenomedullin N-
RT terminal 20 peptide (PAMP).";
RL FEBS Lett. 351:35-37(1994).
CC -1- FUNCTION: AM and PAMP are potent hypotensive and vasodilator
CC agents.
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- TISSUE SPECIFICITY: Highly expressed in adrenal glands, lung and
CC kidney.
CC -1- SIMILARITY: Belongs to the adrenomedullin family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See license@isb-sib.ch).
CC -----
CC EMBL; D14875; BAA03590.1; -.
CC PIR; S41600; S41600.
CC InterPro; IPR001710; Adrenomedullin.
CC InterPro; IPR011038; Calcyclin.
CC Pfam; PF02039; Adrenomedullin; 1.
CC PRINTS; PR00801; ADRENOMEDULLIN.
CC Amadation; Cleavage on pair of basic residues;
CC Direct protein sequencing; Hormone; Signal.
CC KW SIGNAL 1 21
CC PESTIDE 22 41 Proadrenomedullin N-20 terminal peptide.
CC PROPEP 45 92 Adrenomedullin.
CC PESTIDE 95 146 PreproAM C-terminal fragment (By
CC PROPEP 153 188 similarity).
CC FT DISULFID 110 115 By similarity.
CC FT MOD_RES 41 41 Arginine amide (G-42 provides amide
CC group).
CC FT MOD_RES 146 146 Tyrosine amide (G-147 provides amide
CC group).
CC FT MOD_RES 146 146 Tyrosine amide (G-147 provides amide
CC group).
CC SQ SEQUENCE 188 AA; 20893 MW; 717494605660A61 CRC64;
CC -----
CC Query Match 96.3%; Score 157; DB 1; Length 188;
CC Best Local Similarity 96.8%; Pred.No. 3.8e-14;
CC Matches 30; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
CC -----
CC Oy 1 TVOKLAHQIYPTDKDKDNVAPRSKISPGY 31
CC |||||
CC Db 116 TVOKLAHQIYPTDKDKGVAPRSKISPGY 146
CC -----
CC RESULT 4
CC ID ADML CANFA STANDARD; PRT; 188 AA.
CC AC 077559; Q9TVC9;
CC DT 16-OCT-2001 (Rel. 40, Created)
CC DT 16-OCT-2001 (Rel. 40, Last sequence update)
CC DT 05-JUL-2004 (Rel. 44, Last annotation update)
CC DE ADM precursor (Containing: Adrenomedullin (AM); Proadrenomedullin N-20
CC terminal peptide (PROM-AM) (PROM N-terminal 20 peptide) (PAMP)).
CC OS Name=ADM;
CC OS Canis familiaris (Dog).
CC CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
CC CC Mammalia; Eutheria; Carnivora; Placentalia; Canidae; Canis.
CC CC NCBI_Taxid=9615;
CC OK (1)
CC RN SEQUENCE FROM N.A.
CC RP Imoto I., Jouglaaki M.;
CC RT "Cloning of cDNA encoding canine adrenomedullin.";
CC RL Submitted (JAN-1999) to the EMBL/Genbank/DBJ databases.
CC [2]
CC RN SEQUENCE FROM N.A.

```

RA MEDLINE=99002704; PubMed=9786555.  
RX Ono Y., Kojima M., Okada K., Kangawa K.;  
RT "cDNA cloning of canine adrenomedullin and its gene expression in the  
RT heart and blood vessels in endotoxin shock.";  
RL Shock 10;243-247(1998).  
CC -1- FUNCTION: AM and PAMP are potent hypotensive and vasodilator  
CC agents.  
CC -1- SUBCELLULAR LOCATION: Secreted.  
CC -1- SIMILARITY: Belongs to the adrenomedullin family.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>).  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch).  
CC -----  
DR EMBL; AF045773; AAD05423.1; -.  
DR EMBL; U96127; AAD09957.1; -.  
DR InterPro; IPR001710; Adrenomedullin.  
DR Pfam; PF02039; Adrenomedullin.1.  
DR PRINTS; PR00801; ADRENOMEDULLIN.  
KW Amidation; Cleavage on pair of basic residues; Hormone; Signal.  
FT SIGNAL 1 21  
FT PROPEPTIDE 22 41 By similarity.  
FT PROPEPTIDE 45 92 Proadrenomedullin N-20 terminal peptide.  
FT PEPTIDE 95 146 By similarity.  
FT PROPEPTIDE 148 188 Adrenomedullin.  
FT PROPEPTIDE 148 188 PreproAM C-terminal fragment (By  
FT similarity).  
FT DISULFID 110 115 By similarity.  
FT MOD\_RES 41 41 Arginine amide (G-42 provides amide  
FT MOD\_RES 146 146 group) (By similarity).  
FT MOD\_RES 146 146 Tyrosine amide (G-147 provides amide  
FT MOD\_RES 146 146 group) (By similarity).  
FT CONFLICT 130 130 N -> K (in Ref. 2).  
SQ SEQUENCE 188 AA; 20929 MW; 809D6A64F98F5578 CRC64;  
Query Match 93.3%; Score 152; DB 1; Length 188;  
Best Local Similarity 93.5%; Pred. No. 2e-13;  
Matches 29; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Gy 1 TVQKLAHQIYQFTDKDKNVAPRSKISPGY 31  
Db 116 TVQKLAHQIYQFTDNDKGVA PRSKISPGY 146  
RESULT 5  
ADML\_RAT STANDARD; PRT; 185 AA.  
ID ADML\_RAT  
AC P43145;  
DT 01-NOV-1995 (Rel. 32, Created)  
DT 01-NOV-1995 (Rel. 32, Last sequence update)  
DT 05-JUL-2004 (Rel. 44, Last annotation update)  
DE ADM precursor [Contains: Adrenomedullin (AM); Proadrenomedullin N-20  
DE terminal peptide (PROAM-N20) (PROAM-N-terminal 20 peptide) (PAMP)].  
GN Name=Adm;  
OS Rattus norvegicus (Rat).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
OX NCBI\_TaxID=10116;  
RX  
RA MEDLINE=99002704; PubMed=9786555.  
RX Ono Y., Kojima M., Okada K., Kangawa K.;  
RT "cDNA cloning of canine adrenomedullin and its gene expression in the  
RT heart and blood vessels in endotoxin shock.";  
RL Shock 10;243-247(1998).  
CC -1- FUNCTION: AM and PAMP are potent hypotensive and vasodilator  
CC agents.  
CC -1- SUBCELLULAR LOCATION: Secreted.  
CC -1- SIMILARITY: Belongs to the adrenomedullin family.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>).  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch).  
CC -----  
DR EMBL; AF045773; AAD05423.1; -.  
DR EMBL; U96127; AAD09957.1; -.  
DR InterPro; IPR001710; Adrenomedullin.  
DR Pfam; PF02039; Adrenomedullin.1.  
DR PRINTS; PR00801; ADRENOMEDULLIN.  
KW Amidation; Cleavage on pair of basic residues; Hormone; Signal.  
FT SIGNAL 1 21  
FT PROPEPTIDE 22 41 By similarity.  
FT PROPEPTIDE 45 92 Proadrenomedullin N-20 terminal peptide.  
FT PEPTIDE 95 146 By similarity.  
FT PROPEPTIDE 148 188 Adrenomedullin.  
FT PROPEPTIDE 148 188 PreproAM C-terminal fragment (By  
FT similarity).  
FT DISULFID 110 115 By similarity.  
FT MOD\_RES 41 41 Arginine amide (G-42 provides amide  
FT MOD\_RES 146 146 group) (By similarity).  
FT MOD\_RES 146 146 Tyrosine amide (G-147 provides amide  
FT MOD\_RES 146 146 group) (By similarity).  
FT CONFLICT 130 130 N -> K (in Ref. 2).  
SQ SEQUENCE 188 AA; 20929 MW; 809D6A64F98F5578 CRC64;  
Query Match 93.3%; Score 152; DB 1; Length 188;  
Best Local Similarity 93.5%; Pred. No. 2e-13;  
Matches 29; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Gy 1 TVQKLAHQIYQFTDKDKNVAPRSKISPGY 31  
Db 116 TVQKLAHQIYQFTDNDKGVA PRSKISPGY 146



```

RX MEDLINE=96102137; PubMed=8524787;
RA Wang X., Yue T.L., Barone F.C., White R.F., Clark R.K., Willette R.N.,
RA Sulpiizio A.C., Aiyar N.V., Ruffolo R.R. Jr., Feuerstein G.Z.;
RT "Discovery of adrenomedullin in rat ischemic cortex and evidence for
RT its role in exacerbating focal brain ischemic damage.";
RL Proc. Natl. Acad. Sci. U.S.A. 92:11180-11484(1995).
CC
CC -1- FUNCTION: AM and PAMP are potent hypotensive and vasodilator
CC agents.
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- TISSUE SPECIFICITY: Expressed in adrenal glands, lung, kidney,
CC heart, spleen, duodenum and submandibular glands.
CC -1- SIMILARITY: Belongs to the adrenomedullin family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC -----
DR EMBL; D15069; BAA03665.1; -;
DR EMBL; U15419; AAB60519.1; -;
DR PIR; JN0766; JN0766.
DR RGD; 2047; Adm.
DR InterPro; IPR001710; Adrenomedullin.
DR Pfam; PF02039; Adrenomedullin; 1.
DR PRINTS; PR00801; ADRENOMEDULLIN.
KM Antidomain; Cleavage on pair of basic residues; Hormone; Signal.
FT SIGNAL 1 21
FT PEPTIDE 22 41
FT PROPEP 45 91
FT PEPTIDE 94 143
FT PROPEP 149 185
FT
FT DISUFID 107 112
FT MOD_RES 41 41
FT
FT MOD_RES 143 143
FT
SQ SEQUENCE 185 AA; 20636 MW; 35CAD9A9DD19AE35 CRC64;

Query Match 90.8%; Score 148; DB 1; Length 185;
Best Local Similarity 87.1%; Pred. No. 7.2e-13;
Matches 27; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 TWQKLAHQIYQFTDKDKDGNVAPRSKISPGGY 31
Db 113 TWQKLAHQIYQFTDKDKDGNVAPRSKISPGGY 143

RESULT 6
AAH61775 PRELIMINARY; PRT; 185 AA.
ID AAH61775
AC AAH61775;
DT 02-MAR-2004 (TEMBREL. 27, Created)
DT 02-MAR-2004 (TEMBREL. 27, Last sequence update)
DT 02-MAR-2004 (TEMBREL. 27, Last annotation update)
DE Adrenomedullin.
OS Rattus norvegicus (Rat).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OC NCBI_TaxID=10116;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Prostate;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins P.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Hopenhay R.F., Jordan H., Moore T., Max S.T., Wang J., Heien F.,
RA Datchenko L., Marusha K., Farmer A.F., Rubin G.M., Hong L.,
RA Shapiro M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,

```

```

RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abremson R.D., Mullan S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Murny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Faney J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green B.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzyzinski M.I., Skalska U., Smalov D.B., Scherch A., Schen J.B.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Prostate;
RA Strausberg R.;
RA Submitted (NOV-2003) to the EMBL/GenBank/DBJ databases.
RL EMBL; BC061775; AAH61775.1; -;
DR EMBL; BC061775; AAH61775.1; -;
SQ SEQUENCE 185 AA; 20636 MW; 35CAD9A9DD19AE35 CRC64;

Query Match 90.8%; Score 148; DB 2; Length 185;
Best Local Similarity 87.1%; Pred. No. 7.2e-13;
Matches 27; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 TWQKLAHQIYQFTDKDKDGNVAPRSKISPGGY 31
Db 113 TWQKLAHQIYQFTDKDKDGNVAPRSKISPGGY 143

RESULT 7
ADML_BOVIN STANDARD; PRT; 188 AA.
ID ADML_BOVIN
AC 062827;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE ADM precursor [Contains: Adrenomedullin (ADM); Proadrenomedullin N-20
DE terminal peptide (ProADM-N20) (ProADM N-terminal 20 peptide) (PAMP)].
OS Name=ADM;
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovinae; Bos.
OC NCBI_TaxID=9913;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Aorta;
RA MEDLINE=98244567; PubMed=9585168;
RA Barker S., Wood E., Clark A.J.L., Corder R.;
RT "Cloning of bovine preproadrenomedullin and inhibition of its basal
RT expression in vascular endothelial cells by staurosporine.";
RL Life Sci. 62:1407-1415(1998).
CC -1- FUNCTION: Hypotensive peptide. May function as a hormone in
CC circulation control (By similarity).
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- SIMILARITY: Belongs to the adrenomedullin family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC -----
DR EMBL; A0101613; CAA04866.1; -;
DR InterPro; IPR001710; Adrenomedullin.
DR Pfam; PF02039; Adrenomedullin; 1.
DR PRINTS; PR00801; ADRENOMEDULLIN.
KM Antidomain; Cleavage on pair of basic residues; Hormone; Signal.
FT SIGNAL 1 21
FT

```



FT PEPTIDE 22 41 Proadrenomedullin N-20 terminal peptide.  
 FT PROPEP 45 92 By similarity.  
 FT PEPTIDE 95 146 Adrenomedullin.  
 FT PROPEP 148 188 PreproAM C-terminal fragment (By  
 similarity).  
 FT DISULFID 110 115 By similarity.  
 FT MOD\_RES 41 41 Arginine amide (G-42 provides amide  
 group) (By similarity).  
 FT MOD\_RES 146 146 Tyrosine amide (G-147 provides amide  
 group) (By similarity).  
 FT SEQUENCE 188 AA; 20981 MW; 6102E69A756DCA86 CRC64;

Query Match 89.6%; Score 146; DB 1; Length 188;  
 Best Local Similarity 90.3%; Pred. No. 1.4e-12;  
 Matches 28; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGY 31  
 |||||  
 Db 116 TVQKLAHQIYHFTDKDKGSA PRSKISPGY 146

## RESULT 8

Q95KPO PRELIMINARY; PRT; 188 AA.  
 ID Q95KPO  
 AC Q95KPO  
 DT 01-DEC-2001 (TRENBLrel. 19, Created)  
 DT 01-DEC-2001 (TRENBLrel. 19, Last sequence update)  
 DT 01-MAR-2004 (TRENBLrel. 26, Last annotation update)  
 DE Adrenomedullin.  
 GN Name=BDAM-2;  
 OS Bos taurus (Bovine).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Cetartiodactyla; Kuminantia; Pecora; Bovidae;  
 OC Bovinae; Bos.  
 OC NCBI\_TaxID=9913;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=21630318; PubMed=11754956;  
 RA Klamura K., Macaul E., Kato J., Katoh F., Kita T., Tsuji T.,  
 RA Kangawa K., Eto T.;  
 RT "Adrenomedullin (11-26): a novel endogenous hypertensive peptide  
 RT isolated from bovine adrenal medulla.";  
 RL Peptides 22:1713-1718(2001).  
 DR EMBL, AB055107; BAB52176.1;  
 DR GO; GO:0005576; C:extracellular; IEA.  
 DR GO; GO:0005179; F:hormone activity; IEA.  
 DR InterPro; IPR001710; Adrenomedullin.  
 DR Pfam; PF02039; Adrenomedullin; 1.  
 DR PRINTS; PRO0801; ADRENOMEDULLIN.  
 DR SEQUENCE 188 AA; 20963 MW; 6102E69A756DCA86 CRC64;

Query Match 89.6%; Score 146; DB 2; Length 188;  
 Best Local Similarity 90.3%; Pred. No. 1.4e-12;  
 Matches 28; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGY 31  
 |||||  
 Db 116 TVQKLAHQIYHFTDKDKGSA PRSKISPGY 146

## RESULT 9

ADML\_MOUSE STANDARD; PRT; 184 AA.  
 ID ADML\_MOUSE  
 AC P97297; P97453;  
 DT 16-OCT-2001 (Rel. 40, Created)  
 DT 16-OCT-2001 (Rel. 40, Last sequence update)  
 DT 05-JUN-2004 (Rel. 44, Last annotation update)  
 DE ADM precursor [Contains: Adrenomedullin (AM); Proadrenomedullin N-20  
 DE terminal peptide (ProAM-N20) (ProAM N-terminal 20 peptide) (PAMP)].  
 GN Name=Adm;  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

OX NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=129/Sv;  
 RX MEDLINE=97092892; PubMed=8938454;  
 RA Okazaki T., Ogawa Y., Tamura N., Mori Y., Ise N., Aoki T.,  
 RA Rochelle J.M., Taketo M.M., Seldin M.F., Nakao K.;  
 RT "Genomic organization, expression, and chromosomal mapping of the  
 RT mouse adrenomedullin gene.";  
 RL Genomics 37:395-399(1996).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J;  
 RX MEDLINE=99046755; PubMed=9808778;  
 RA Yotsumoto S., Shimada T., Cui C.Y., Nakashima H., Fujiwara H.,  
 RA Ko M.S.H.;

RT "Expression of adrenomedullin, a hypotensive peptide, in the  
 RT trophoblast giant cells at the embryo implantation site in mouse.";  
 RL Dev. Biol. 203:264-275(1998).  
 CC -1- FUNCTION: AM and PAMP are potent hypotensive and vasodilator  
 agents.  
 CC -1- SUBCELLULAR LOCATION: Secreted.  
 CC -1- SIMILARITY: Belongs to the adrenomedullin family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.ebi.ac.uk/announcements> or send an email to [license@ebi.ac.uk](mailto:license@ebi.ac.uk)).

DR EMBL, D78349; BA11367.1; -;  
 DR EMBL, U77630; AAB36535.1; -;  
 DR MGD; MGI:108058; Adm.  
 DR InterPro; IPR001710; Adrenomedullin.  
 DR Pfam; PF02039; Adrenomedullin; 1.  
 DR PRINTS; PRO0801; ADRENOMEDULLIN.

DR Amidation; Cleavage on pair of basic residues; Hormone; Signal.  
 KW SIGNAL 1 21  
 FT 1 By similarity.  
 FT PROPEP 22 41 Proadrenomedullin N-20 terminal peptide.  
 FT PROPEP 45 92 By similarity.  
 FT PEPTIDE 95 144 Adrenomedullin.  
 FT PROPEP 151 184 PreproAM C-terminal fragment (By  
 similarity).  
 FT DISULFID 108 113 Arginine amide (G-42 provides amide  
 group) (By similarity).  
 FT MOD\_RES 41 41 Tyrosine amide (G-145 provides amide  
 group) (By similarity).  
 FT MOD\_RES 144 144 Tyrosine amide (G-145 provides amide  
 group) (By similarity).  
 FT CONFLICT 173 173 A -> G (in Ref. 2).  
 FT SEQUENCE 184 AA; 20764 MW; C88C9045A79C898 CRC64;

Query Match 85.9%; Score 140; DB 1; Length 184;  
 Best Local Similarity 83.9%; Pred. No. 1e-11;  
 Matches 26; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGY 31  
 |||||  
 Db 114 TVQKLAHQIYQFTDKDKGSA PRSKISPGY 144

## RESULT 10

AAH52665 PRELIMINARY; PRT; 184 AA.  
 ID AAH52665  
 AC AAH52665;  
 DT 02-MAR-2004 (TRENBLrel. 27, Created)  
 DT 02-MAR-2004 (TRENBLrel. 27, Last sequence update)  
 DT 02-MAR-2004 (TRENBLrel. 27, Last annotation update)  
 DE Adrenomedullin.  
 GN Name=Adm;  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

OK NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=Egg;  
 RX MEDLINE=22388257; PubMed=12477932;  
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins S., Wagner L., Sherman C.M., Schuler G.D.,  
 RA Altschul S.F., Zeeberg B., Buetow K.H., Scheefer C.F., Bhat N.K.,  
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
 RA Diatchenko L., Marsden K., Farmer A.A., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
 RA Brownstein M.J., Umedin T.B., Toshiyuki S., Canninci P., Prange C.,  
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mulhally S.J.,  
 RA Bosak S.A., McEwan P.U., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulys S.W.,  
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Fahy J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,  
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
 RA Blakeley R.W., Touchman J.W., Green E.D., Dickson W.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Buttefield Y.S.,  
 RA Kozynski M.I., Skaleka U., Smallus D.E., Scherch A., Schein J.E.,  
 RA Jones S.J., Marra M.A.;  
 RT "Generation and initial analysis of more than 15,000 full-length human  
 RT and mouse cDNA sequences.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=Egg;  
 RA Strausberg R.;  
 RU Submitted (May-2003) to the EMBL/GenBank/DBJ databases.  
 DR EMBL, BC052665; AAH52665.1; -.  
 SQ SEQUENCE 184 AA; 20750 MW; C98C903C479C898 CRC64;

Query Match 85.9%; Score 140; DB 2; Length 184;  
 Best Local Similarity 83.9%; Pred. No. 1e-11; Indels 0; Gaps 0;  
 Matches 26; Conservative 2; Mismatches 3;  
 Db 114 TVQKLAHQIYQFTDKDKDNVAPRSKISPGY 144

RESULT 11  
 Q9TRZ6 PRELIMINARY; PRT; 27 AA.  
 ID Q9TRZ6;  
 AC Q9TRZ6;  
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)  
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
 DE ADRENOMEDULLIN.  
 OS Sus scrofa (Pig).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.  
 OC NCBI\_TaxID=9823;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=96157714; PubMed=8576091;  
 RA Ichihara Y., Kitamura K., Kangawa K., Kawamoto M., Matsuo H., Eco T.;  
 RT "Distribution and characterization of immunoreactive adrenomedullin in  
 RT porcine tissue, and isolation of adrenomedullin [26-52] and  
 RT adrenomedullin [34-52] from porcine duodenum.";  
 RL J. Biochem. 118:765-770 (1995).  
 DR GO: GO:0005576; C:extracellular; IEA.  
 DR GO: GO:0005179; F:hormone activity; IEA.  
 DR InterPro: IPR001710; Adrenomedullin.  
 DR Pfam: PF02039; Adrenomedullin; 1.  
 DR PRINTS: PR00801; ADRENOMEDULLIN.  
 SQ SEQUENCE 27 AA; 3063 MW; B8DC7FA18DB8B3D90 CRC64;

Query Match 84.7%; Score 138; DB 2; Length 27;  
 Best Local Similarity 96.3%; Pred. No. 2.3e-12;  
 Matches 26; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 LAHQIYQFTDKDKDNVAPRSKISPGY 31  
 Db 1 LAHQIYQFTDKDKDNVAPRSKISPGY 27

RESULT 12  
 ID Q75XW8 PRELIMINARY; PRT; 174 AA.  
 AC Q75XW8;  
 DT 05-JUL-2004 (TrEMBLrel. 27, Created)  
 DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)  
 DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)  
 DE Adrenomedullin-1.  
 OS Name=ADML;  
 OS Pugu rubripes (Japanese pufferfish) (Takifugu rubripes).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
 OC Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes;  
 OC Tetraodontidae; Tetraodontidae; Takifugu.  
 OC NCBI\_TaxID=31033;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=22984567; PubMed=14623291;  
 RA Ogoshi M., Inoue K., Takei Y.;  
 RT "Identification of a novel adrenomedullin gene family in teleost  
 RT fish.";  
 RL Biochem. Biophys. Res. Commun. 311:1072-1077 (2003).  
 DR EMBL, AB120295; BAD02341.1; -.  
 DR InterPro: IPR001710; Adrenomedullin.  
 DR Pfam: PF02039; Adrenomedullin; 1.  
 SQ SEQUENCE 174 AA; 20222 MW; 61535E41FCF88D4D CRC64;

Query Match 42.9%; Score 70; DB 2; Length 174;  
 Best Local Similarity 48.4%; Pred. No. 0.094;  
 Matches 15; Conservative 6; Mismatches 10; Indels 0; Gaps 0;  
 QY 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGY 31  
 Db 102 TVHDLAFRLHQLGFGYKIDIAVDKISPGY 132

RESULT 13  
 ID BAD02341 PRELIMINARY; PRT; 174 AA.  
 AC BAD02341;  
 DT 14-APR-2004 (TrEMBLrel. 27, Created)  
 DT 14-APR-2004 (TrEMBLrel. 27, Last sequence update)  
 DT 14-APR-2004 (TrEMBLrel. 27, Last annotation update)  
 DE Adrenomedullin-1.  
 OS ADML.  
 OS Pugu rubripes (Japanese pufferfish) (Takifugu rubripes).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
 OC Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes;  
 OC Tetraodontidae; Tetraodontidae; Takifugu.  
 OC NCBI\_TaxID=31033;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=22984567; PubMed=14623291;  
 RA Ogoshi M., Inoue K., Takei Y.;  
 RT "Identification of a novel adrenomedullin gene family in teleost  
 RT fish.";  
 RL Biochem. Biophys. Res. Commun. 311:1072-1077 (2003).  
 DR EMBL, AB120295; BAD02341.1; -.  
 SQ SEQUENCE 174 AA; 20222 MW; 61535E41FCF88D4D CRC64;

Query Match 42.9%; Score 70; DB 2; Length 174;  
 Best Local Similarity 48.4%; Pred. No. 0.094;  
 Matches 15; Conservative 6; Mismatches 10; Indels 0; Gaps 0;  
 QY 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGY 31  
 Db 102 TVHDLAFRLHQLGFGYKIDIAVDKISPGY 132

## RESULT 14

06L8K5  
ID 06L8K5 PRELIMINARY; PRT; 171 AA.  
AC 06L8K5;  
DT 05-JUL-2004 (TREMBLrel. 27, Created)  
DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update)  
DT 05-JUL-2004 (TREMBLrel. 27, Last annotation update)  
DE Preproadrenomedullin precursor.  
GN Name=preproAM;  
OS Cyprinus carpio (Common carp).  
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
OC Actinopterygii; Neopterygii; Teleostei; Osteiophysi; Cypriniformes;  
OC Cyprinidae; Cyprinus.  
OX NCBI\_TaxID=7962;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Liver;  
RX PubMed=15242754;  
RA Kono T., Sakai M.,  
RT "Molecular cloning and expression of preproadrenomedullin gene from  
common carp Cyprinus carpio L.";  
RL Gen. Comp. Endocrinol. 138:78-88(2004).  
DR EMBL; AB120940; BAD19046.1; -;  
DR InterPro: IPR001710; Adrenomedullin.  
DR Pfam: PF02039; Adrenomedullin.1.  
DR PRINTS; PR00801; ADRENOMEDULN.  
KM Signal.  
FT SIGNAL.  
FT CHAIN 79 127 Potential.  
SQ SEQUENCE 171 AA; 19412 MW; A9595B9A11B5AC36 CRC64;

Query Match 40.5%; Score 66; DB 2; Length 171;  
Best Local Similarity 45.2%; Pred. No. 0.34;  
Matches 14; Conservative 5; Mismatches 12; Indels 0; Gaps 0;

Cy 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGCY 31  
Db 97 TVHVLARLHDLNKKLGNAFADKINPFGY 127

## RESULT 15

BAD19046  
ID BAD19046 PRELIMINARY; PRT; 171 AA.  
AC BAD19046;  
DT 20-MAY-2004 (TREMBLrel. 27, Created)  
DT 20-MAY-2004 (TREMBLrel. 27, Last sequence update)  
DT 20-MAY-2004 (TREMBLrel. 27, Last annotation update)  
DE Preproadrenomedullin precursor.  
GN PREPROAM.  
OS Cyprinus carpio (Common carp).  
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
OC Actinopterygii; Neopterygii; Teleostei; Osteiophysi; Cypriniformes;  
OC Cyprinidae; Cyprinus.  
OX NCBI\_TaxID=7962;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Liver;  
RA Kono T., Sakai M.,  
RT "Molecular cloning of a novel preproadrenomedullin gene from common  
carp Cyprinus carpio L. and its expression.";  
RL Submitted (SEP-2003) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AB120940; BAD19046.1; -;  
KM Signal.  
FT SIGNAL.  
FT CHAIN 79 127 Potential.  
SQ SEQUENCE 171 AA; 19412 MW; A9595B9A11B5AC36 CRC64;

Query Match 40.5%; Score 66; DB 2; Length 171;  
Best Local Similarity 45.2%; Pred. No. 0.34;  
Matches 14; Conservative 5; Mismatches 12; Indels 0; Gaps 0;

Cy 1 TVQKLAHQIYQFTDKDKDNVAPRSKISPGCY 31  
Db 97 TVHVLARLHDLNKKLGNAFADKINPFGY 127

Search completed: January 5, 2005, 08:43:47  
Job time : 179.955 secs

**This Page Blank (uspto)**